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Abstract 
 
Mitochondria have their own protein synthesis machinery that synthesises the 
oxidative phosphorylation components encoded by their mtDNA. This 
translation process consists of four main phases: initiation, elongation, 
termination and ribosome recycling. Termination and its control have been the 
least investigated. Recently, however, the termination factor, mtRF1a, has been 
characterised as sufficient to release all the nascent proteins from the 
mitoribosome. Furthermore, bioinformatics has identified three additional 
members of this mitochondrial release factor family namely, mtRF1, C12orf65 
and ICT1. The latter is now known to be incorporated into the mitoribosome but 
its exact function remains unclear. 
My project has therefore focussed on characterising the remaining two factors; 
mtRF1 and C12orf65, and investigating their possible involvement in 
mitochondrial protein synthesis.  
It has been demonstrated that protein synthesis is not perfect and bacterial 
ribosomes not infrequently stall during translation. This can result from limiting 
amounts of charged tRNAs, stable secondary structures, or truncated/degraded 
transcripts. Ribosome stalling has been shown to cause growth arrest.  In order 
to prevent that and maintain high efficiency of mitochondrial protein synthesis 
such stalled complexes need to be rapidly recycled. Bacteria have developed at 
least three distinct mechanisms by which ribosomes can be rescued. 
Contrastingly, despite the presence of truncated mRNAs in mitochondria, no 
such quality control mechanisms have been identified in these organelles. This 
study investigates the potential role of mtRF1 and C12orf65 in quality control of 
protein synthesis in mitochondria. Both mtRF1 and C12orf65 demonstrate 
conservative motifs which would suggest their potential role in ribosome rescue. 
My findings indicate that the conserved motifs in mtRF1 are crucial to maintain 
normal cell metabolism and that its mutated forms negatively affect cell growth. 
Since these motifs are required for ribosome dependent peptidyl-tRNA 
hydrolysis, the data presented strongly imply that mtRF1 plays a crucial role in 
intra-organellar protein synthesis. 
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Chapter 1. Introduction 
1.1. Mitochondria- the importance and uniqueness    
1.1.1. Evolution of Mitochondria 
Early in the life on earth mitochondria, most probably as proteobacteria, 
became a part of an anaerobic archaeobacteria based on a symbiotic 
relationship. This theory has been widely accepted and more recently proven by 
comparison to the genome of Rickettsia, an intracellular causative 
proteobacteria of typhus, where the mitochondrial genome revealed high 
similarity that had not been recognised before (Andersson et al., 1998). 
However, the close relation between these two has also allowed the assumption 
to be made that since the initial endosymbiosis and during the long course of 
evolution mitochondrial DNA (mtDNA) from some organisms must have either 
been lost (non-coding DNA) or translocated to the nucleus (a reduction genome 
evolution) (Gray et al., 1999). Their loss from mtDNA contributed to reduction of 
the mitochondrial genome size and the stabilization of the symbiotic 
relationship. According to Andersson et al., (1998) good candidates for such 
genes are especially those crucial for mitochondria including the genes involved 
in the biosynthesis of amino acids and nucleotides and their regulation or genes 
of anaerobic glycolyis. Now that many genes have been lost from the mtDNA, 
especially in humans and replaced by nuclear homologues, the present day 
mitochondria depend on their ‘host’ for the majority of the proteins that are 
required for correct function of the organelles. Thus, approximately 99% 
(Adams and Plamer, 2003) of the ~1500 proteins that are required to generate 
and maintain the mammalian mitochondrion are encoded by nucleus. The 
mitochondrion has now become an integral component of all nucleated 
eukaryotic cells and is responsible for or/and linked to wide variety of cellular 
activities, which are crucial for cell survival, some of which are described below. 
Moreover, it has been shown recently that the loss of the mitochondrial genome 
results in growth rate reduction, cell-cycle arrest and nuclear instability (Veatch 
et al., 2009).  
Mitochondrial size, morphology, number and position in cells can vary and 
depends on energy demand of a tissue (Forner et al., 2006; Johnson et al., 
2007). They are very dynamic organelles, which undergo constant fusion and 
fission events (Youle and Bliek, 2012; Hoppins and Nunnari, 2012).  
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A            B 
 
 
 
Figure 1. 1. Mitochondrial structure.  
(A) The schematic of mitochondria indicates the different compartments and position of 
intramitochondrial particles (Frey and Mannella, 2000). (B) Similar features are shown in an 
electron microscopy image of a chick embryo mitochondrion (taken from 
http://www.bmb.leeds.ac.uk/illingworth/6form/index.htm). 
 
1.1.2.  General Structural Characteristics of mitochondria  
Mitochondria have a number of unique features compared to other mammalian 
organelles, including a dynamic structure, possession of a genome that is 
essential for multiple mitochondrial functions, together with specific translation 
apparatus responsible for intraorganellar translation of mt-mRNAs that differs 
from the cytosolic proteins. The organelle is divided into a number of 
compartments (as depicted in Figure 1.1) and described here. It is enclosed by 
two membranes, the outer mitochondrial membrane (OMM), which separates it 
from the cytosol, contains porin forming channels and Translocase of the Outer 
Membrane (TOM) complexes to transport mitochondrial targeted polypeptides 
through the lipid bilayer, which makes OMM permeable to molecules smaller than 
1500 Daltons. The inner mitochondrial membrane (IMM) plays a role in 
maintenance of the electrochemical potential and is more selectively permeable 
due to the different molecular composition including the presence of cardiolipin. It 
therefore contains various membrane transporters, such as TIM23 and the five 
oxidative phosphorylation (OXPHOS) complexes. The inner membrane is 
invaginated and so forms cristae with cristae junctions that are contacts sites with 
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the outer membrane, illustrated in Figure 1.1. 
The inter-membrane space (IMS) harbours, among others proteins, cytochrome 
c, whereas the compartment surrounded by the inner membrane, matrix, hosts 
most of the mitochondrial proteins responsible for metabolic processes including 
fatty acids beta-oxidation, Krebs cycle and the intraorganellar protein synthesis, 
performed on specific mitochondria translation apparatus (all briefly reviewed by 
McBride et al., 2006). Moreover, the matrix of each mitochondrion contains 2-10 
copies of circular mtDNA (Anderson et al., 1981) and factors involved in 
maintenance and its gene expression.    
 
1.1.3. Mitochondrial Functions 
A central contribution of mitochondria to the cell is in energy transduction in the 
form of ATP generated by harnessing oxidative phosphorylation. Metabolic 
substrates such as carbohydrates are oxidised by the tricarboxylic acid cycle 
(Krebs cycle), and fats are broken down by the enzymes of the beta-oxidation 
cascade. Both of the processes result in the production of reduced cofactors i.e. 
NADH and FADH2, and are re-oxidised by the transfer of electrons to the 
mitochondrial electron transport chain. Following the oxidation of those 
cofactors by Complex I and II, electrons reduce Coenzyme Q (CoQ) to ubiquinol 
(QH2) and protons are pumped into the IMS by Complex I (Galkin et al., 2006). 
Then, the electrons are transported further by QH2, which is oxidised to 
ubiquinone. The electrons now are transferred from Complex III to IV by the 
cytochrome c and finally to ½ O2 and 2H
+ by Complex IV (with water as the end 
product). Protons are pumped into the IMS by Complexes I, III and IV 
generating the electrochemical gradient. Thus, with the oxygen as a final 
electron acceptor and by the trans-membrane electrochemical gradient 
formation, together with a subsequent ADP and Pi condensation, ATP is 
produced (Figure 1.2). Then, the adenine nucleotide translocator (ANT), a 
mitochondrial protein, exchanges mitochondria-generated ATP for the cytosolic 
ADP. The amount of ATP released from the organelle is about 10 fold greater 
than the production from glycolysis in the cytosol and thus mitochondria tend to 
be referred to as ‘the power house of the cell’ (Ballerd et al., 2004). However, 
apart from ATP production when respiring, mitochondria convert about 1% of 
oxygen to generate reactive oxygen species (ROS), such as hydrogen 
peroxide, superoxide or hydroperoxides. Despite the low level, which is believed 
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Figure 1. 2. A cartoon depicting the mitochondrial oxidative phosphorylation complexes. 
The schematic is taken from Yoboue and Devin, 2012. Four respiratory complexes (I, II, III, and 
IV) are indicated. The largest, 980kDa Complex I (NADH:ubiquione oxidoreductase) consists of 
a hydrophobic membrane arm and hydrophilic matrix arm. Seven proteins (ND1, ND2, ND3, 
ND4, ND4L, ND5 and ND6) are mitochondrially encoded and 8 iron-sulphur clusters mediate 
the electron conduction. Complex II (succinate:ubiquinone oxidoreductase) has four subunits 
and delivers electrons to ubiquinone. Complex III, ~ 480 kDa (ubiquinol:cytochrome c 
reductase) forms a stable dimer, together 22 subunits, of which only cytochrome b is 
mitochondrially encoded. Complex III requires electron carriers and each electron transferred 
to cytochrome c results in two protons being pumped into the IMS. Complex IV (cytochrome c 
oxidase) also forms a dimer, 26 subunits make up ~ 408 kDa. Subunits COX1, COX2, each of 
which contains copper centres promoting the electron transfer, and COX3, a part of a 
structural core, are mitochondrially encoded. Complex V (the ATP synthetase) is composed of 
5 subunits and forms a hydrophobic transmembrane part and a hydrophilic head. (Complexes 
described in review: Vogel et al., 2006; Rutter et al., 2010; Saraste, 1999; Yoshida et al., 
2001).  
to be minimised by uncoupling of respiration (‘uncoupling to survive’ theory) 
(Speakman et al., 2004), these toxic radicals cause oxidative damage to DNA, 
proteins and lipids. ROS production increases with age and thus mitochondria 
have been implicated to play an important role in ageing process (reviewed by 
Lesnefsky and Hoppel, 2006). 
Other important processes in which the organelles have been shown to be 
significant, include calcium buffering (Rizzutto et al., 2003; Hopper et al., 2006; 
reviewed by Glancy and Balaban, 2012), FeS cluster formation (Stemmler et al., 
2010; Veatch et al., 2009) and programmed cell death, where released 
cytochrome c, one of the electron transport chain proteins, contributes to 
apoptosis (Phaneuf and Leeuwenburgh, 2002). Due to the fact that 
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Figure 1. 3. Organisation of the human mitochondrial genome.  
The guanine-rich heavy strand encodes most of the mitochondrial genes, 2 rRNAs (purple 
bars), 14 tRNAs (black diamonds, with single letter code) and 12 ORFs (green = complex I, blue 
= complex III, orange = complex IV, grey/blue = complex V). The guanine poor light strand 
encodes 8 tRNAs and 1 ORF (ND6). The genome lacks introns and harbours the displacement 
loop (D-loop or 7S DNA), the only triple stranded regulatory non-coding region. Transcription 
initiation promoters (IH1, IH2, IL) and their directions are indicated by bent arrows. The image 
was adapted from Kyriakouli et al., 2008. 
mitochondria are not static in the cell as they move, fuse and divide, the 
involvement in a wide range of cell signalling cascades as well as in cell cycle 
control (Veatch et al., 2009) is strongly supported and connects those important 
organelles to development biology but also to abnormal responses such as in 
disease (reviewed by McBride et al., 2006). 
 
1.1.4. The human mitochondrial genome, its maintenance and 
transcription. 
Even though the genetic role is universally conserved, mtDNA shows quite 
incredible variation in size, conformation and even gene content (Gray et al., 
1998). Many mtDNA are circular, however linear molecules were found as well 
(reviewed by Nosek et al., 1998). Mitochondrial genome size can range from 6 
kbp in the human malaria parasite to 367kbp, which is the largest mitochondrial 
genome sequenced (Unseld et al., 1997). Human mtDNA is quite distinct in its 
form and size. It is a double stranded, closed covalent circular genome that is 
relatively small in size, 16 596bp and encodes 13 polypeptides, ribosomal RNA 
16S and 12S, and 22 tRNAs (Figure 1.3). All the protein encoding genes that 
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are transcribed from mtDNA and the transcripts subsequently translated 
generate components of complexes involved in oxidative phosphorylation. The 
mitochondrial genome is protected by DNA-binding proteins that help compact 
the structure and form nucleoids. Due to its dynamic characteristic, the 
composition of nucleoids in mitochondria is debated as additional factors may 
be recruited when genome is copied and expressed. Moreover, there is no 
physical barrier between transcription and translation in mitochondria and these 
processes may be linked (Wang et al., 2007; Rorbach et al., 2008). Enriched 
preparation of mammalian mtDNA has given a number of nucleoid proteins, 
which could be peripheral (Bogenhagen et al., 2008; He et al., 2007; Reyes et 
al., 2011). This may suggest that such packaging functions as an important 
regulator of gene expression containing all the key factors required for the 
replication, transcription of the mtDNA and possibly translation, however it is not 
agreed upon in the field (Bogenhagen, 2012; Kukat et al., 2011; He et al., 
2012). Moreover, nucleoids association with IMM facilitates the import, complex 
assembly and coordination with cytosolic translation and nuclear encoded 
proteins insertion. Peripheral nucleoid proteins were suggested to provide 
intertalk between ER-bound cytosolic ribosomes and mitochondrial 
transcription/translation that occurs close to the assembly point (Spelbrink, 
2010). Mitochondrial transcription is initiated in the D-loop region, where two 
promoters (IH1 and IH2) are located only about 100 bp away from each other and 
transcribe in the same direction (illustrated in Figure 1.4). The third transcription 
initiation site (IL) is also situated in the D-loop and transcribes in the opposite 
direction (Figure 1.4) (reviewed by Falkenberg et al., 2007; Peralta et al., 2012). 
Transcription initiation requires cooperation of three proteins: mitochondrial 
transcription factor A (TFAM), mitochondrial transcription factor B (TFB1M and 
TFB2M) and mitochondrial RNA polymerase (POLRMT) (Falkenberg et al., 
2002; McCulloch and Shadel, 2003; Metodiev et al., 2009; Sologub et al., 2009; 
Litonin et al., 2010). TFAM as the main component of the nucleoids, without 
sequence specificity binds, unwinds and bends DNA, playing a function in both 
mtDNA maintenance and transcription (Parisi and Clayton, 1991; Dairaghi et al., 
1995; Kukat et al., 2011). For transcription, TFAM forms a dimer and recognises 
specific sequences upstream of IH1 and  IH2 promoters, unwinding DNA to 
provide access for the other components. TFB1M was shown to methylate the 
two adenines at the 3' terminus of 12S RNA (Metodiev et al., 2009) and TFB2M 
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Figure 1. 4. mtDNA transcription machinery in the D-loop.  
Initiation from IH1 promoter results in transcription of only 2 rRNAs and two tRNA (Val and 
Phe) terminating at the MTERF1 bound to the tRNA (Leu). IH2 and IL originated transcripts 
represent the full length of mtDNA. The position of the origin of replication on the heavy 
strand (OH) is also indicated. The proteins MTERF1, MTERF 2 and MTERF3 bind to the 
promoter region and play modulating functions. The image was adopted from Peralta et al, 
2012.     
acts as a heterodimer with the RNA polymerase, POLRMT. This protein is a 
single subunit protein (140kDa) composed of a C-terminal domain exerting 
conserved catalytic activity and N-terminal domain containing two putative 
pentatricopeptide repeat (PPR) motifs. The family of MTERF proteins have 
roles, not only in initiation, termination, but also in modulation of transcription by 
replication pausing and translation. In vertebrates there have been four 
members identified, MTERF1-4 (Kruse et al.,1989; Linder et al., 2005; 
Yakubovskaya et al., 2010; Wenz et al., 2009; Pellegrini et al., 2009; Camara et 
al., 2011; Peralta et al., 2012). The transcribed polycistronic transcripts are 
punctuated with the tRNAs that are assumed to signal for the 5' endonucleolytic 
cleavage by RNase P (Ojala et al., 1981) and 3' end cleaving by RNase Z type 
protein ELAC2 (Vogel et al., 2005; Rossmanith, 2011) of the tRNAs. This 
processing of transcription units results in separate species of rRNAs, tRNAs 
and mRNAs. Further maturation is required for all but the mt-rRNAs and 
includes the addition of the CCA triplet to the 3' end of tRNAs by the 
ATP(CTP):tRNA nucleotidyltransferase (Rossmanith et al., 1995) and 
subsequently the addition of an amino acid by the specific aminoacyl-tRNA 
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synthetase. Mitochondrial mRNAs are finally matured by addition of either oligo- 
or poly(A) and their 3' ends.    
         
1.2.  Mitochondrial protein synthesis in human organelles 
There are aspects of protein synthesis in mitochondria that differ from the 
cytosol, however the process is still divided into three steps as in other systems; 
initiation, elongation, and termination followed by ribosome recycling. In order to 
synthesise the 13 mtDNA encoded proteins, human mitochondria use their own 
translational apparatus that is different from the one found in the cytosol. First of 
all, the mammalian mitochondrial ribosomes (mitoribosomes) responsible for 
protein synthesis differ extensively from the counterpart found either in cytosol, 
bacteria, chloroplasts or indeed a number of mitochondrial ribosomes from 
yeast and other species (Suzuki et al., 2001a and 2001b; Koc et al., 2001a; 
Chrzanowska-Lightowlers et al., 2011). 
Second, mammalian mitochondrial mRNAs are either monocistronic transcripts 
as in the majority of cases (9 of 13 ORFs) or present as bicistronic transcripts. 
This situation occurs only twice where there are overlapping reading open 
frame within RNA14, the transcript encoding ATP8 as the upstream ORF with 
ATP6 as the second ORF. There is a similar arrangement in RNA7, with ND4L 
at the 5’ end and ND4 as the more 3’ ORF. The typical Shine-Dalgarno 
sequence, found in prokaryotes for recognition and determinant of the correct 
selection for the start side on the ribosome, is absent in mitochondrial mRNAs. 
Instead the majority of start codons are found at the very 5' terminus or within 3 
nucleotides of this (MTND1, MTCO1 and MTATP8). The exceptions are the 
downstream ORFs of the bicistrons (Anderson et al., 1981). Analysis using 
SHAPE chemistry by (Jones et al., 2008) suggests that the majority of the 
mitochondrial transcripts are highly unstructured at the 5’ end but that two of 
them (MTCyB and MTND5) predict stem loop structures near the start site or 
closer to 3' terminus, respectively. Therefore it is posited that recruitment of 
ribosomes in mitochondria starts directly at the 5’ terminus, which in most cases 
is accessible within single stranded regions (Liu and Spremulli, 2000). A further 
unusual feature relevant to translation is the absence of 3' untranslated (UTR) 
regions in the majority of transcripts (described in Temperley et al., 2010a). This 
feature is derived from the compactness of the genome and means that for 
26 
 
seven mt-transcripts the 3’ stop codons are generated only upon 
polyadenylation where the poly(A) tail completes the UAA stop codon 
(Temperley et al., 2010b). Apart from the stop codon formation the function of 
poly(A) tail addition in mitochondrial transcripts is not clear (Gagliardi et al., 
2004). Poly(A) tails extensions can have different length between the transcripts 
and between different cell types, reports of which show conflicting data 
concerning poly(A) function in mt-transcripts stability or a function as translation 
modulator (Temperley et al., 2003; Tomecki et al., 2004; Nagaike et al., 2005; 
Slomovic et al., 2008, Wydro et al., 2010). 
Due to the essential lack of UTRs on human mitochondrial mRNAs, there must 
be other mechanisms that promote and maintain stabilization and translation of 
transcripts, which is essential for gene expression. In Saccharomyces 
cerevisiae expression of each mitochondrial mRNA is regulated by individual, 
well characterised translational activators and most of them bind to 5' UTRs 
(reviewed in Herrmann et al., 2012). Very little is known about translation 
regulation in mammalian mitochondria and to date only the synthesis of 
cytochrome c oxidase subunit I have been shown to have translational activator, 
TACO1 (Weraarpachai et al., 2009). Its mutation results in cytochrome c 
oxidase deficiency, even though the mRNA levels remain normal. The COX 
synthesis and assembly could be restored by expression of the wild type 
TACO1 in patient fibroblasts. Yet, exact molecular mechanism remains elusive. 
Human mitochondrial poly(A) polymerase (hmtPAP) has also been identified 
and shown to be responsible for polyadenylating 3' termini of mitochondrial 
transcripts (Tomecki et al., 2004, Nagaike et al., 2005). However the mutated 
hmtPAP has been shown to accompany short tails but the effect on stability is 
not the same for all the transcripts (Crosby et al., 2010; personal 
communication with W.C. Wilson), which was also seen in Tomecki et al., and 
Nagaike et al., data. Recent characterisation of the first poly(A)-specific 
exoribonuclease in mitochondria, PDE12, also supported the observations that 
there is no universal rule in the behaviour of mt-mRNAs in the absence of a 
poly(A) tail. The over-expression of this deadenylating enzyme in cultured cells 
resulted in levels of three transcripts being unregulated (MTND1, MTND2 and 
MTND5) and other three tested showed a decrease (MTCO1, MTCO2 and 
RNA14) (Rorbach et al., 2011). 
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All the data thus shows that there is no single behaviour common to all 
transcripts in the absence of a poly(A) tail. Moreover, there may still be an 
uncharacterised mitochondrial poly(A) binding protein, that is required for 
correct translation efficiency (Wydro et al., 2010), whether those enzymes (i.e. 
hmtPAP, PDE12 and mtPABP1) themselves contributes to the stability of 
mitochondrial messengers and whether other factors are involved to contribute 
to the translation process via poly(A) tails remains an open question.  
Understanding the regulation of mitochondrial transcript metabolism is still far 
from complete and many other factors need to be identified and for those that 
have been reported the molecular mechanism of action requires to be further 
characterised.  Recent years studies on mechanisms underlying mitochondrial 
diseases hugely contribute to our understanding. Associated with a 
mitochondrial disease, Leigh syndrome French Canadian, a leucine-rich 
pentatricopeptide-repeat containing protein (LRPPRC) has been shown to be 
involved in translational control of mitochondrial mRNAs. The latest conditional 
Lrpprc knockout mice studies showed that in mammalian mitochondria 
LRPPRC not only is necessary for maintenance and stability of non-translated 
mRNAs pools via an RNA-independent complex formation with a stem-loop 
interacting RNA binding protein (SLIRP)(Sasarman et al., 2010), but also 
controls polyadenylation, thus affecting translation (Ruzzenente et al., 2012). 
Moreover, its post-translational regulation role together with SLIRP has been 
connected to its ability to bind mRNA coding sequences and suppress 3' 
degradation by exonucleolytic PNPase (Chujo et al., 2012). 
Finally, for many years one of the most characteristic and striking features in the 
mitochondrial translation mechanism has been the predicted changes to its 
genetic code (Anderson et al., 1981). These centred on the termination codons, 
the standard UGA is now decoded as tryptophan. The UAA termination triplet is 
used by 9 of the 13 mitochondrial open reading frames (MTCyt b, MTATP6, 
MTCO3, MTND1, MTND2, MTND3, MTND4, MTND4L and MTND5) whilst both 
MTCO2 and MTATP8 use UAG. The three nucleotides following the final coding 
triplet in mitochondrial transcripts MTCOI and MTND6 were identified as AGA 
and AGG respectively (Anderson et al., 1981). None of mitochondrial tRNAs 
has a capacity to decode these triplets that would normally be recognised as 
arginine. Therefore these were interpreted and became accepted as termination 
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signals and the literature described human mitochondria as employing 4 stops; 
UAA, UAG, AGA and AGG. 
However recently, human mitochondrial ribosomes have been shown to 
frameshift when either AGA or AGG reach the A-site during translation 
(Temperley et al., 2010a). In such a position those codons cannot be 
recognized by either mt-tRNA or any release factor and the stable secondary 
structure generated downstream of the triplet blocks forward movement of the 
ribosome. The analysis of MTCOI and MTND6 transcripts has shown that each 
of the codons is directly preceded by a ‘U’, which could now be shifted from the 
P-site and localised to the 5’-most position in the A-site. Therefore, by 
performing one nucleotide shift ribosomes position a standard stop triplet, UAG 
in the A-site, which now can be recognised by mtRF1a and the termination 
followed by recycling can continue (Lightowlers and Chrzanowska-Lightowlers, 
2010). 
 
1.2.1. Characteristics of the mammalian mitochondrial ribosome 
There are highly conserved morphological regions accurately reflecting the tight 
functional and structural constraints on all ribosomes, based on several 3D 
cryo-EM maps. Analysis of bovine 55S mammalian mitoribosomes reveal an 
evolutionary divergent form of ribosome compared to all known ribosomal 
structures (Sharma et al., 2003; Koc et al., 2001a; Koc et al., 2001b).  
The mammalian mitoribosomes consist of a small 28S subunit (mt-SSU), which 
contains the 12S rRNA, and the large 39S subunit (mt-LSU) with 16S rRNA. 
When together as a complete monosome they have relatively small 
sedimentation coefficient of 55S compared with bacterial ribosomes 70S (Figure 
1.5), eukaryotic 80S and even yeast mitoribosomes that are also 70S. They do, 
however, have a slightly larger molecular mass of 2.71MDa than the ribosomes 
from E. coli (2.49MDa), suggesting a more porous structure to the 
mitoribosome. Another unusual feature is the loss of significant regions of 
rRNA. Perhaps the most dramatic and striking feature is the reversal of the 
RNA:Protein ratio. While in bacteria ribosomes there is conventionally 70% 
rRNA with 30% protein, the mammalian mitoribosomes has removed various 
regions of sequence from the rRNA and acquired a larger repertoire of proteins 
to generate 70% protein and only 30% rRNA (Sharma et al., 2003 and 2009). It 
appears that during the course of evolution a number of proteins, some of which 
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Figure 1. 5. Cryo-EM map of ribosomes adopted from Sharma et al, 2009.  
(A) E. coli 70S ribosome. (B) Mammalian 55S ribosome.  For both panels LSU is indicated in 
blue and SSU in yellow. The map shows characteristic features of a ribosome: central 
protuberance (CP), stalk base L7/L12 (Sb) on the LSU and the head with the shoulder of the 
SSU, mRNA gate (mtg).  
A B 
are novel proteins without bacterial ortologues, have taken over some of lost 
rRNA functions (O'Brien, 2003 includes a table of human mitochondrial 
ribosomes, compared to E. coli ribosomal proteins). As opposed to the cytosolic 
ribosomes, subunits of which are mostly connected via RNA-RNA bridges, 
truncation of several helices of mt-rRNA in both mt-SSU and mt-LSU are 
structurally replaced with proteins affecting intersubunit space, which gives rise 
to a wider opening in this region that is crucial for tRNAs and translation factor 
access.The two proteins that mainly cause this alteration are S4 and S20, which 
are missing in mt-SSU, but in bacteria are placed close to tRNA in A- and P-site 
(Koc et al., 2010). This is the region of the subunit that interacts with the central 
protuberance of the mt-LSU (Koc et al., 2010). As a consequence the mt-SSU 
and mt-LSU are held by seven protein-protein bridges, two protein-RNA 
bridges, five RNA-RNA bridges and one connection that recruits both 
components of both subunits (Sharma et al., 2003). In this altered composition 
of ribosomal proteins there are 12 prokaryotic ribosomal proteins absent from 
mitoribosomes (Koc et al., 2001a, Koc et al., 2001b). There are also additional 
proteins that have no bacterial orthologues causing the reversed RNA to protein 
ratio. This additional protein mass quite heavily shields the major part of mt-
rRNA. 
The secondary structure of 12S rRNA (Figure 1.6) (950 nucleotides compared 
with 1542 in E. coli) lacks an anti-Shine-Dalgarno sequence, reflecting the 
A B 
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Figure 1. 6. The diagram of small and large subunit RNA of bovine mitoribosome adopted 
from Sharma et al, 2003.  
(A) Secondary structure of mitochondrial SSU rRNA (yellow) with characteristic features 
indicated and (B) mt-LSU rRNA (purple) with six domains of the structure numbered.  In both 
panels the fragments absent from 55S, but present in bacterial 70S are indicated in black.    
A B 
specific characteristics of mt-mRNAs, also fifteen helices are missing and 
several of existing ones are shorter (Koc et al., 2001a; Sharma et al., 2003).  
The 3’ terminus of 12S rRNA has two highly conserved dimethylated adenines 
and the disruption of the methyltransferase TFB1M (TFB1M and TFB2M are the 
only rRNA modifying enzymes known in mitochondria to date) responsible for 
this modification was shown to be embryonic lethal due to the impaired 
ribosomal assembly and defective mitochondrial translation (Metodiev et al., 
2009). Most of the lost fragments are situated on peripheries or away from the 
decoding centre (DC) of the mt-SSU. The only protein in the DC left that is the 
most conserved is MRPS12. It makes the direct contact with the tRNA at the 
subunit interface (Koc et al., 2010). The cryo-EM map also reveals that only 
19% of the lost rRNA has been replaced by protein mass (Sharma et al., 2003), 
Therefore the mt-SSU is longer, but significantly narrower in the midbody than 
bacterial 30S (Sharma et al., 2003). Currently the literature describes the mt-
SSU as containing 29 proteins, 14 of them have bacterial homologues, each of 
which is 4-25 kDa larger than and only 20-40% identical to bacterial equivalent, 
whereas the 15 remaining proteins are specific to mitochondria only (Koc et al., 
2001). Some of the new mitochondrial proteins also have adopted 
supplementary roles for the cell, this includes DAP3 (MRPS29), which as the 
TNF-α and FAS positive mediators together with MRPS30 have been reported 
31 
 
to play a role in apoptosis (Suzuki et al., 2001). MRPS36 also influences cell 
cycle and cell growth (Koc et al., 2010). 
The structural organisation of one of the most remarkable features of SSU is a 
triangular gate like structure allowing the mRNA to enter, which has evolved to 
recognise unusual mitochondrial mRNA. In bacteria it is surrounded by 3 
proteins S5, S3 and the S4 protein, which has been shown to be important in 
proofreading during translation (Van Acken, 1975). Loss of S3 and S4 is 
compensated by mitoribosome-specific proteins and by S5 being larger 
(Sharma et al., 2003). Moreover, as this structure is situated on the solvent side 
of the mt-SSU it is ideally positioned to play a part in regulating mitochondrial 
translation initiation.  
Another significant structural feature is a central platform of mt-SSU. The mt-
SSU proteins that contribute to formation of the P-site in the complete 
monosome are well conserved and one of these is MRPS18. In human 
mitochondrial there are 3 variants, whilst in bacteria there is a single orthologue 
that is located in the middle of the platform and changes conformation upon 
mRNA binding (Koc et al., 2001a). The 3 mt-isoforms are only 25-30% identical 
and originate from different genes, which again may implicate for the existence 
of mt-SSU sub-populations or other possible specific mitochondrial translation 
roles in different cells or tissues. 
Similarly to the mt-SSU, the mt-LSU is also larger than the bacterial large 
subunit. It consists of ~48 proteins, 28 of which have bacterial homologues, all 
more than 75% identical, but due to structural differences between bacterial 
50S and mt-39S, 5 of the bacterial proteins could not be localised on the cryo-
EM mitoribosome map (Sharma et al., 2003). Twenty of remaining proteins are 
specific to mitochondria only and mostly located on the porous subunit surface 
(Koc et al., 2001b). The mt-rRNA 16S of the large subunit is 1571 nucleotides 
long and is highly truncated relative to the bacterial equivalent (Cannone et al., 
2002). The truncations mainly affect i) secondary structures outside the main 
body of the subunit, ii) a domain situated below the L7/L12 stalk that is involved 
in the GTPase activities of several of translational factors and iii) crucial helices 
involved in the peptidyl-transferase centre (PTC) function. The highly variable 
stem-loop region just outside PTC is lost in 16S in the peptidyl-transferase loop, 
and the loss of which has been shown to slow the protein release extremely 
(Das et al., 2011). This lost region in mitoribosomes, in bacteria is responsible 
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for releasing the folding competent state (FCS) of proteins transformed from 
unfolded state by PTC. Overall about 28% of the ‘lost’ regions of 16S are 
replaced by mitochondrial proteins (Koc et al., 2010), some of which again may 
have overtaken functions of lost rRNA to maintain the protein synthesis 
efficiency.  
The most striking and debatable RNA loss locates to the central protuberance 
of mt-LSU. In bacteria it is formed by 5S rRNA and MRPL1, both of which are 
missing in mitoribosomes. However the mitochondrial genome does not code 
for 5S rRNA, a prokaryotic 5S rRNA binding protein homologue, MRPL18, has 
been found in 55S suggesting its translocation from the cytosol. Investigations 
by Koc et al. in 2001 on possible incorporation of 5S into mitoribosomes from 
cytosol showed that after extracting rRNA from bovine mitochondria, cytosolic 
and bacterial ribosomal subunits, no 5S or other corresponding RNA species 
could be found in 55S compared to 80S and 70S ribosomes (Koc et al., 2001b). 
These findings were also supported by the fact that the MRPL18 lacks the 
typical arginine rich N-terminal part, responsible for binding 5S in bacteria. 
Further attempts to detect 5S rRNA in mitochondrial ribosomes were 
unsuccessful (Sharma et al., 2009; Sharma et al., 2003). Therefore its function 
inside the organelles and the import processes provoked a debate until Smirnov 
et al., (2010 and 2011) decided to readdress the question of 5S presence in 
mitoribosomes. It has been then claimed that the association of 5S rRNA with 
the core of mt-LSU is rather fragile. Thus using milder and more rapid isolations 
of mitoribosomes, via co-immunoprecipitation of FLAG tagged versions of either 
the mt-LSU protein, ICT1, or mt-SSU protein, MRPS27, 5S could be detected in 
mitochondrial ribosomes. Moreover, two new factors have been reported to 
participate in redirecting this rRNA from cytosol to mitochondrial matrix, namely 
MRPL18 via formation of non-canonical complex with S5, and rhodanese 
(Smirnov et al., 2010; Smirnov et al., 2011). 
Other regions of mt-16S rRNA that have been lost compared with bacterial 
ribosomes are mapped to two domains, I and III, which most importantly focus 
around polypeptide exit tunnel. These rRNA regions are dramatically shorter, 
making it difficult to predict the secondary structure (Figure 1.6.). Reconstitution 
of mitoribosomal exit tunnel by cryo-electron microscopy revealed a 
substantially different structure with additional mass and protuberances 
33 
 
compared with other ribosomes (Sharma et al., 2009; Sharma et al., 2003). 
Moreover it was shown to be wide enough to allow an access to the solvent via 
the polypeptide accessible site (PAS), provoking a hypothesis that there may be 
two different pathways for newly synthesised polypeptides to leave the 
mitoribosome (Koc et al., 2010). The detailed yeast analysis of chemically 
cross-linked mitoribosomal proteins and mass spectrometry characterised a 
unique complex network of interacting proteins found in this region that are 
specific to mitochondria (Gruschke et al., 2010). In yeast mitoribosomes there 
are four proteins (MRPL4, MRPL40, MRP20, and MRPL22) that form the rim of 
the mitochondrial exit tunnel and make a direct contact with nascent polypeptide 
chain. MRPL27, MRPL13 and MRPL3 were found in close proximity to the 
tunnel indirectly supporting the formation and stability of the structure. 
Similarly, the portion of L7/L12 stalk tertiary structure is lost implying alternative 
mitochondrial organisation of this region in order to be retained on the 
peripheries of the subunit, as observed on cryo-EM (Sharma et al., 2009; 
Sharma et al., 2003).  
The interface part of mt-LSU also lacks several helical segments and as a 
consequence the tRNA binding sites on the mt-LSU have been altered. Apart 
from the A-site finger that contacts the D- and T loop of tRNAs, both structures 
of which are significantly smaller in mt-tRNA, the rest of this pocket has been 
conserved. Mitochondrial P-site however, with most tRNA contact points 
preserved, exhibits additional and unique P-site finger composed entirely of 
unidentified proteins and possibly providing stronger or additional interaction 
with tRNAs or specific mitochondria translation factors (Koc et al., 2010). Most 
of the E-site tRNA contacts found in bacterial LSU have been either lost in 
mitochondria or the region significantly altered with only one contact point 
present. This essentially means that no E-site exists in mammalian 
mitoribosomes (Koc et al., 2010). 
The initial observation of ribosomes inside mitochondria (O'Brien et al., 1967, 
O'Brien et al., 1971) and further detailed proteomics analysis carried out by Koc, 
Spremulli, Suzuki and Watanabe has contributed to an immense progress in 
understanding of the structure and function of mammalian mitoribosomes. 
However, due to conformational heterogeneity and low abundance of the 
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mitoribosomes and therefore lack of high- resolution structural information much 
remains to be learned. Not only is the list of ribosomal proteins still growing 
(Richter et al., 2010b), but also the list of the nuclear encoded partners 
interacting with mitoribosome, which are involved in a variety of processes 
ranging from the biogenesis and modifications through processing and 
assembly to activity.  
It has long been suggested that in order to perform translation mitoribosomes 
interact peripherally with the inner membrane, in part due to the hydrophobicity 
of the synthesised proteins (Liu and Spremulli, 2000). Recent studies have 
identified partners that are in close association with the rim of the large subunit 
exit tunnel proteins and act to facilitate co-translational insertion of the nascent 
polypeptide chains in to the mitochondrial inner membrane. The most studied 
protein of the insertion machinery is Oxa1p in yeast. It has been shown that 
Oxa1p is an integral membrane protein with its hydrophilic C-terminal tail 
exposed to mitochondrial matrix space, supporting the protein-ribosome 
interaction (Jia et al., 2003; Jia et al., 2009). Further analysis has shown that 
Oxa1 lies in a close proximity with MRPL20 and MRPL40, components of the 
exit tunnel, all of which can be chemically cross-linked and affinity purified with 
each other and emerging nascent chain (Hell et al., 2001). MRPL40 also 
contains a mitochondrial specific C-terminus that is crucial for the accurate 
translation and assembly of synthesised products (Jia et al., 2009). Additionally 
to Oxa1p, there are a number of yeast proteins identified to play a role in 
insertion machinery and some of them, such as Mba1 and Mdm38, directly 
interact with mitoribosomes and are responsible for inner membrane insertion of 
different specific OXPHOS proteins (Bauerschmitt et al., 2010, Gruschke et al., 
2010, Gruschke et al., 2011, Lupo et al., 2011). To date however only three 
yeast homologues have been reported to be represented in mammalian 
mitoribosomes, i.e. Oxa1L as a homologue of Oxa1p, LETM1 (Mdm38 in yeast) 
and Cox18 (Oxa2 in yeast) (Gaisne and Bonnefoy, 2006, Haque et al., 2010, 
Piao et al., 2009). In addition, mitochondrial elongation factor-Tu has been 
hypothesized to also have some chaperone properties based on its in vitro 
ability to enhance protein folding and prevent thermal aggregation of proteins. It 
can, therefore, be a candidate to contribute to insertion/ folding of newly 
synthesised protein but further investigation is required (Suzuki et al., 2007). 
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Human Oxa1L, like its yeast homologue, binds mitoribosomes via C-terminal tail 
(CTT), but unlike Oxa1p, the tail of mammalian protein forms different structure. 
This cross-links to mitochondrial specific ribosomal proteins, MRPL48, 49 and 
51 that are present at the back of the mammalian mt-LSU but do not exist in 
yeast mitoribosomes (Haque et al., 2010). Oxa1L-CTT does not seem to 
interact directly with the exit tunnel, but rather with the solvent side of the 
mammalian mt-LSU close to PAS and is part of a larger complex, the 
composition of which is unknown (Stiburek et al., 2007). As mentioned before 
methylation of small ribosomal subunit RNA is not the only post transcriptional 
modification found in mitochondria. Another three modification positions have 
been found on both 12S and 16S rRNA, which need to be confirmed and no 
responsible enzymes have been found (reviewed by (Rorbach and Minczuk, 
2012). Another well-known modification involving ribosomes is post-translation 
phosphorylation of ribosomal proteins that also regulates a variety of other 
mitochondrial processes such as oxidative phosphorylation, mitochondrial 
induced apoptosis via DAP3 and MRPL40 or translation elongation (He et al., 
2001). The pilot study by (Miller et al., 2009) identified 24 mitoribosomal 
proteins that are phosphorylated at serine, threonine or tyrosine residues. 
Proteins involved in these regulatory processes were found mainly in ribosomal 
functional sites, such as the polypeptide exit tunnel and mRNA binding regions, 
but also the L7/L12 stalk region. It has been suggested that phosphorylation 
may introduce conformational or structural changes altering protein-protein and 
protein-RNA cross-talk during stages of translation (Miller et al., 2009).  
Even though remarkable progress has been made in the past decade 
concerning function and structure of 55S, the knowledge about the transcription 
of rRNA genes encoded by mtDNA and its coordination with the transcription, 
translation and the import of ribosomal proteins encoded by nuclear genome is 
limited, therefore very little is known about biogenesis, assembly of 
mitoribosomal subunits and the control over those processes. Detailed 
investigation of ERAL1, a GTP-ase RNA binding mitochondrial protein, has 
demonstrated that it binds a stem loop at 3' of 12S mt-rRNA, where 
dimethylation of two adenines was identified in ribosome maturation events. 
Since ERAL1 depletion results in decreased protein synthesis with lost stability 
of mRNA due to rapid decay of the 12S mt-rRNA it has been characterised as a 
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mitochondrial RNA chaperone that protects mt-SSU rRNA during formation of 
subunit (Dennerlein et al., 2010; Metodiev et al., 2009; Uchiumi et al., 2010). 
ERAL1 is the only factor characterized to play such a role to date. However, 
another protein, pentatricopeptide repeat domain protein 3 (PTCD3), has been 
shown to associate with rRNA of the small subunit and to regulate mitochondrial 
translation, its exact role and underlying mechanism of the process remains 
unknown (Davies et al., 2009). In contrast, there are a number of proteins 
implicated to play a role in the biogenesis and assembly of 16S mt-rRNA. First 
of all, mTERF4 that is a member of transcription factors family has been 
unexpectedly shown to have a direct role in ribosomal biogenesis in 
mitochondria (Camara et al., 2011). The depletion of mTERF4 results in 
increased levels of both subunits, however they are unable to assemble a 
monosome, and so reduce translation. It exerts its action due to its ability to 
bind 16S rRNA. It forms a stoichimetric complex with NSUN4, which belongs to 
m5C RNA methyltransferases, but lacks the targeting domain, thus needs to be 
recruited to the large mitochondrial subunit. However its contribution in 
ribosome maturation remains unclear. Inaccurate ribosome assembly was also 
observed in the absence of nitric oxide-associated-1 (NOA1) knock-out mouse 
embryonic fibroblasts cells (MEFs). Apart from the fact that the loss of this GTP 
binding protein impairs the protein synthesis it also caused aberrant migration of 
mt-LSU observed by sucrose gradient centrifugation, indicating that NOA1 has 
a role in correct assembly of 55S (Kolanczyk et al., 2011). Another GTPase, 
Mtg1, has been localised to mammalian mitochondria (Barrientos et al., 2003). 
It is a homologue of a yeast GTPase protein family, three members of which 
have been identified to regulate the assembly of LSU (Paul et al., 2012) and 
even though Mtg1 has been shown to partially rescue the respiratory deficiency 
in a yeast mtg1 mutants, its exact function in mammalian mitochondria again 
has not been characterised. A different mitochondrial protein, C7orf30, however 
has recently been shown to associate with the 55S and thereby directly 
regulates the formation of mitochondrial monosomes (Rorbach et al., 2012, 
Wanschers et al., 2012). 
Finally, a detailed mechanism of action contributing to ribosomal biogenesis and 
involved in regulation of ribosomal integrity has been reported in (Bonn et al., 
2011). Here the m-AAA protease that is present in the IMM is involved in a 
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quality control of proteins by processing and mediating protein maturation 
during mitochondrial biogenesis. The maturation of imported ribosomal proteins 
is essential for assembly of ribosomes and one example is MRPL32. The final 
processing and folding of this depends on mAAA protease and unusual 
MRPL32 features. It demonstrates presequence-assisted folding after the 
import into the matrix space, which differs to the majority of presequence-
containing proteins that are processed upon import by the mitochondrial 
processing peptidase (MPP). The integrity of a tightly folded cysteine containing 
domain of MRPL32 ensures its folding and inhibits the proteolysis initiated at 
the N terminus by mAAA of newly imported proteins.   
 
1.2.2. Initiation of mitochondrial protein synthesis 
Since the mt-SSU has been demonstrated to have GTP binding activity it is 
probable that this subunit is involved in the initiation step of translation (Suzuki 
et al., 2001) and requires recruitment of the mt-mRNA. With the exception of the 
2 bicistronic transcripts, mammalian mitochondrial mRNAs generally do not 
possess either 5’ (maximum of three nucleotides preceding a start codon) or 3’ 
untranslated regions, which in other systems often contribute to mRNA 
recognition and ribosome binding (Liu and Spremulli, 2000). Thus, translation in 
mitochondrion is essentially assumed to start directly at the 5’ terminus. 
Mitochondrial ribosomes have been shown to be highly inefficient in recognising 
mRNAs containing more than 3 nucleotides prior to the start codon (Montoya et 
al., 1981). The formation of a stable initiation complex was decreased by 80% 
when the transcript encoding subunit II of cytochrome c oxidase was extended 
by 12 nucleotides at 5' end. This emphasised the leaderless nature of 
mitochondrial transcripts (Christian and Spremulli, 2010). Despite two initiation 
factors having been characterised (Koc and Spremulli, 2002) initiation factor 2 
(IF2) promoting the binding of fMet-t-RNA to the small subunit and IF3, which 
facilitates dissociation of 55S ribosomes stimulating initiation complex 
formation, the exact mechanism behind directing mitoribosomes to the initiation 
codon is not known. The mitochondrial IF3 interacts with 55S particles to loosen 
subunits interactions to promote disassociation, maintain the subunits in the 
dissociated state and facilitate subsequent binding of fMet-tRNA in the 
presence of mRNA and mtIF2 (reviewed in Christian and Spremulli, 2010). After 
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the subunits have been disassociated mtIF3 has been shown to have the ability 
to remove prematurely bound fMet-tRNA and mtIF2 in the absence of mRNA 
from 28S.  When the mRNA is bound however, mtIF3 has no effect on further 
interactions (Bhargava and Spremulli, 2005). This has led to a conclusion that 
the formation of the initiation complex requires a specific order, in which first 
mRNA is positioned randomly on the mitochondrial small subunit entering via 
the protein-rich mRNA entrance gate and only binding of mtIF3 can mediate 5' 
start codon to be positioned correctly in the P-site. Also, the binding of this 
initiation factor to the platform region of 28S is achieved in a way that the 
intersubunit bridges cannot be physically formed when mtIF3 is bound (Haque 
et al., 2011). The latter protein consists of two domains, N-domain and C-
domain, separated by a flexible linker. The C-domain shows a strong affinity for 
the 28S SSU and the contacts are slightly facilitated by the linker. This was 
identified by studying mutations that were introduced in this region and that 
resulted in the loss of complex formation and subunit disassociation activity 
(Christian and Spremulli, 2009). The N-domain of the protein is positioned near 
the anticodon stem-loop of the initiator tRNA in the P-site suggesting a role 
reducing the binding of fMet-tRNA when no mRNA is present on the small 
subunit or in facilitating the correct positioning of mRNA (Haque and Spremulli, 
2008). Toeprint analysis of the mitochondrial initiation complex revealed that 
after the first 17 nucleotides of the transcript have bound the 28S, the subunit 
pauses to inspect the mRNA and this also occurs in the absence of start codon 
(Christian and Spremulli, 2010). Moreover, it shows that the mitochondrial 
ribosomes can discriminate between the 5' terminus or internal AUG, and so 
when the start codon is not present at the 5' –end, the mRNA continues sliding 
off without associating. The binding of fMet-tRNA to the ribosome and codon-
anticodon interaction is mediated by the mtIF2-GTP. In mtDNA there is only one 
gene coding for Met-tRNA that takes part in both initiation and elongation and 
formylation of the Met-tRNA. This allows it to bind mtIF2 and the elongation 
factor shows no detectable affinity to fMet-tRNA and the participation of the 
tRNA between phases occurs by a competition between the transformylase and 
the elongation factor (mtEF-Tu) (Spencer and Spremulli, 2004). The binding of 
mtIF2 is influenced by GDPNP, the non-hydrolyzable analogue, and is 
organized into four domains. These include the N-terminal domain that interact 
with the small ribosomal subunit, a central G-domain (G1, G2 and G3) that 
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organises the structure of the protein, thus  facilitating binding and contact with 
the LSU, and two C-terminal domains, involved in binding the initiator tRNA 
(Spencer and Spremulli, 2005). Interactions between mRNA, mtIF3, mtIF2 and 
fMet-tRNA with the 28S SSU are followed by the large subunit joining, 
hydrolysis of GTP to GDP, release of the initiation factors and the full 55S 
initiation complex formation, which is then ready to move to the next step of 
synthesis.  
1.2.3. Elongation of mitochondrial translation 
Limited information is available regarding translation elongation, where to date 
only three factors are known to be involved, mitochondrial elongation factor-Tu 
(mtEF-Tu), Ts (mtEF-Ts) and G1 (mtEF-G1). Elongation factors are very 
abundant and highly conserved throughout evolution and because of the high 
sequence similarities it is believed that elongation in mitochondria proceeds in a 
similar fashion to bacteria. This involves the EFs introducing aminoacylated 
tRNAs to the ribosomal A-site thus facilitating formation of the translation 
complex (Jeppesen et al., 2005). However, the mechanism of the process 
consists of at least seven separate steps, recurrence of which leads to 
formation of full-length newly synthesized proteins. In contrast to prokaryotes 
factors mtEF-Tu does not appear to be present is a free form and can only be 
isolated from mitochondrial extracts of a bovine liver as a complex with mtEF-
Ts, therefore it was postulated that the ratio of two factor in mitochondria is 1:1 
(Woriax et al., 1997). This is in contrast to S. cerevisiae where only EFTu is 
present (Rosenthal and Bodley, 1987). During elongation the EF-Tu is known to 
interact with guanine nucleotides, however in mitochondria the mtEF-Tu-Ts 
complex do not disassociate even at high concentrations of guanine nucleotides 
and its stability depends on the aa-tRNA (Cai Yc Fau - Bullard et al., 2000). 
Moreover, the dissociation constant for the mtEF-Tu-GDP and for mtEF-Tu-
GTP was shown to be more than two orders of magnitude and about 60-fold 
higher, respectively, than in prokaryotes (Cai Yc Fau - Bullard et al., 2000). The 
crystal structure of the bovine mitochondrial EF-Tu was obtained and has 
showed that the protein is organized in three domains as in the bacterial 
counterpart and they share up to 60% similarity (Woriax et al., 1995). 
Mitochondrial domain I and domain II interact with the small subunit of the 
ribosome also providing the binding site for aa-tRNA and guanine nucleotides, 
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while domain III also interacts with the 5' end and the acceptor stem loop of aa-
tRNA organizing the structure in a pocket for the tRNA (Jeppesen et al., 2005). 
When the mtEF-Tu forms the complex with the mtEF-Ts its structure is changed 
and differs extensively from either the EF-Tu GTP or GDP-bound isolated from 
bacteria. There are three points of contact between the factors, which are G-
domain and domain III of mtEF-Tu that mostly contact the core of the mt-EF-Ts 
and the region of both factors contribute to nucleotide exchange process. In 
contrast, the role of mtEF-Ts is mostly to promote guanine nucleotide exchange 
with mtEF-Tu. It shares only ~ 30% of sequence conservation with bacterial 
factors and the most striking difference is the loss of the majority of the coiled-
coil domain, which in bacteria has been shown to promote the ability to compete 
guanine nucleotide binding (Karring et al., 2003). The core of the protein 
consists of β-sandwich in bacteria, whilst in mitochondria its organization differs 
by the number of β-strands and their arrangement, the N-terminal domain folds 
in a very similar way (Jeppesen et al., 2005). 
The translocation step in elongation of protein synthesis depends on an EF-G 
(Bhargava et al., 2004). The protein consist of 5 domains, domains II, III and IV 
interact with SSU proteins whereas domain I and V with LSU. During 
translocation the movement of domains III-V inserts in to the decoding centre 
causing movement of tRNA, while the domains I-II exert the activity of the 
protein (Shoji et al., 2009). In mitochondria, surprisingly 2 forms of this protein 
have been identified, mtEF-G1 and mtEF-G2 (Hammarsund et al., 2001). It is 
mtEF-G1 that is involved in elongation step. This has been verified by cloned 
and purified preparations being active on both bacterial and mitochondrial 
ribosomes (Bhargava et al., 2004).  
The current model for the elongation of translation in mammalian mitochondrial 
system (Christian and Spremulli, 2012) begins with the GTP-bound active form 
of mtEF-Tu. This complex is able to bind aminoacyl-tRNA (aa-tRNA), protecting 
it from degradation by forming a ternary complex that is now able to enter the 
ribosome. If cognate codon-anticodon interactions occur to dock the complex in 
the acceptor site, GTP is hydrolysed to GDP and EF-Tu-GDP is released. Then 
subsequent interaction with mtEF-Ts and the formation of intermediate complex 
with mtEF-Tu mediates the transition of GDP to GTP bound to mtEF-Tu for 
another cycle. Meanwhile, the peptide bond formation between aa-tRNA in the 
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A-site and the last amino acid on the nascent polypeptide chain bound to the 
tRNA in the P-site, catalyzed by the ribosome results in the deacylated tRNA in 
the P-site and one residue longer peptidyl-tRNA in the A-site. The translocation 
of the peptidyl-tRNA to the P-site occurs with the help of EF-G1 and the 
deacylated-tRNA is removed from the translating ribosome. Elongation is 
followed by termination and ribosome recycling.  
1.2.4. Termination of mitochondrial translation 
In terms of translation termination and identification of the proteins involved, the 
matter seems to be more complex and less studied compared with initiation and 
elongation. Unlike sense codons that are recognized by tRNA anticodons during 
elongation, when stop codons reach the decoding site in the ribosomal A-site, 
the recognition is mediated by a group of proteins termed class I release factors 
(RFs), the elongation is ceased and nascent polypeptide released from post- 
translational complex. Efficient termination of protein synthesis requires 
participation of two classes of RF. Class I RFs have sequence specificity and 
bind only to A-site stop codons to promote release of nascent polypeptide by 
triggering hydrolysis of the ester bond between the completed protein and the 
terminal tRNA. This hydrolysis occurs in the peptidyl-transferase centre (PTC) 
where the configuration of the rRNA and RF is critical to facilitate translation 
termination. Subsequently, class II RFs that a codon independent, but can 
enhance class I activity and/or act as GTPases dissociate class I RF from the 
translation complex (Youngman et al., 2008, (Martin et al., 2005).  
In bacteria codon recognition is facilitated by two class I proteins. RF1 is able to 
bind UAA and UAG, while RF2 shows activity with UAG but also functions with 
UAA (Youngman et al., 2008). In contrast, the same three codons are used but 
are recognised by a single protein eRF1 in eukaryotes and aRF1 in archaea. 
The crystal structure analysis of bacterial RF1 has revealed the specific regions 
required for the release function (Laurberg et al., 2008; Petry et al., 2005). It has 
been shown that there are three RF domains (domain 2, 3 and 4) that can 
occupy the ribosomal A-site. Domain 2 contains a conserved tripeptide motif of 
proline and threonine separated by variable amino acids (PXT) in RF1 types 
and serine, proline and phenylalanine (SPF) in RF2 types, which in concert with 
the tip of the α5 helix interact with the stop codon bases in the decoding centre 
of the ribosome. This recognition is accompanied by conformational 
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rearrangement between domains 3 and 4 to mediate the position of another 
conserved region, Gly-Gly-Gln (GGQ), extending it towards the 
peptidyltransferase center (PTC) in the large subunit. Brought to the close 
proximity with the ester bond linking the P-site terminal tRNA with the newly 
synthesized polypeptide chain, the GGQ motif promotes the hydrolysis and 
consequent polypeptide release (Seit-Nebi et al., 2001).  
In mitochondria there is only one protein that has been shown in vitro and in 
vivo to be active on all mitochondrial stop codons, directly recognizing UAA and 
UAG while promoting rather indirect termination through programmed ribosome 
frameshifting on mt-ORFs that are followed by with AGG and AGA triplets. Due 
to its greater similarity not only in sequence but also in length to RF1-type 
proteins in both prokaryotes and eukaryotes, the human mitochondrial factor 
was named mtRF1a (Soleimanpour-Lichaei et al., 2007, Temperley et al., 
2010a). The amino acid sequence alignments of all mitochondrial factors 
indicate similarities with only RF1-type proteins rather than with RF-2, thus up to 
date mitochondria are not known to have or need an RF2 counterpart.      
 
1.2.5. Ribosome recycling in mitochondria 
The 55S with deacylated tRNA and mRNA is targeted for the last step of 
translation.  The post-translational complex requires to be disassembled so that 
all the components of translation can be reused for the next rounds of 
synthesis. It was only few years ago that a candidate protein proposed by 
bioinformatics analyses has been biochemically characterized and shown to be 
involved in the mechanism of ribosome recycling (Rorbach et al., 2008). The 
mtRRF was shown to strongly bind mitoribosomes in vivo and depletion of the 
factor resulted in reduction of free ribosomal subunits and an increase in 
monosome formation. Moreover, the expression of human mtRRF was shown 
to suppress the partial deletion of rrf1 gene in fission yeast in vivo. 
Even though mtRRF is an essential protein for cell viability and its depletion 
caused general mitochondrial dysfunction, it was reported that the efficient 
disassembly process requires mtRRF to work in conjugation with mtEF-G2, thus 
the latter was renamed for mtRRF2 (Tsuboi et al., 2009). In contrast with 
bacterial systems, where a single protein had been assumed to be required for 
both elongation and recycling process, it was unusual to observe two separate 
43 
 
factors for tRNA translocation step and for disassociation of subunits. Now, 
however, there have been a number of bacterial EF-G2 proteins identified. 
mtEF-G2 has no significant translocation activity, however its over-expression in 
patient fibroblasts habouring a mutation in mtEF-G1 slightly elevates levels of 
fully assembled oxidative phosphorylation complexes suggesting to some 
extent its dual function (Coenen et al., 2004). The domain swapping between 
mt-EF-G2 revealed that the different function of the factors depends mostly on 
domains III and IV. Moreover, mtEF-G2 has strong ribosome-dependent 
GTPase activity and unlike bacterial systems the mitochondrial subunit 
recycling does not require GTP hydrolysis, but rather the GTP hydrolysis take 
place after the monosomes split and release mtEF-G2 and mtRRF bound from 
the large subunit (Tsuboi et al., 2009). In order to prevent factor free ribosomal 
subunits from reassembling mtIF-3 binding to the SSU is required (Christian 
and Spremulli, 2012). 
 
1.2.6. Human mitochondrial release factor family 
In 1998 bioinformatic analyses revealed a mitochondrial RF protein candidate 
based on sequence similarities with other RFs. This was termed mtRF1 (Zhang 
et al., 1998) and was referred to in the literature as the only translation 
termination factor in mammalian mitochondria that was anticipated to have RF 
activity on all 4 predicted stop codons. No release function, however, has been 
detected in in vitro studies of mtRF1 on bacterial ribosomes against UAA, AGA 
and AGG (Soleimanpour-Lichaeiet al., 2007; Nozaki et al., 2008) or any other 
triplet tested (personal communication Z. Chrzanowska-Lightowlers) nor did an 
in vivo approach in yeast yield any detectable activity (Soleimanpour-Lichaei et 
al., 2007). In the latter investigation the overexpression of human mtRF1 could 
not rescue the respiratory deficiency caused by deletion of endogenous yeast 
MTRF1. A further candidate, mtRF1a, was then characterised and 
demonstrates activity only in response to UAA and UAG but not to AGA and 
AGG (Soleimanpour-Lichaei et al., 2007) or other codons tested (personal 
communication Z. Chrzanowska-Lightowlers). Both mtRF1a and mtRF1 have 
the conserved GGQ motif, but their amino acid sequences in the regions 
conferring codon recognition differ slightly. Across the tripeptide domain 
mtRF1a has PKT, conforming to the PXT consensus. In contrast, mtRF1 
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displays an extended hexapeptide motif, PEVGLS. At the tip of the α5 helix of 
domain 2 both proteins differ slightly from the E. coli proteins but again mtRF1a 
shares greater similarity than mtRF1. A consequent bioinformatics search 
revealed further 2 new members of the family, ICT1 and C12orf65. These two 
new predicted members of the mitochondrial release factor family, however, 
lack the sequences spanning codon recognition although they do retain the 
GGQ motif required for hydrolysis of nascent polypeptide chain.    
The GGQ motif is present in all class I RFs and it is conserved in all eubacterial, 
archeal and eukaryotic release factors. The mutations of any of three residues 
results in significant decrease of its catalytic activity or in complete loss of 
function with poor ability to be even expressed in E. coli (Frolova et al. 1999; 
Mora et al., 2003). In both bacterial factors (RF1 and RF2) Gln residue is post-
translationaly methylated, which contributes to the activity (Heurgue-Hamard et 
al., 2002). The same modification is made to yeast eRF1 (Heurgué-Hamard et 
al., 2005) and to the Gln of tripeptide motif in mtRF1a is believed to the modified 
by HMPrmC, a methyltransferase that is targeted to mitochondria (Ishizawa et 
al., 2008).  
Richter et al. (2010) has already shown that ICT1 is able to immunoprecipitate 
the whole mitochondrial monosome, it co-sediments with both 39S and whole 
55S articles. Ribosomes lacking ICT1 cannot be fully assembled, indicating it to 
be an integral part of the large subunit. Even though ICT1 has been tested for 
activity on E. coli ribosomes and was shown to act as a ribosome-dependant 
codon-independent peptidyl-tRNA hydrolase regardless of the codon presence 
or absence in the A-site, it is not possible to test this activity directly on 
mitoribosomes. Due to its known characteristics it is proposed to be involved in 
a mitochondrial strategy of dealing with mRNA that has lost the translation 
termination codon. When mitochondrial ribosomes encounter a 3' end of a non-
stop mRNA, ICT1 is predicted to cleave the peptidyl-tRNA freeing the nascent 
chain allowing the ribosome and the tRNAs to undergo proper recycling.  
Furthermore, structural differences between active domains of ICT1 and RFs 
have been implicated and linked to a specific function of ICT1 other than the 
translation termination mediated by RFs (Handa et al., 2010). The solution 
structure reveals a β1–β2–α1–β3–α2 topology (Figure 1.7 A) and the catalytic 
domain, including the mobile 15 residue GGQ loop of mouse ICT1 has been 
shown by to be identical in structural framework and length with domain 3 of 
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Figure 1. 7Ribbon diagrams of ICT1 and domain 3 of RF2. 
The structures have been taken from Hanada et al., 2010. See description in the main text. (A) 
The structure of ICT1 where, the α-helix 1 is coloured in blue and α2 is shown in cyan.  The 310 
helices are indicated in yellow, β-strands in green and GGQ loop in brown. 
A B 
bacterial RF2. The only difference observed was in the region bridging β2 and 
β3, where ICT1 has 10-residue α-helix (α-1) that is sandwiched between the α-2 
and β-sheets and its existence influences a different angle of α-2 against β-
sheets, which is not present in bacterial RF2. The last α-helix is followed by 
rather unstructured C-terminal region of basic residues, which could be involved 
in direct ribosome binding or sensing stalled ribosomes as has been shown in 
the E. coli ICT1 homologue, YaeJ (Handa et al., 2011).  
Following on from Richter et al. (2010) findings and trying to elucidate the 
function of mtRF1 in mitochondria, its 3D structure has been modelled in the 
ribosome. The structural differences between mtRF1a and mtRF1 developed a 
hypothetical function of the factor. Based on the structural implications, mtRF1 
is only likely to bind to the A-site of the ribosome and exert its function if there is 
no mRNA present (Huynen et al., 2012). The translation of truncated, stop-
codon less mRNA would result in such an empty A-site and stalled ribosomes.  
As mentioned above, mechanism of recycling stalled ribosomes is not known in 
mammalian mitochondria, therefore ICT1 and now mtRF1 became positional 
candidates to release this biological dilemma. The last member of the 
mitochondrial release factor family is the C12orf65 protein. Even though 
mutations in this protein has been found in two patients diagnosed with an 
encephalomyopathic mitochondrial disease (Antonicka et al., 2010), and the 
solution structure of a mouse form has been determined (Kogure  et al., 2012) 
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its physiological function remains unknown. C12orf65 was also characterised by 
the presence of a GGQ motif, the structural topology of which more resembles 
that of RF than ICT1. NMR shows that β2 and β3 in C12orf65 are connected by 
6 residue turn that is similar to ICT1, an unstructured C-terminal extension (see 
chapter 7.1). 
Homozygosity mapping and DNA sequence analysis identified two different 1bp 
C12orf65 deletions in two patients, both resulting in premature truncation of the 
protein. The molecular phenotype was mirrored in a decrease in complex I, IV, 
V and III assembly. Steady state levels of mitochondrial transcripts, tRNAs, 
rRNA as well as ribosomal proteins and elongation factors were not reduced. 
The assembly of complex I, V, III and IV could be only partially rescued by over-
expression of ICT1, but not by mtRF1 or mtRF1a. C12orf65 does not show any 
detectable peptidyl-tRNA hydrolase activity when tested on bacterial ribosomes 
using any codon or no codon in the in vitro assays (Antonicka et al., 2010). 
Since it has now been shown that there is only one human mitochondrial 
release factor, mtRF1a, that is both necessary and sufficient to terminate 
translation of all 13 open reading frames, the presence of the 3 remaining family 
members is an intellectual dilemma as they are left with uncharacterised activity 
(mtRF1, ICT1 and C7orf65). Even though ICTI 1 has already been shown to be 
an integral part of 55S (Richter et al., 2010) its exact function in this context 
along with that of C12orf65 and, more importantly, mtRF1 still remains 
unanswered. 
 
1.3.  Overview of gene expression quality control 
Unlike the distinguishable aberrant mRNA, such as those lacking a 5' cap or 3' 
poly(A) tail that are highly unlikely to be introduced into a translation process, 
mRNAs with more subtle errors are more difficult to be easily discriminated. 
Thus, in order to minimize those errors and the detrimental effects that 
translation those aberrant transcripts may have, cells have evolved the 
mechanism to monitor transcripts for degradation during translation (Keiler et 
al., 1996 and reviewed by Nicholson et al., 2012). Most of those mechanisms, 
termed mRNA surveillance, directly implicate translation in the process, due to 
the fact that factors involved act directly on the ribosome itself. In bacteria there 
are three distinct pathways, the most characterized depends on a functional 
RNA, tmRNA (transfer-messenger RNA) and others less studied pathways 
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depend on release factors homologues (Pech and Nierhaus, 2012). Eukaryotes 
have been identified to have three distinct surveillance pathways each of which 
act on different aberrant mRNA substrates (Isken and Maquat, 2007). Even 
though the mechanism of ribosome rescue differs between the prokaryotes and 
eukaryotes, the outcomes of the pathways are conserved.   
1.1.1. Prokaryotic mRNA surveillance pathways 
1.1.1.1. Trans translation 
The most universal and best characterized system in bacteria to rescue stalled 
ribosomes at the end of non-stop mRNA is the classical tmRNA/SmpB system 
(Keiler et al., 1997). It mostly depends on action of bi-functional transfer-
messenger RNA (tmRNA) that is also known as SsrA or 10Sa RNA and is 
highly structured with properties of both tRNA and mRNA. It also recruits other 
molecular partners such as EF-Tu, SmpB protein and alanyl-tRNA synthetase. 
The essential parts of the tmRNA for its function are its 5’ and 3’ ends. The 
folding of these domains forms tRNA-mimic and an mRNA strand (Felden et al., 
1997; Komine et al., 1994). The tRNA domain does not contain anticodon loop, 
like conventional tRNAs, but includes an acceptor arm that can be 
aminoacetylated at its 3’ terminus, with recognition sites for EF-Tu and SmpB, D 
loop and a T arm. The connector stem links the tRNA mimic domain with the 
rest of the molecule, mRNA-linker domain, which contains between several 
pseudoknots (PKs) and helical stems, a short internal open reading frame 
(ORF) that functions as mRNA template (Figure 1.8 B). While the function of the 
pseudoknot is controversial and has been suggested to play a role in overall 
folding, maintaining correct geometry or slowing down the degradation of the 
molecule, the ORF plays a crucial role in tmRNA function (Williams et al., 1999). 
It is the sequence of this ORF that when translated acts as a tag and dictates 
which proteases are going to degrade the protein. When a truncated or 
otherwise defective transcript, such as rare codons, a highly structure mRNA or 
strong interaction between nascent peptide and exit tunnel, causes the 
ribosome to stall and both elongation and termination are prevented, pausing is 
observed for long periods and subsequent pausing-dependent mRNA cleavage 
together with the poor occupancy of the A-site seem to direct the recognition of 
the stalled complex (Hayes and Sauer, 2003; Sunohara et al., 2004a and 
2004b). The trans-translation events, i.e. SmpB-tmRNA-EF-Tu by changing the 
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Figure 1. 8. Trans-translation process in bacteria. 
(A) The model shows stalled ribosome rescue by tmRNA- mediated tagging.(Hayes and 
Keiler, 2009) (B) Simplified tmRNA structure includes tRNA-mimic domain connected (the 
connector stem is not complete) to the pseudoknots and ORF part. Adopted from (Moore 
and Sauer, 2007) 
mRNA template, allow translation to continue. EF-Tu binds the acceptor and T 
arm of the tmRNA, protecting the ester from hydrolysis, as during normal 
translation, and delivers it to the A-site of the stalled ribosome mediating the 
addition of the nascent peptide on to the alanine at tRNA- mimic domain of 
tmRNA (Figure 1.8 A). The binding of tmRNA to the stalled ribosome is 
facilitated by two SmpB proteins that have been shown to bind 23S RNA of 50S 
and 16S close to the anticodon regions of P-site and E-site simultaneously with 
EF-Tu (Valle et al., 2003, Barends et al., 2001). Recent crystal structures of 
tmRNA, SmpB in complex with EF-Tu and the ribosome have shown that SmpB 
mimics codon-anticodon in the absence of mRNA in the A-site (Neubauer et al., 
2012) and upon binding, the conformational changes on the ribosome as well 
as on the tmRNA occur. Consequently, the peptidyl-tmRNA is translocated into 
the P-site, then the first codon of tmRNA ORF is positioned into the A-site 
allowing the addition of the first encoded tag residue and translation resumes as 
with mRNA. The main event facilitating the correct translocation and positioning 
of the tmRNA ORF is the unique extra-large swivel movement of the 30S head 
(Ramrath et al., 2012). The hybrid protein product is eventually degraded by 
proteases, e.g. CIpXP and tm-RNA rescued ribosomes are ready for common 
recycling for further circles of translation (Gottesman et al., 1998).   
Apart from the pausing-dependent cleavage there are also other mechanisms in 
bacteria by which active and stalled ribosomes with no mRNA or short 3’ end 
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extensions are discriminated (Ivanova et al., 2004). If the A-site is unoccupied 
or incompletely filled, basic residues of 30S will not interact with the mRNA, and 
so the mRNA entrance tunnel, due to conformational changes, stays open 
allowing tmRNA ORF access. The opening also seems to be partially 
accompanied by the actions of EF-Tu (Ramrath et al., 2012).  In the scenario 
where a ribosome stalls at the 3’ end that is about 20 bases and it emerges 
from the mRNA tunnel, ribosome pausing occurs triggering the cleavage by 
RelE toxin. That enzyme is then able to cleave A-site codon, but action of this is 
normally regulated by ReLB antitoxin expression. It has been shown that RelE 
cleavage can create more active substrates and increase tmRNA recognition 
(Ivanova et al., 2004). Such pausing-depended cleavage by RelE has been only 
shown by E. coli, whereas other strains lacking toxin-antitoxin systems can still 
cleave stalled mRNA and rescue ribosomes with tmRNA.  It is possible, 
therefore, that after a long translational pause the ribosome itself is able to 
cleave mRNA in the A-site or that another rescue pathway resolves such 
problems. 
 
1.1.1.2. Other ribosome-rescue pathway 
In addition to the tmRNA/SmpB system there are other two rescue mechanisms 
found in bacteria that free stalled ribosomes and seem to be mostly dependent 
on release factor homologues. The first such novel protein characterised in E. 
coli, YaeJ, has been shown in vitro to hydrolyze peptidyl-tRNA from stalled 
ribosomes on non-stop mRNAs as well as on rare codons occupying the A-site. 
This action would block the ingress of Ala-tmRNA/SmpB. In vivo, yaej as a 
multicopy gene, it is also able to suppress the lethal phenotype of ssrA arfA 
double mutant (Chadani et al., 2011, Handa et al., 2011). YaeJ is a small basic 
protein that is similar in sequence and structure to domain 3 of the class I type 
RF (ICT1 is its mitochondrial orthologue)(Richter et al., 2010a). It contains the 
GGQ motif and missing domains 2 and 4 are replaced with unstructured C-
terminal basic residue-rich extension. It therefore functions as a codon 
independent factor and has been renamed ArfB, an alternative ribosome factor 
B. It was shown to bind ribosomes tightly and mutations in the GGQ and 
deletion of C-terminal tail eliminated the ribosome rescue activity (Chadani et 
al., 2011). Recent crystal structure of the protein bound to 70S reveals 
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Figure 1. 9. Structure and ribosomal binding of alternative ribosomal rescue factors.  
(A) Binding of the ArfB to the ribosome according to Gangon et al., (2012). (B) Proposed 
arrangement  of ArfA with RF2 on the ribosome. Both images adopted from (Pech and 
Nierhaus, 2012). 
A B 
mechanism by which the ribosomes are rescued. The C-terminal was shown to 
bind the mRNA entry channel downstream of the A-site, between the head and 
the shoulder of small ribosomal subunit, which suggested that it samples the 
pocket to discriminate between active and stalled ribosomes (Figure 1.9A) 
(Gagnon et al., 2012). In addition, it was shown to function in vitro on stalled 
ribosomes with an empty A-site as well as on stalled ribosomes with mRNA of 
sufficient length (Shimizu, 2012).   
The synthetic lethality screening by (Chadani et al., 2011) have shown that E. 
coli cannot survive simultaneous deletion of SsrA (tmRNA) and YhdL (novel 
rescue factor) genes. The latter has been named accordingly ArfA and was 
demonstrated to rescue stalled ribosomes in vivo and in vitro on non-stop 
mRNAs. Moreover, ArfA associates with the large subunit, but it does not have 
the typical GGQ motif to mediate peptidyl hydrolysis. Thus ArfA functions in 
collaboration with RF2 (Figure 1.9 B), which can only bind to the stalled 
ribosome with an empty A-site in the presence of ArfA (Shimizu, 2012; Chadani 
et al., 2012). Thus, it was suggested that the ArfA binds an empty A-site first, 
possibly associating with tRNA in the P-site and recruits RF2, which in turn 
catalyses the hydrolysis to release the polypeptide chain in a codon-
independent manner.      
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Figure 1. 10. Models for Nonsense-mediated decay.  
(A) First EJC model and (B) 3'UTR model, both described in the main text.   
A 
B 
1.1.2. Eukaryotic mRNA surveillance pathways 
1.1.2.1. Nonsense-mediated mRNA decay (NMD) 
 The NMD pathway specifically recognizes mRNAs with premature termination 
codons (PTC). There are two models for the mechanisms that define the 
substrate in such cases. Normal stop codons are typically located at the end of 
the most 3' exon of mRNAs and are recognized by exon junction complexes 
(EJC). The close proximity of such junctions to the poly(A) tail and its cognate 
binding proteins act as a positive influence on peptide release under 
physiological conditions. When the close interaction between eRF3 and PABP 
is disrupted by a PTC that is upstream of the normal stop site, ribosome stalls. 
The normal communication between termination factors and the EJC is affected 
so that NMD is invoked and is coordinated by key factors including the UPF 
(upstream frameshifting) proteins, 1, 2 and 3 that modify canonical termination 
(Maquat et al., 2010). The second model proposes that the Upf1 directly coats 
the 3'UTR of the defective mRNA way before it reaches the ribosome providing 
clear target for other factors involved in the process (Hogg and Goff, 2010) 
(Figure 1.10). 
 All key NMD factors (Upf1, Upf2, Upf3) are conserved in eukaryotes, but the 
direct catalytic activity and interaction with termination factors (eRF3 and eRF1) 
has been ascribed only to Upf1 (Weng et al., 1996), whereas Upf2 and Upf3 
have been thought to provide scaffolding for Upf1, thus modulating its activity 
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(He et al,. 1997). In terms of ribosome recovery and ribosome reinitiation Upf1 
also seems to be involved, however it is possible that the canonical recycling 
factors may be recruited by the NMD factors (Ghosh et al., 2010). Nevertheless, 
PTC recognition and the mechanism of its downstream events, as well as 
competition between stimulators of NMD mRNA decay and canonical 
termination factors are not well defined. 
 
1.1.2.2. Nonstop mRNA decay (NSD) 
This pathway functions on mRNA without in-frame stop codons, in which the 
ribosome translates to the end of the transcript due either to its truncation and 
lack of poly(A) tail or if the tail is present the translation runs through the poly(A) 
tail potentially generating a poly-lysine tag (Ito-Harashima et al., 2007; 
Frischmeyer et al, 2002). It has been shown that by translating adenosine 
nucleotides into positively charged lysines there is an interaction with negatively 
charged regions of the ribosomal exit tunnel that results in transient arrests 
during the elongation phase (Lu and Deutsch, 2008). Therefore, poly(A) tail 
read-through is rather referred to peptide-mediated internal stalling, based on 
recognized substrates classified as NoGoDecay (see 1.1.2.3.). Stalls from ‘end 
of nonstop messages’ in yeast are recognized by Ski7p, that specifically binds 
to an empty aminoacyl- site on the ribosome stalled at a transcript’s 3' end, and 
promotes the exosome and the Ski complex to rapidly degrade the truncated 
mRNA (van Hoof et al., 2002). The C-terminus of Ski7 factor is closely related 
to a translational GTPase, such as EF1a and eRF3 and is believed to promote 
ribosome binding, whereas the N-terminus is thought to promote exosome 
recruitment to the ribosome. The poly(Lys) peptides in the exit tunnel arrest 
translation and due to the strong electrostatic interactions it can even stay 
associated after ribosomes disassemble. Such stalling causes Ltn1, an E3 
ubiquitin ligase, to interact with the ribosome and its RING domain is able to 
recruit ubiquitin-charged E2s that in turn mark the nonstop protein with ubiquitin 
for proteolytic degradation by the proteosome (Bengtson et al, 2010). It is not 
known what is the exact signal that allows recognition of the stalled ribosome by 
Ltn1, whether the nonstop mRNA decay machinery components are required 
for this or whether the Ltn1 begins ubiquitylating substrate on stalled 80S and 
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promotes immediate disassociation staying attached to 60S as was mostly 
observed.   
Once the NSD targets mRNA, the transcript is endonucleotically cleaved 
upstream of the stalled ribosome (Gatfield and Izaurralde, 2004).  Messenger 
RNA decay is typically slow, tightly regulated and usually occurs either as 5’->3' 
or 3'->5' degradation. The process is initiated with deadenylation mediated by 
the CCR4-POP2-NOT complex (Chen et al., 2002). This is followed by 
degradation in the 5'-3' that starts with the mRNA cap structure being removed 
by the decapping enzyme Dcp2. The degradation then proceeds with 5' 
exonuclease activity by Xrn1 (Hsu and Stavens, 1993). In 3'->5' degradation, 
deadenylation is followed by the exosome activity, which is a pore-like structure 
and its core domain exerts its exoRNase function (Dziembowski et al., 2007). 
Ski7 has been shown to have a dual role in the pathway and apart from 
recognition of an empty ribosomal A-site, together with Ski2, Ski3 and Ski8 it 
can binds the cytoplasmic exosome (Araki et al., 2001).  
 
1.1.2.3. No-go decay (NGD) 
NGD specifically targets ribosome stalls caused by mRNA with structural 
features such as damaged RNA bases, GC-rich sequences, pseudoknots or 
stable stem loops. More subtle mRNA characteristics such as strings of certain 
codons (mRNA mediated targets) or certain peptide sequences (peptide 
mediated targets) as mentioned above, may also stimulate NGD (Doma and 
Parker, 2006) (Reviewed by Doma and Parker, 2007).  
If NGD complex stalls at the 3' end containing only a limited number of aberrant 
mRNA nucleotides downstream of the P-site, it is recognized and recycled by 
two interacting proteins Dom34 (yeast)/ Pelota (mammals) and Hbs1 (Pisareva 
et al., 2011). Both factors are structurally related to the canonical termination 
factors and they mimic the complexes of eRF1 and eRF3 or even eEF and 
tRNA, supporting the fact that Dom34-Hbs1 complex binds to the ribosomal A-
site (Becker et al., 2011). Dom34 resembles eRF1 and both proteins share the 
sequence similarity of the central and C-terminal domains (CTDs), but differ in 
their N-terminal domains (NTDs). The NTD of eRF1 contains conserved NIKS 
loop that recognizes the stop codon in the ribosomal A-site, whereas NTD of 
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Dom34 harbours an RNA-binding Sm fold that was suggested to trigger 
cleavage (Doma and Parker, 2006; Lee et al., 2007), which in turn would initiate 
mRNA degradation. Therefore Dom34-Hbs1 dissociates stalled ribosomes in a 
codon independent manner. Some further studies could not support that, where 
endonucleotic cleavage is not well understood and the nuclease that mediates it 
is not known (Passos et al., 2009). Hbs1 belongs to the family of eEF1A-like 
GTPases and resembles eRF3. Both proteins share conserved G, II and III 
domains, but differ in NTD (Inagaki and Ford Doolittle, 2000; Tsuboi et al., 
2009). Similarly to eRF3, the direct binding to the ribosome of Dom32 and Hbs1 
increases Hbs1's affinity to GTP and the formation of Dom34-Hbs1-GTP or 
Pelota-aEF1a-GTP complexes promotes the Dom34 and Pelota to adopt 
conformation similar to tRNA, which increases the A-site binding affinity 
(Kobayashi et al., 2010). Further structural studies (Becker et al., 2011) 
demonstrated that upon binding Dom34 together with N-terminal of Hbs1 
directly interact with rRNA and proteins of the tunnel-like mRNA entry site, thus 
possibly monitoring the length or mRNA in this position or marking the complex 
for subsequent events. Despite the similarities to eRF1 Dom34 does not contain 
a conserved GGQ motif. Therefore it is thought that the Dom34-Hbs1 binds to 
the ribosome and by destabilization of mRNA-tRNA interactions it recruits both 
mRNA degradation and additional factors in order to rescue stalled complexes. 
Following the endonucleolytic cleavage of mRNA targeted for NDG, the 3' and 
5' termini are then degraded by Xrn1 and the exosome respectively (Doma and 
Parker 2006). 
Ski7p was originally implicated in Non Stop Decay (van Hoof et al., 2002) but 
since it is found only in a subset of yeast (Atkinson et al., 2008) some data 
suggest that Dom34 and Hbs1 may be involved in release of ribosomes that are 
stalled at the 3'-ends of non-stop mRNAs (NSD) (Kobayashi et al., 2010).  
           
1.1.3. Release factors and protein quality control 
Examination of eRF1, eRF3 and their evolution by sequence similarity, multiple 
alignment and phylogenetic analysis (Atkinson et al., 2008) has revealed that it 
is possible that the three eukaryotic mRNA decay systems have arisen by 
duplication of erf1 and erf3 genes. It has been hypothesized that Dom34- 
mediated NGD was present in the last common ancestor of eukaryotes and 
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archaea, then in early eukaryotes eEF1A was duplicated giving rise to eRF3-
like factor, which as a eRF1 partner was recruited for translation termination 
and from which from NMD have evolved. Further duplication of eRF3 may have 
given rise to Hbs1, which assists Dom34 in NGD. The last gene duplication in 
small subset of yeast may have led to Ski7p possibly as a specialized factor for 
Hbs1 in NSD. 
 
1.4.  The aims of this study 
Since it is now clear that human mitochondria exploit the phenomenon of 
ribosomal frameshifting and therefore mtRF1a is both sufficient and necessary 
for release activity in mitoribosomes, this study aims to investigate the possible 
function of mtRF1 in quality control in relation to rescue of stalled ribosomes or 
aberrant translation in human mitochondria. This work will build on the current 
understanding and the characterization of mtRF1a data along with structural 
knowledge of mtRF1 and surveillance mechanisms in other species. 
In mitochondrial RF1 and RF1a there are versions of the 5- helix sequence 
and the tripeptide (PXT) motifs that have been described as important for 
recognition of termination triplets but these differ from bacterial counterparts 
(not shown) and also from each other (Figure 3.1, chapter 3 sequence 
alignment). Outside these regions much of the amino acid sequence is similar 
possibly providing scaffolding for the crucial motifs. Those similarities could 
facilitate binding of mtRF1 and its possible function on the same ribosomal site 
as mtRF1a has been shown to do (Soleimanpour-Lichaei et al., 2007). 
Moreover, the fact that the highly conserved motifs present in all release factors 
in mtRF1 are extended making the protein larger, i.e. 445aa, than mtRF1a 
(380aa) leads to the assumption that mtRF1 could still interact with A-site. 
However this would only happen if there is more space for it to fit, for instance in 
an absence of mRNA in the decoding centre (DC) (Huynen et al., 2012). 
Truncated mRNA may occur in mitochondria as a result of incorrect 
transcription, misprocessing of polycistronic RNA precursors or/and due to 
exonucleases cleavage (Borowski et al., 2010). If the mt-mRNA transcript is 
truncated the subsequent addition of poly(A) tail fails to generate a termination 
signal. Eventually this results in truncated ORF, stalled ribosome with peptidyl-
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tRNA in P-site and an empty A-site. Therefore an obvious question arises: how 
can mitochondria cope with such a problem? 
In bacteria stalled ribosomes are rescued by tmRNA (Hayes and Keiler, 2009), 
a specialised RNA with properties of both mRNA and tRNA that tags the 
nascent polypeptide chain for degradation and releases it from ribosomes 
enhancing higher efficiency of ribosomal usage. Further, another factor ArfA 
(alternative ribosome-rescue factor), essential for the viability of E. coli in the 
absence of SsrA (tmRNA)-mediated trans-translation has been identified 
(Chadani et al., 2010). It has since been shown that the combination of 
synthetically lethal ssrA and arfA mutations can be suppressed by 
overexpression of another protein YaeJ (Chadani et al., 2011), which is a 
putative RF and ICT1 homologue that also contains a GGQ motif indicative of 
ribosome dependent peptidyl hydrolase activity. Taken all together bacteria 
maintain at least 3 distinct mechanisms by which stalled ribosomes may be 
rescued. However, to date no such mechanisms have been characterised in 
mitochondria 
mtRF1 is of interest as it has been demonstrated to be mitochondrial and also 
its depletion affects not only organelles but cell growth, indicating it to be an 
essential protein (Soleimanpour-Lichaeiet al., 2007). Furthermore, purified 
mtRF1 shows no activity on 70S ribosomes with any of tested codons and yet it 
is still highly similar to the main mitochondrial release factor, mtRF1a. This was 
in stark contrast to the RF assays performed with ICT1 where release activity 
was observed with any codon in the A-site. Thus, we hypothesised that mtRF1 
as a mitochondrial protein crucial for cell survival is a good candidate to play a 
role in the rescue of aberrant transcripts or stalled mitoribosomes. 
mtRF1, C12orf65 and ICT1 are interesting candidates for such quality control 
mechanisms as they have been demonstrated to be mitochondrial and also 
their depletion affects not only organellar function but cell growth, indicating 
them to be an essential proteins. Furthermore, purified mtRF1 or C12orf65 
show no activity on 70S ribosomes with any of tested codons and yet they both 
retain motifs that are highly conserved for release factors as are retained in the 
main mitochondrial release factor, mtRF1a. This was in stark contrast to the RF 
assays performed with ICT1 where release activity was observed with any 
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codon or indeed no codon in the A-site (Richter et al., 2010). Consequently, the 
current hypothesis is that mtRF1, together with C12orf65 and ICT1 are 
mitochondrial proteins that are crucial for cell survival and are candidates to 
function in the rescue of aberrant transcripts or stalled mitoribosomes 
analogous to factors involved in ribosome rescue in bacteria.  
This investigation will focus on the main following aspects: 
 What is the effect of mtRF1 or C12orf65 depletion in human cell lines? 
 Is GGQ important for the function of these proteins? 
 Does mtRF1 or C12orf65 associate with the monosome?  
 And if it does, can it recognise and bind an empty A-site allowing 
subsequent recycling after stalled mitoribosome state? 
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Chapter 2. Materials and Methods 
 
2.1. Plasmid manipulations and use of DNA oligonucleotides. 
Generation of FLAG-tagged constructs in pcDNA5/FRT/TO (i.e. C12orf65-WT-
FLAG, mtRF1a-WT-FLAG, mtRF1-WT-FLAG, mtRF1-GSQ-FLAG and mtRF1-
AGQ-FLAG) was kindly carried out in my host lab prior to the start of the mtRF1 
project. The glutathione-S-transferase (GST)-tagged variant (C12orf65Δ26) was 
kindly prepared by Dr Paul Smith. (GST)-tagged and FLAG- tagged release 
factors GGQ mutants (i.e. mtRF1-AGQ; mtRF1-GSQ; C12orf65-AGQ and 
C12orf65-GSQ) were generated by Site-Directed Mutagenesis using 
QuikChange II Kit (Stratagene Catalog #200523). The fragments of interest 
were amplified by polymerase-chain-reaction (PCR) using the primers in Table 
1. The PCR fragments of tagged ORFs of all targeted genes were cloned into 
BamH1 and Not1 restriction sites of pGEX-6P-1, an E. coli expression vector. 
pcDNA5/FRT/TO with mtRF1/1a GGQ or C12orf65 GGQ-FLAG tagged mutants 
incorporated, were used as templates in both PCR amplification in order to 
clone constructs into E. coli expression vector pGEX-6P-1 and in QuikChange II 
Site-Directed Mutagenesis PCR reaction to generate silent mutations (SM) 
across the siRNA targeting region (primers and siRNAs indicated in Table 1.). 
For bacterial expression of the recombinant matured protein, the mitochondrial 
targeting sequence was removed, hence the ORF of the wild type mtRF1a as 
well as mtRF1 wild type and the mutants lack the N-terminal 32 and 49 amino 
acids  respectively (designated as RF1a Δ32; RF1 Δ49; RF1 Δ49-GSQ; 
RF1Δ49-AGQ). Similarly the open reading frame of the wild type and mutant 
C12orf65 lack 26 amino acids at the N-terminus (C12orf65Δ26; C12orf65 Δ26-
GSQ; C12orf65Δ26-AGQ). Additionally, cleavage of these amino acids removed 
hydrophobic stretches so that the protein was not only corresponding to the 
mature form but was more likely to be obtained in a solution form.  
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Table 2. 1. The primers used for formation of the wild type and mutants 
constructs for this study.  
 _For - 5’ to 3’ _Rev - 5’ to 3’ 
Accession 
No./Image 
clone No. 
mtRF1Δ49 
pGEX6.1   
5’tctctcggatc
ccttcatctgtta
agtaagaattgg3
’ 
5’Ctctccgcggc
cgcttattttgct
gatttaaggtg3’ 
BC042196 
mtRF1a-AGQ  ccagtggagctgc
ggggcagcatgta
aatacc 
ggtatttacatgc
tgccccgcagctc
cactgg 
BC011873 
 
mtRF1a-GSQ ccagtggagctgg
gtcgcagcatgta
aatacc 
ggtatttacatgc
tgcgacccagctc
cactgg 
BC011873 
 
mtRF1-AGQ  ccaaaggagcagc
agggcagcatgtt
aataaaactg 
cagttttattaac
atgctgccctgct
gctcctttgg 
BC042196 
mtRF1-GSQ ccaaaggagcagg
atcgcagcatgtt
aataaaactg 
cagttttattaac
atgctgcgatcct
gctcctttgg 
BC042196 
mtRF1-SM gctagactctacc
aacaaataataga
aaaggacaagcgt
cag 
ctgacgcttgtcc
ttttctattattt
gttggtagagtct
agc 
BC042196 
C12orf65-AGQ ggacacggtccag
cgggccaggcaac
caac 
gttggttgcctgg
cccgctggaccgt
gtcc 
BC062329 
C12orf65-GSQ cacggtccagggt
cccaggcaaccaa
c 
gttggttgcctgg
gaccctggaccgt
g 
BC062329 
C12orf65- SM ctccggctttggg
aaaaattaacatt
gttatccccagga
a 
ttcctggggataa
caatgttaatttt
tcccaaagccgga
g 
BC062329 
Restriction sites are indicated in green (BamH1) and blue (Not1). Red nucleotides 
mirror the GGQ motif and bold indicate the introduced mutations. All primers were 
ordered form EUROGENTEC S.A.  
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2.2. Cell culture 
2.2.1. Cell culture maintenance, storage and microscopy  
Hek293 cells used in this study were cultured in 75cm² tissue culture flasks with 15ml 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma D6429) supplemented with 10% 
(v/v) foetal bovine serum (FBS), 1x non essential amino acids and 50μg/ml uridine. 
HeLa cells and fibroblasts were cultured in Earle’s Minimal Essential Medium (EMEM) 
(Sigma, product M0643) with 10% FBS, 1x non essential amino acids, 50μg/ml uridine 
and 1mM sodium pyruvate. The cells were grown under stable conditions of 37°C and 
humidified 5% CO2 in the presence of 10 μg/ml blasticidin S to maintain the tet 
represor on pcDNA6/TR vector that was already independently integrated into the host 
cell line of HEK293T and the media were changed every 3 days. When the monolayer 
of cells reached 80% confluency the media was removed and the cells were harvested 
in 1mM EDTA/PBS. After pelleting at 230 xg (bench centrifuge) for 4 minutes, cells 
were resuspended in 2 ml of fresh media and for genral maintenance 1/10 of the cells 
were transferred to a new flask (with 15ml fresh media). In order to store the cells for 
later use they were harvested as for splitting and resuspended in 0.5ml FBS with 10% 
DMSO. The resuspension was transferred to the cryostorage vials, which were then 
transferred to -80°C in a container that would gradually lower the temperature and after 
24h were transferred to liquid nitrogen.  
All tissue culture manipulations were performed in a class II cabinet and cells were 
inspected daily under Inverted microscope Axiovert25 (Zeiss). To induce protein 
expression, the cultures were grown in the presence of 1μg/ml tetracycline unless 
otherwise indicated.    
 
2.2.2. Cell counting 
The cells were cultured in 75cm² flasks containing 15ml as described above, or in 
medium lacking glucose but with 0.9 mg/ml galactose. After 3 days an equal number of 
cells were transferred to individual wells in a 6-well plate. The following day was 
designated day 0, and remaining wells were induced with tetracycline. Cells were 
counted by taking 10μl of harvested and resuspended cells and adding to a 
haemocytometer, where 8 peripheral squares were counted and in order to obtain the 
amount of cells per ml, the average value was multiplied by 10,000.  
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Table 2. 2. All siRNAs sequences used for this study.   
  
siRNA-mtRF1#3  CCA GCA GAU UAU UGA GAA ATT 
siRNA- C12orf65  GGG AGA AGC UGA CGU UGU U 
siRNA NT siRNA non-targeting negative control duplex OR-0030-
NEG05 
 
2.2.3. Mycoplasma testing 
Cells were kindly tested for Mycoplasma infection every 3 months by Debra Jones. 
MycoAlert® Mycoplasma Detection Kit (Lonza) was used following the manufacturer’s 
instruction.  In case of an infection, cells were treated with Plasmocin (1:1000) for 
minimum 2 weeks and the Mycoplasma test was repeated. 
 
2.2.4. Forward and reverse siRNA transfection of HeLa and 
HEK293T cell lines. 
The transfection of HEK293-Flp-In™ with siRNA was carried out in 6-well plates or 
75cm² flasks. For each transfection for 6 well-plate or 75cm² one tube was prepared 
with 250µl or 1.5ml Opti-MEM® I+Glutatmax™I (Gibco 51985-026), 2.5µl or 15µl 
desired siRNA and 2µl or 12µl Lipofectamine RNAiMAX (Invitrogen), respectively. Such 
a mix was added to an empty flask and incubated for 10 to 20 min at room 
temperature. During this time cells were counted and 30,000 in volume of 1.25 ml 
added to each well or 900,000 in volume of 7.5 ml per a 75cm² flask. After 3 days the 
cells were harvested or retransfected. For further treatment forward transfection was 
carried out. The old media was removed and the same volume of fresh one replaced 
with the same amount of siRNA and transfections reagents.  
All siRNAs were custom synthesised by Eurogentec (Table 2.2) and stored as 20 μM or 
100 μM stocks in RNase free water at -20°C. 
 
 
2.2.5. Stable Transfection of HEK293-Flp-InTMT-RexTM cells. 
In order to generate a stable cell line with pcDNA5/FRT/TO Tetracycline inducible 
expression vector (Hygromycin and ampicillin resistance, Invitrogen) containing the 
gene of interest, HEK293-Flp-InTMT-RExTM were co-transfected with pcDNA5/FRT/TO 
and pOG44 (Ampicillin resistance) using the ration of 1:7.5 and following the protocol 
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Table 2. 3. The buffers and media components used.  
Luria- Bertani (LB) medium –pH 7.5 ‘Rapid lysate Buffer’ 
-1% Bacto- tryptone 
-0.5% Yeast extract  
-1% NaCl   
-( for plates – 2% agar) 
-50 mM NaOH 
-0.5% SDS  
-5 mM EDTA  
-10% Glycerol  
-0.025% bromocresol green 
 
 
 
 
 
 
 
 
 
from Qiagen (Superfect Transfection Reagent Handbook). Stable inducible 
transfections of HEK293T cells for mtRF1-GSQ and mtRF1-AGQ were kindly carried 
out by Ricarda Richter.  
 
2.3. Bacterial strains and general bacterial culture  
All bacteria were grown on LB (Table 2.3) agar plates or LB media. For amplification of 
plasmids bacteria were grown in suspension with appropriate antibiotics at 37°C, 
usually overnight. For a longer storage bacteria were frozen in LB media containing 15 
% (v/v) glycerol at -80°C. 
 
2.3.1. Transformation of bacterial strains with plasmids. 
 
Transformation of chemically competent cells with pGEX-6P-1 (Amersham Bioscience), 
an IPTG inducible expression vector used for production of N terminal GST fusions of 
proteins of interest was carried out following manufacturers’ instructions (Bioline α-
select chemically competent cells, BIO- 85025). E. coli expression strain Rosetta (DE3 
pLysS, for inducible overexpression of recombinant GSTfusion protein, Novagen) was 
transfected with 100 ng of DNA and further steps were followed as recommended by 
the manufacturer. For longer storage bacteria with the plasmid of interest were 
immortalised as described earlier. 
  
2.3.2. Colony screening 
In order to find colonies with a desired plasmid, bacteria were lysed in 25μl ‘rapid lysate 
cracking buffer’ (Table 2.3). The clone and buffer were mixed by short vortexing, 
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incubated for 30 minutes in 68°C followed by another mixing by vortex. The lysed 
bacteria were pelleted at 13,000 g for 8 minutes and 18μl of supernatant was dry-
loaded on a 0.75% agarose gel (without ethidium bromide), followed by the 
electrophoresis at 65V for 40 minutes. The gel was then stained with 0.2μg/ml ethidium 
bromide for 15 minutes and washed twice in dH20 for 5 minutes and analysed under 
UV light. 
 
2.3.3. Plasmid DNA purification 
Once colonies with plasmids of interest were identified, the bacteria were grown in 5ml 
LB-ampicillin overnight at 37°C. The plasmid DNA was isolated from bacteria using the 
Wizard PlusSV Minipreps kit (Promega A1460). The plasmid DNA was finally eluted in 
50μl of dH20 and used to transform Rosetta Cells.  
 
2.4. DNA manipulation  
2.4.1. Polymerase chain reaction (PCR) 
All PCR reactions for cloning purposes used proof-reading DNA polymerase, and were 
carried out in 0.5 ml thin-walled tubes with final volumes of 50μl for each reaction. All 
reaction preparations were performed in a UV- sterilised cabinet. Components and 
conditions under which both PCR were carried out are listed in Table 2.4  
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Table 2. 4. PCR components and conditions. 
  PCR for cloning (Novagen) 
-proof-reading KOD DNA polymerase 
PCR thermal conditions Initial denaturation - 95°C: 2 min.  
Denaturation - 95°C: 30 
sec. 
Annealing   - 55°C: 30 sec.  
Extension   - 70°C: 45 sec. 
 
    30 cycles 
Final Extension      - 70°C: 5 min. 
Storage                  - 4˚C until stopped 
Components and final 
concentrations per reaction  
-1x buffer for KOD HotStart DNA Polymerase 
-1.5mM MgSO4 
-0.2mM dNTPs 
-1U KOD Hot Start DNA Polymerase  
-1μM primer – forward 
-1μM primer – reverse  
-50ng DNA template  
 
 
 
2.4.2. Purification of PCR products  
PCR products were purified either straight from PCR reaction (if there was single DNA 
product of the correct size when analysed by agarose gel electrophoresis) or excised 
and extracted from 1% low melting agarose gels. In both cases the centrifugation 
procedure was carried out as described in QIAquick PCR Purification Kit (QIAGEN 
Catalogue #28106) or QIAquick Gel Extraction Kit (QIAGEN Catalogue #28706), 
respectively. 
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2.4.3. Restriction enzyme digestion  
The digestion reactions were incubated at 37°C for 5h or overnight. 1 U of restriction 
enzyme was used to digest 1μg of DNA in the final volume of 10μl to 25μl where the 
amount of DNA varied from 0.2μg to 10μg. The enzymes used in this study were NotI 
and BamHI that were provided by either BioLabs or Roche and the conditions for each 
reaction were followed as recommended by the manufacturer. 
 
2.4.4. Dephosphorylation of linearised vectors  
Vectors were 5’ dephosphorylated with 1U Alkaline Phosphate in 1x dephosphorylation 
buffer, both of which were supplied by Roche. Samples were incubated at 37°C for 1h. 
 
2.4.5. Phenol/chloroform extraction and precipitation of DNA  
DNA samples were diluted up to 100μl with dH2O to which 100μl (equal volume) of 
phenol was added. The solution was vigorously mixed by vortexing and to separate the 
phases it was centrifuged for 2 minutes at 14,000 g. The upper aqueous phase was 
carefully removed to a new tube and 50μl of phenol and 50μl of 
chloroform/isoamylalcohol (24:1) was added. The mixture was vortexed and 
centrifuged again. At this stage the aqueous phase was again retained in a new tube 
and in order to ensure complete precipitation of the DNA, 1μl of linear acrylamide was 
added as a carrier with 10μl (1/10 of the total volume) 3M sodium acetate and 250μl 
(2.5 volumes) 100% ethanol, followed by at least 1h of incubation in -80°C. This was 
then centrifuged at 20,000 g, 4˚C for 30 minutes and resulted in pelleted DNA. The 
ethanol was removed and the pellet was resuspended in 10μl of sterile dH2O. 
 
2.4.6. Ligation  
The ligation reaction of linear DNA fragments i.e. digested PCR product with a vector 
was catalysed by T4 DNA ligase in a presence of 1x ligation buffer (both provided by 
Roche) and 1mM ATP in a total volume of 10μl. The molar ratio of insert to vector for 
each sample was 1:3 and 1:6. The samples were incubated at 16°C overnight. 
 
2.4.7. Electrophoresis  
0.7% - 1 % agarose gels and 1% - 3% low- melt agarose gels were prepared by 
dissolving agarose in 1x TAE buffer (40mM Tris acetate, 1mM EDTA pH 8.0) using a 
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microwave. After the gel was dissolved ethidium bromide (0.5μg/ml final concentration) 
was added to facilitate DNA visualisation with UV light. The prepared gel was placed in 
the electrophoresis chamber with 1xTAE buffer, the samples (containing 1x loading 
buffer) and the 1kb ladder (as a molecular weight marker) were loaded and the 
electrophoresed at constant voltage (60 – 80V). 
10x loading buffer: 
- 0.25% bromophenol blue 
- 0.25% xylene cyanol FF 
- 30% (v/v) glycerol 
 
2.4.8. Site Directed Mutagenesis  
To introduce specific mutations into genes of interest the QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene 200523) was used and the manufacturer’s protocol 
followed. The plasmids with mutated genes were used to transform XL1-Blue 
supercompetent cells (Stratagene) also following the manufacturer’s protocol.  
 
2.4.9. DNA concentration measurements and sequencing   
The concentration of DNA samples was measured with Nano-drop Spectrophotometer 
ND-1000, using a molar extinction coefficient of 33 for single stranded DNA and 50 for 
double stranded DNA (40 for RNA). All required sequencing of constructs was kindly 
performed by Agata Rozanska. 
 
2.5. RNA manipulation  
For all RNA work and solutions used water was 0.1% DEPC treated and autoclaved.    
 
2.5.1. Extraction  
All RNA was isolated from human cells using Trizol Reagent from Invitrogen following 
the manufacturer's protocol. In order to resuspend the harvested pellet 0.5ml of Trizol 
was added and it was incubated for 5min at room temperature. Then, after 0.1ml of 
chloroform was added, each sample was shaken by hand for 15s and incubated for 
3min at room temperature prior to 15min centrifugation at 12,000 xg (4°C). A clear 
supernatant was collected and transferred into a fresh tube, to which 250µl of 
isopropanol was added, tubes were gently inverted to mix, then incubated at room 
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temperature for 10min and centrifuged at 12,000 xg for another 10min at 4°C. The final 
pellet was washed with 75% (v/v) ethanol and finally resuspended in 10-20µl of DEPC 
treated water containing 1U of RNAguard per 1µl, then left on ice for at least 30min in 
order to fully dissolve the RNA pellet before freezing.  
If RNA was isolated form gradient fractions (80µl) 240µl of Trizol LS was used and all 
the steps followed the same. Accordingly, 48µl of chloroform and 0.15 ml of 
Isopropanol (to which 1.5µl linear acrylamite was added) were used in further 
steps.The final RNA pellet was resuspended always in 10µl of DEPC treated water 
containg 1U of RNAguard per 1µl.       
       
2.5.2. Northern blotting  
The RNA samples were prepared in 20µl, which contained 1-4µg in 8µl H2O, 1x MOPS, 
35 % (v/v) formamide and 5.5 % (v/v) formaldehyde.The samples are incubated at 
55°C for 15min, cooled down on ice and ethidium bromide (0.1 μg/ μl final) and 1x RNA 
loading buffer were added before loading the samples on the 1.2% (w/v) denaturing 
agarose gel (1x MOPS and 0.9% formaldehyde). The samples were separated at 50 V 
and after 6 to 7 h of elctrophoresisthe gel was rinsed in 5 volumes of DEPC water and 
transferred on a GeneScreen Plus membrane over-night in 10x SSPE buffer. After the 
transfer was completed the membrane was rinsed in 2x SSPE and vacuum baked at 
80°C for 2h followed by prehybridisation in 10ml of  50 % (v/v) formamide, 5x SSPE, 
1% (w/v) SDS and 5x Denhardt’s solution for minimum 2 h at 42°C. 
The RNA was then labelled with 50-100ng of DNA fragment, which was denatured in 
9µl DEPC water at 95°C for 4 min. When cooled down on ice3 μl random hexamer mix, 
5U Klenow DNA polymerase I and 2 μl of 32P dCTP (~ 10-20 μCi, PerkinElmer 
NEG513H) were added and probe incubated at 37°C for 1 h. In order to purify the 
probe, it volume was increased up to 100µl and added to a Nick column to completely 
enter the bed of it. The addition of another 400µl of DEPC water allowed to enter the 
column and the first flowthrough was discarded, while the second flowthrough (the final 
probe) after addition of further 400µl of DEPC water was collected in a fresh tube. The 
activity of the probe was measured by a Cerenkov counter and minimum of 500,000cps 
were added to 10 ml of hybridisation buffer to incubate over night at 42°C. Then, the 
membrane was washed twice for 15min. with 2x SSPE at room temperature and one 
15min washing with 2xSSPE/2%(w/v) SDS at 65°C. If further washes were not 
necessary the membrane was exposed to a screen in the     Phosphor-Imager 
cassette. The radiolabelled RNAs were visualised and analysed using Phosphor-
Imager and Image-Quant software (Molecular Dynamics, GE Healthcare). If reprobing 
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was required the membrane was washed twice in boiling 0.1x SSC and once with 0.1x 
SSC/ 0.1% (w/v) SDS for stripping the old singals. Then the membrane was pre-
hybridised again as described above.  
 
2.5.3. Reverse transcription 
In order to synthesise a cDNA form isolated RNA from cells the reverse transcription 
was used (SuperScript™ First-Strand Synthesis System for RT-PCR from Invitrogen). 
Following the random primer protocol, first the RNA (up to 0.5μg) was mixed with 50ng 
of random hexamers, 1μl of 10 μM dNTP (final concentration 0.5 
μM) to a final volume of 10 μl. The mix was then incubated at 65˚ C for 5 min., on ice 
for 1 min. to add 2 µl of 10x buffer, 2mM MgCl2 (4 µl), 0.1M DTT (2 µl) and RNA guard 
(1 µl). Before 2 min incubation at 25˚C 50 U of Superscript was added to the reaction 
for further incubation at 25˚C (10 min.), 42˚C (50 min.) and finally 70˚C for 15 min.  
 
2.6. Protein manipulation  
2.6.1. Cell lysate preparation  
Following the cell harvesting, the pellets were washed with PBS, and 50µl of cold lysis 
buffer (Table 2.5) was added to ~10mg of wet pellets. If the lysis buffer containing 
Triton X-100 was used then the samples were incubated for 30 min at 4°C on rotating 
wheel. Finally, lysed cells were centrifuged for 10 min at 12,000xg at 4°C and the 
supernatant collected into a new pre-chilled tube. If the lysis buffer contained Nonidet 
P-40 detergent, the samples were vortexed for 30sec and centrifuged for 2 min. at 
2.300 rpm (1100g) at 4°C, then the supernatant was collected in a new pre-chilled 
tube. Samples were snap frozen in liquid nitrogen and kept in -80°C for longer than few 
week storage and in -20°C for more immediate use.  
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Table 2. 5. Lysis buffers used in this project.  
Triton X-100: 
- 50 mM Tris/HCl pH 7.4 
- 150mM NaCl 
- 1mM EDTA 
- 1% Triton X-100 
- PI-Mix, (Roche) 
 -1mM PMSF and 10mM MgCl2 (added before 
use) 
Nonidet P-40 : 
- 50 mM Tris/HCl pH 7.4 
- 130mM NaCl 
- 2mM MgCl2 
- 1mM PMSF 
 - PI-Mix (Roche), 1% Nonidet P-40 
 - benzonase (added before use) 
 
 
 
 
2.6.2. Mitochondrial isolation by differential centrifugation  
The cells for this procedure were seeded, induced with tetracycline where 
applicable, and grown for 2 days in 225 cm² flasks until they reached 80-85% 
confluency. They were harvested and the pellet was resuspended in 2 ml of 
Homogenisation Buffer (0.6 Mannitol, 10mM Tris pH 7.4 and 1mM EGTA) with 
0.1% BSA and 1mM PMSF. This was then homogenised at 4°C in a Glas Col 
Homogeniser (15 passes) using a drill and then the suspension was centrifuged 
at 4°C, 400 g for 10 minutes. The supernatant was saved in a new tube and the 
remaining pellet underwent the step again followed by another centrifugation for 
5 minutes. To pellet mitochondria supernatants were centrifuged at 11,000 g for 
10 minutes, and then washed in 100μl homogenisation buffer lacking BSA and 
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centrifuged again for 5 minutes to be finally resuspended in 100μl 
homogenisation buffer lacking BSA. The obtained mitochondrial suspension 
was treated with 1μg proteinase K per 100μg of mitochondria to reduce 
contamination from cytosolic proteins. Following 30 minutes incubation on ice 
the reaction was terminated with PMSF (2mM final concentration) and washed 
twice with homogenisation buffer.   
 
2.6.3. Protein concentration measurement by Bradford assay 
Protein concentration was estimated by Bradford Assay. 1μl of each sample 
was added to the total volume of 800μl (including 200μl of Bradford- BioRad), 
mixed by vortexing and 2x 200μl aliquots of the solution were loaded onto 96 
well-plate (flat bottom) to be measured in Microplate Reader (Elx800) at the 
absorbance of 595nm. The standard curve was generated by using different 
BSA (bovine serum albumin) concentrations ranging from 0, 2, 5, 10, 15 to 
20mg/ml. BSA standard samples were loaded in duplicate and their 
concentration was measured together with proteins samples.      
 
2.6.4. SDS-PAGE 
Proteins in this study were separated by SDS-PAGE with a 12% or 14% 
resolving gel and 3.75% stacking gel (Table 2.6). The components of the first 
were mixed at room temperature and transferred to the casting apparatus 
(Hoefer/Amersham) with dH2O applied on the top to prevent air inhibiting 
polymerisation and to obtain a level gel interface. After the gel polymerised the 
water was removed and stacking gel was poured in. Before loading, the 
samples were incubated in 1x(final) dissociation buffer (6.25mM Tris-HCl pH 
6.8, 2% SDS, 10% Glycerol, 0.01% Bromophenol Blue and 100mM DTT) for 3 
minutes at 95°C and centrifuged for 1 minute at room temperature. Proteins 
were separated in 1x running buffer (192mM Glycine, 25mM Tris and 0.1% 
SDS) at 80V through stacking gel and 120V through resolving gel. Post 
electrophoresis the acrylamide gels were either stained or used for 
immunodetection.   
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Table 2. 6. SDS-PAGE gel components (for 1 8x10cm gel with 0.75mm 
spacers) 
 12% Resolving Gel  3.75% Stacking Gel  
29:1 30% Bisacrylamide 2 ml  0.625ml  
3.75 M Tris/HCl pH 8.5 0.5ml  ---- 
dH2O 2.395ml  3.02ml  
0.5 M Tris/HCl pH 6.8  ----- 1.25ml 
10 % SDS  50µl  50µl 
TEMED 5µl 5µl 
10% APS  50µl 50µl 
 
 
2.6.5. Coomassie blue and silver staining of polyacrylamide gels. 
For Coomassie Brilliant Blue (CBB) staining, gels were incubated for 15 minutes 
in CBB solution (45% (v/v) methanol, 10% (v/v) acetic acid and 0.2% (w/v) 
Coomassie Blue R) then destained for 2 x 10 minutes in the CBB destaining 
solution (45% (v/v) methanol and 10% (v/v) aceticaAcid). For detection of, as 
low as 5ng proteins, SimplyBlue Safe Stain was used (following the invitrogen –
LC6060, instruction manual for the most sensitive detection).  
For silver staining the gel was incubated in 50 %(v/v) methanol for 1 h, followed 
by the incubation in staining solution (8% (w/v) AgNO3, 1.4% (v/v) NH4OH 
0.075% (w/v) NaOH) for 15 min. Staining solution needs to be make up fresh 
and it is important to prepare it in a spotless glass vessel to notice the change in 
color before it is overstaurated. Before development with 0.055% (v/v) 
formaldehyde and 0.05% (w/v) citric acid (which also need to be make up fresh) 
the gel was washed 5 min for 3 times with dH2O, then the reaction was stopped 
using fixer (45% (v/v) methanol and 10 % (v/v) acetic acid).  
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2.6.6. Western blotting and immunodetection  
For western analysis proteins were immobilised on PVDF membrane 
(Immobilon-P, Millipore Corporation) by wet transfer. Before the gel and 
membrane were placed in between 2 layers of Whatman paper and transfer 
sponges, the separated proteins were equilibrated in 1x transfer buffer (25mM 
Tris, 192mM Glycine, 0.02% SDS and 15% methanol). The PVDF membrane 
was activated in 100% methanol and washed in water and then transfer buffer. 
The transfer was carried out at 100V for 2 h at 4°C in 1x transfer buffer with 
constant mixing. Next, the membrane was blocked in 5% milk in TBS (20mM 
Tris, 0.5 M NaCl) for a minimum of 1 hour at room temperature and proteins 
were decorated with primary antibodies (Table 2.7) at 4°C overnight in the same 
buffer. Following 3 washes in TBS with Tween 20 (TTBS) (each wash for 15 
min.), secondary HRP- conjugated antibodies (DAKO Cytomation) were added 
for 1h incubation at room temperature. The membrane was washed again as 
before and signals detected with the ECL+ kit (Amersham) following instructions 
and visualised using both X-ray Films and PhosphoImager, where signal was 
quantified with ImageQuant programme. 
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Table 2. 7. Antibodies used in this study 
 
Antibodies  Working 
dilutions  
Produced in  
Anti-Mouse/HRP(Dako Cytomation 
P0260) secondary  
1:2000 Rabbit (polyclonal) 
Anti-Rabbit/HRP(Dako Cytomation 
P0339) secondary 
1:3000 Swine (polyclonal) 
Anti-Goat/HRP (Dako Cytomation 
P0449) secondary 
1:2000 Rabbit (polyclonal)  
Anti-NDUFB8/20 kDa SU complex I 
(Mitosciences MS105) 
1:1000 Mouse (monoclonal)  
Anti-Cox II (Molecular Probes 
A6404) 
1:1000 Mouse (monoclonal) 
Anti-porin (Molecular probes 
A31855) 
1:10000 Mouse (monoclonal) 
Anti-mtRF1 (Eurogentec) 1: 2000 Rabbit  (polyclonal) 
Anti-mtRF1a (Eurogentec) 1:1000 Rabbit  (polyclonal) 
Anti-mtRRF (Eurogentec) 1:1000 Rabbit  (polyclonal) 
Anti-FLAG (Sigma F1804)  1:2000 Mouse (monoclonal) 
Anti-MRPS18B (ProteinTech Group 
6139-1-AP) 
1:4000 Rabbit  (monoclonal) 
Anti-DAP3 (Abcam ab11928) 1:1000 Mouse (monoclonal) 
Anti-MRPL3 (Abcam ab39268) 1:2000  Goat (monoclonal) 
Anti- MRPL12 (Eurogentec) 1:1000 Rabbit (polyclonal)  
   
 
 
2.6.7. Overexpression and purification of GST-fusion proteins from 
bacteria for release assay or in vitro ribosome binding  
Transformed Rosetta colonies were grown overnight in 5 ml LB media with 
appropriate antibiotics. To express the proteins 500 ml media containing the 
antibiotics were inoculated with 2x 5ml of overnight culture and incubated for 2- 
2.5 h at 37°C. When the A600 was between 0.4 and 0.5, 1 mM (final 
concentration) of IPTG (isopropyl-1-thio-b-D-galactopyranoside) was added to 
the large bacteria cultures and incubated overnight at 16°C. To harvest cells the 
large cultures were centrifuged at 5,000 rpm (GSA rotor), 4°C for 15 minutes 
and PBS (containing 1 tablet of protease inhibitor cocktail mix, 1mM PMSF- 
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final concentration and 1μl Benzonase) was added to the pellet, which was then 
resuspended by vortexing and incubated on ice for 20 minutes. This was 
followed by 15 pulses of 10 seconds sonication (Soniprep 150) with 18 microns 
amplitude and hard centrifugation at 30,000g in 4°C for 30 minutes. The 
supernatant was filtered (0.45μm filter) and applied to the column (0.5ml of 
Glutathione Sepharose 4B beads). The column was washed with sterile dH2O 
and PBS, and after incubation overnight on a rocking table at 4°C it was 
washed again 5 times with 50 ml PBS containing PI-Mix and 1mM PMSF and 
then washed 5 times with 50 ml PBS. Finally, to release the proteins from GST, 
the column was washed with 600μl of PBS containing 25μl PreScission 
Protease, 1mM EDTA and 1mM DTT. This was followed by collection of elution 
fraction, which was to be used for release assay. The aggregation state of 
purified proteins was measured by dynamic light scattering (Zetasizer 1600). 
The release assay was kindly performed by Professor Zofia Chrzanowska-
Lightowlers. 
 
2.6.8. Dynamic light scattering  
Small aliquots of protein samples (20µl) were measured in low-volume glass 
cuvettes using a commercial Zetasizer 1600 (Malvern Instruments) equipped 
with a He–Ne laser (633 nm, 5 mW). Measurements were carried out at 25°C 
for 70s for 5 times. 
 
2.6.9. Antibody purification 
After the recombinant GST protein was successfully purified as described 
above in section 2.6.7, it was run on the 14% SDS-PAGE and the band of 
interest was cut out of the gel to be used for the Immunisation (performed by 
Eurogentec using their Speedy protocol for Custom Anti-protein Polyclonal 
Antibody Production). After the final bleed was obtained Antibody purification 
was procceded using 'NHS-activated Shepharose 4 Fast Flow' (GE Healthcare 
Life Sciences). After the sepharose beads were added to 10ml BioRad Column 
to a final volume of 0.6ml, they were washed 3 times with cold 1mM HCl.  
Then, the purified earlier protein of interest (1-2mg in elution buffer) was applied 
to the column and incubated overnight at 4°C. The next day the flowthrough 
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was saved and the beads on the column incubated with 0.1M Tris/HCl (ph7.4) 
again overnight. After the blocking was finished, the column with the beads was 
washed 5 times with PBS and 7ml of filterised (using 0.45µm and 0.2µm filters) 
serum with 3ml of PBS were added to the column for overnight incubation on 
the rocker at 4°C. Then, the flowthrough was saved again and the beads 
washed 2 times with PBS, once with Tris-buffer of pH 8.0 (50mM Tris/HCl 
pH8.0, 0.1% Triton X-100, 0.5M NaCl), once with Tris-buffer of pH 9.0 (50mM 
Tris/HCl pH 9.0, 0.1% Triton X-100, 0.5M NaCl) and once with Sodium-
phosphate-buffer pH 6.3 (50mM Sodium phosphate pH 6.3, 0.1% Triton X-100, 
0.5M NaCl ). Finally, in order to elute the antibodies from the column, 5ml of 
Glycine-buffer of pH 2.5 (50mM Glycine pH 2.5, 0.1% Triton X-100 and 0.15M 
NCl) was added to the column and immediately neutralized by adding 1ml of 1M 
Tris/HCl of pH 9.0. In order to concentrate the affinity purified antibodies the 
buffer exchange for PBS was performed using concentration centrifugal devices 
(Millipore). The antibodies were stored in 10% Glycerol and 0.02% of sodium 
azide in 50µl aliquots in - 20°C.        
 
2.6.10. Immunoprecipitation via FLAG moiety 
Cells for this experiment were prepared in 3 x 300cm² flasks and induced for 3 
days with tetracycline as described above. The mitochondria were isolated as 
described above. The pelleted mitochondria were then lysed with 500μl Sigma 
lysis buffer (supplemented with 10mM MgCl2; 1mM PMSF and RNAguar) and 
further steps were performed as described by Sigma (FLAG Tagged Protein 
Immunoprecipitation Kit). 
 
2.6.11. Isokinetic sucrose gradient analysis  
0.5ml of 10% sucrose in 1x buffer (Table 2.8) was added to the Ultra Clear 
plastic tube (for 1ml volume with an open top, Beckman 343778). Using a 
needle with 1ml syringe, 0.5ml of 30 % sucrose in 1x buffer was loaded under 
10 % sucrose being careful not to mix the two. The linear gradient was formed 
by a 55 seconds process called tilted tube rotation (Biocomp Gradient Maker 
instrument; using programme for TL55, 10-30% S1/1 0:55/85.0/22). Such 
gradients were then incubated at 4°C for an hour prior to use. Meanwhile the 
cells were harvested and depending on the pellet size resuspended in 100-
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Table 2. 8. Buffers required for the isokinetic sucrose gradient 
 Components 
10x gradient 
buffer  
 
 
 
 
 
Lysis Buffer  
 
 
 
- 0.5 M Tris-HCl pH 7.2  
-  0.1 M MgOAc  
- 0.4 M NH4Cl 
- 1 M KCl  
- 1mM PMSF and 50μg/ml chloramphenicol  (the stocks 
were prepared in 100% ethanol and stores at -20 °C) 
(both added before use)  
Triton X-100: 
- 50 mM Tris/HCl pH 7.4 
- 150mM NaCl 
- 1mM EDTA 
- 1% Triton X-100 
- PI-Mix, 1mM PMSF and 10mM MgCl2 (added before use) 
  
300μl lysis buffer (Table 2.8). After the cell lysate was incubated for 30 minutes 
on rotating wheel at 4°C it was centrifuged (10 minutes, 12,000g, 4°C) and 
700μg of totlat cell lysate of supernatant was loaded on to the top of the 
gradient. The centrifugation was then performed for 2h 15 min at 4°C at 39,000 
rpm (Beckman bench ultra rotor TLS 55, acceleration 1 and deceleration  4) and 
ten fractions were collected to separate tubes (frozen in liquid nitrogen and kept 
at -20°C until required). 
 
 
 
 
 
 
 
2.7. Statistics  
The standard deviation of all the means obtained from the data in this project 
were calculated using a t-test available on the webpage: 
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http://www.graphpad.com/quickcalcs/ttest1.cfm.  The differences of the 
significance in the results were specified as:  
to be not statistically significant when  p > 0.05, 
as significant (*), when p = 0.01 to 0.05, 
as very significant (**) with  p = 0.001 to 0.01,  
and as extremely significant (***) with p < 0.001. 
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3. Chapter 3: Depletion of mtRF1 in human cells – Does this affect cell 
viability and what are the consequences on mitochondrial 
metabolism?  
3.1.  Introduction 
Mitochondrial Release Factor 1 (mtRF1) is one of four members of the 
mitochondrial release family and one of three factors whose role in translation 
has not yet been characterised. Previous preliminary studies have 
demonstrated that a mtRF1-GFP fluorescence signal that overlapped with the 
mitochondria stained with mitotracker CMH2X-Ros, confirming its mitochondrial 
colocalisation (Soleimanpour-Lichaei et al., 2007). After its original identification 
in silico (Zhang and Spremulli, 1998) mtRF1 was consistently referred to in the 
literature as the only release factor present in the mitochondria. The first 
biochemical characterisation, therefore, attempted to elucidate the function. 
These studies focused on testing mtRF1’s ability to recognise termination 
signals and hydrolyse the ester bond between a P-site tRNA and its amino acid 
moiety in vitro. The substrate was generated with E. coli ribosomes loaded with 
a synthetic AUG start triplet and f[3H]Met-tRNAMET in the P site. To this was 
added a triplet corresponding to the perceived mitochondrial stop codon (UAA, 
UAG, AGA and AGG) and finally the recombinant RF of choice. When mtRF1 
was assessed against the panel of triplets, no free f[3H]Met could be detected to 
indicate any release activity. Moreover, mtRF1 failed to suppress the respiratory 
deficiency caused by loss of endogenous mitochondrial RF1 (Δmrf1) from both 
model yeasts in vivo. Those findings led to a search for the second human 
mitochondrial release factor. The revealed candidate, mtRF1a, was then 
characterised as a mitochondrial factor capable of terminating translation at 
UAA and UAG as demonstrated via the in vitro release assay described above. 
It was also capable of in vivo restoration of yeast (S. pombe and S. cerevisiae) 
Δmrf1 phenotype (Soleimanpour-Lichaei et al., 2007). Further discovery of the 
ability of human mitoribosomes to -1 frameshift proved that mtRF1a is the only 
ribosome-dependent peptidyl-tRNA hydrolase with sequence specificity 
required to terminate all 13 mitochondrial ORFs (Temperley et al., 2010). 
Another member of the mitochondrial release factor family, ICT1, has been 
reported as a codon independent peptidyl-tRNA hydrolase and a mitoribosomal 
protein (Richter et al., 2010). It has been suggested to be involved in a quality 
control mechanism of resolving non-stop mRNA in mitochondria, however, 
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direct examination of such function and further experimental confirmation is 
required.  
The precise function of the fourth family member, C12orf65, remains unknown 
and is the subject of the second part of this thesis. All four factors have been 
classified based on their sequence homology with class I RF. 
Analysis of the mtRF1 sequence and comparison to bacterial release factors 
revealed sequence similarities so that mtRF1 was initially identified as a class I 
sequence specific RF1 type protein (Zhang and Spremulli, 1998). mtRF1 is a 
polypeptide of 445 amino acids with a molecular mass of 52,153 kDa and as 
indicated above, it more closely resembles the prokaryotic RF1-type factors 
rather than lower eukaryotic mitochondrial factors (Zhang and Spremulli, 1998). 
All known class I RFs have a GGQ motif that catalyzes the hydrolysis of the 
ester bond between nascent polypeptide chain and tRNA in the P site (Seit-
Nebi et al., 2001). This motif is also present in mtRF1. There are 2 regions that 
are important in codon recognition. The PXT motif and region of α5 helix in a 
linier alignment separated from each other (Figure 3.1 A) need to come together 
to recognise the A-site codon (indicted by the blue boxes in Figure 3.1 B). 
mtRF1 has extensions in both of these domains and you will need to extend the 
alignment in the figure above. The sequence spanning codon recognition 
motifs, even though highly conserved in mtRF1a, varies in mtRF1 where it 
contains a hexapeptide PEVLGS. The fact the mtRF1 has arisen from a 
duplication of mtRF1a early in vertebrate evolution and that both genes can now 
be found in a number of vertebrates suggests that both are equally essential 
(Young et al., 2010). Moreover the fact that there is high sequence homology 
with mtRF1a, particularly within domains 2, 3 and 4 that are predicted to occupy 
the A-site ribosomal pocket, implies that both factors would occupy the same 
site in the ribosome. This also could be substantiated by the fact that when the 
ribosome was immunoprecipitated by mtRRF, it did not contain bound mtRF1a 
as both factors recognize the same A-site and only 1 could be present at any 
one time (Rorbach et al, 2008). This could also be the reason for mtRF1 not 
being found on those immunoprecipitated ribosomes. Further 3D molecular 
modelling of mtRF1 bound to the ribosome has highlighted the structural 
implications of the differences between mtRF1a and mtRF1, which will be 
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Figure 3. 1Structural comparison between mtRF1a and mtRF1 with their sequences alignment. 
(A) The amino acids sequences of mtRF1 and mtRF1a were aligned with CLUSTAL 2.0.12 multiple 
sequence alignment. The fully conserved RF residues of functional regions between the proteins 
are indicated in bold. Conservations in all three proteins are indicated by an asterisk. Three crucial 
motifs described in the text are coloured, α5 in green, PXT in red and GGQ in yellow.(B) Both 
structures were modelled using SWISS-PDB-Viewer based on available crystallised models from 
PDB through blast selection against ExPDB and show open comrofmation upon ribosome binding 
of mtRF1a and mtRF1. Domains 4 and 2 interact with ribosomal SSU (via sequence recognition 
motives, boxed in blue) and once they are docked domain 3 swings away to deliver GGQ (green 
boxes) at the distal tip of the protein to the PTC on the LSU.  
 
A 
B 
discussed later. The models serve to predict that mtRF1 is able to function on 
ribosomes with an empty A-site (Huynen et al., 2012).   
Taken all together, mtRF1 has been described as a member of mitochondrial 
release factor family and given that mtRF1a is sufficient for all translation 
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termination, it makes searching for a function other than canonical translation 
termination for mtRF1 an interesting, but also challenging study. This first 
results chapter therefore focuses on investigating whether mtRF1 is an 
essential protein that is required for maintaining viable cells and fully functional 
mitochondria and what are the consequences of its loss.  
   
3.2. Effect of mtRF1 depletion on cell growth  
First to answer whether mtRF1 is required for cell viability, transient mtRF1 
gene silencing by siRNA was performed (as described in methods 2.2.4). Three 
siRNA duplexes were designed and synthesised but after initial experiments to 
determine specificity, efficacy and reproducibility, duplex # 3 was chosen to be 
used throughout this investigation. In this project the final concentration used 
was 0.33 µM and the targeting specificity was optimised in my host lab prior to 
the start of my studies.   
A known number of Hek293 cells and HeLa cells were treated with siRNA 
against mtRF1 (si-RF1) then grown in the presence of galactose, rather than 
glucose, to force respiration. Cells were maintained in this medium and after 3 
days examined, after 4 days they were counted or retransfected to maintain 7 
days of depletion. The western blot analysis of isolated mitochondria lysates (5 
and 10 µg) from Hek293T clearly shows depletion of endogenous mtRF1 to non 
detectable levels after 3 days and this very significant depletion was maintained 
over 7 days (Figure 3.2 A). Similarly, mtRF1 was effectively depleted in HeLa 
cells after 3 days of treatment as determined by western blot analysis of 10 µg 
of mitochondrial lysates (Figure 3.2 D).   
The number of the cells decreased dramatically as a consequence of mtRF1 
depletion. After 4 days of treating HEK293T cells, there were twice as many 
control si-NT cells as si-RF1 cells (Figure 3.2) and this effect became even 
more striking after 7 days (p=0.0061**) indicating reduced growth rate. A 
similar, but less profound effect was observed in the experiment with HeLa 
cells, where the number of cells also decreased significantly compared with 
control after 4 days (p=0.0165*) and 7 days (p=0.0250*). Due to the fact that the 
HeLa cell growth defect is less dramatic further investigation focused primarily 
on HEK293T cell line. The morphology and cell phenotype was examined after 
3 days of siRNA treatment and the mtRF1 depleted cells show a significant 
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Figure 3. 2. mtRF1 depletion in HEK293T and HeLa cells.  
Mitochondrial lysate (5 or 10μg) was separated by 12% SDS-PAGE, proteins were transferred to PVDF 
membrane and western blots performed with antibodies against mtRF1 to confirm depletion (si-RF1) 
in HEK293T cells (A) and in HeLa cells (D) after 3 and 6 days compared with non-targeting control 
(NT). Porin and 70kDa subunit of SDH were used as a loading control. The blot accurately reflects 
three experiments. (B) The doubling time in galactose medium of HEK293T (left panel of B, panel 
right shows morphology of HEK293T cells after 3 days of depletion) and HeLa cells (C) treated with 
siRNA directed against endogenous mtRF1 (si-RF1) or non-targeted (NT) siRNA was monitored after 7 
days (day 0 represents initial starting cell number). The mean numbers with standard deviation 
represents three independent experiments (n=3; HeLa day 4 p=0.0165*, day 7 p=0.0250*; HEK293T: 
day 4 p=0.0834; day 7 p=0.0061**).  
                 
A B 
C D 
change (Figure 3.2 B). The mtRF1 depleted cells are elongated and do not 
grow close to each other, which contrasts with the cells treated with siRNA that 
does not target (NT) any transcripts. Together with the decreased cell number, 
the morphology data suggest mtRF1 to be crucial and essential for cell viability. 
This corresponds with earlier findings (Soleimanpour-Lichaei et al., 2007). 
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3.3. Effect of mtRF1 loss on mitochondrial morphology. 
Following on robust decrease in cell growth rate and the overall change in 
phenotype upon mtRF1 depletion, mitochondrial morphology was also 
investigated. In order to assess any changes that might occur in mitochondrial 
organisation following siRNA transfection after either 3 or 6 days HEK293 and 
HeLa cells were stained with two fluorescent dyes. TMRM will enter 
mitochondria in a membrane potential dependent manner and Pico Green, 
which fluoresce upon binding to dsDNA. Staining of DNA with this dye hugely 
depends on DNA conformation, where supercoiled DNA produces lower signal 
as opposed to relaxed circles of this milecule (Reyes et al., 2011). Combined 
staining allows visualization of, the mitochondrial network as well as the nucleus 
and mt-nucleoids. As seen in my previous experiments cells become elongated 
and the mitochondria network of HEK293T cells after 3 and 6 days mtRF1 
siRNA treatment (Figure 3.3 B and C) appear disrupted and more punctate, 
almost granules being placed more at the peripheries of the cells compared with 
mitochondria of HEK293T transfected with NT siRNA (Figure 3.3 A). HEK293T 
cells tend to be more loosely attached to the flask surface when in culture and 
their shape is more round making it more difficult to focus the zoom on one 
plane, therefore HeLa cells, which are generally more flat in culture, were 
incubated with the same dyes for better network visualisation. Mitochondria of 
HeLa cells treated with NT siRNA represent a characteristic reticular 
mitochondrial network evenly distributed within normal healthy cells (Figure 3.3 
D). This network becomes disrupted into small fragmented units, seen clearly 
after 6 days, which tend to accumulate around nucleus. The experiment was 
performed in non quench mode, where lower dye concentrations were used in 
order to avoid dye aggregation or quenching in mitochondria. Thus the 
prediction would be that the lower fluorescence reflects depolarized 
mitochondria, which seem to be the case with mtRF1 depletion in this 
experiment. However, the directional changes in mitochondrial fluorescence 
cannot be interpreted here as no agent that would affect the membrane 
potential and confirm dye behaviour was used.  
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Figure 3. 3. Morphological changes of mitochondria upon mtRF1 depletion.  
Representative fluorescent images of HEK293T (A to C) and HeLa cells (D to F) after 3 and 6 days of 
mtRF1 depletion with siRNA.  Mitochondria were treated with TMRM to detect mitochondrial network 
(red) and mitochondrial DNA was visualised with PicoGreen, which stains both mitochondrial nucleoids 
and nuclear DNA green. siRNA targeted to mtRF1 led to visible deformation in mitochondrial network 
morphology in both cell lines after 3 and 6 days based on TMRM.      
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Figure 3. 4. Steady state levels of proteins after mtRF1 depletion.  
(A) Western blot analysis of cell lysates (50μg) after 4 and 6 days of siRNA (siRF1 or NT) treatment with 
antibodies against proteins sensitive to mitochondrial translation inhibition (complex I subunit NDUFB8 
and COX II), mitochondrial ribosome proteins (DAP3, MRPS18B, MRPL3, ICT1 and MRPL12) and other 
mitochondrial proteins including mtRF1, POLRMT and mtRF1a. Nuclear-encoded Porin and β-actin were 
used as loading controls. (B) Signals from panel B were quantified with Image-Quant software and the 
diagram represents three repeat experiments.   
 
A B 
3.4.  Investigating the steady state levels of mitochondrial 
proteins 
With the evidence that mtRF1 is an essential protein, the next aspect that 
needed to be considered was: why do cells grow more slowly without this 
protein? With the assumption that mtRF1 plays a role in translation, its 
termination or the quality control of the process, and to further investigate the 
consequences of mtRF1 depletion and the cause of such a robust effect on cell 
growth rate, the effect of the depletion on the steady state levels of 
mitochondrial synthesised proteins, was analysed by western blot.  
Hek293 cells were treated with either siRNA- mtRF1 or siRNA-NT for 4 and 6 
days and 50µg of total cell lysates were separated by SDS-PAGE, followed by a 
transfer and immunodetection of the proteins of interest. The Figure 3.4 B (top 
panel) shows that the transfection with siRNA was efficient and after 3 days 
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there was no detectable signal for mtRF1 (indicated by an arrow in Figure 3.4). 
Apart from this there were not any significant changes in mitochondrial encoded 
protein (COX II) in comparison with the control. There was also no defect in 
other, nuclear encoded, important mitochondrial proteins including mtRF1a, 
POLRMT or NDUFB8. In the absence of antibodies to all the mt-encoded 
proteins, NDUFB8 is used as a highly sensitive marker to defective assembly 
and stability of complex I that occurs in the absence of mt-encoded ND 
polypeptides. Components of the mitoribosome such as MRPL3, DAP3, 
MRPS18B and ICT1 remain stable, but interestingly MRPL12 consistently 
decreased.     
Due to the fact that the results after 3 days of depletion do not directly correlate 
with the severe growth defect observed, a longer 6 day siRNA transfection of 
HEK293 cells was carried out. Since the number of cells (Figure 3.2) after 7 
days treatment was significantly decreased one would predict this defect would 
be reflected on crucial proteins participating in mitochondrial processes. After 6 
days of siRNA treatment, whole cell lysates were again separated by SDS-
PAGE. The level of mtRF1 was dramatically decreased consistent with the 
growth curve data from 7 days of treatment. However, level of mitochondrial 
encoded COX II seems unchanged, with mitoribosomal proteins also being 
stable (MRPL3, ICT1, MRPS18B and DPA3). Whilst the depletion of mtRF1 for 
3 days resulted in a noticeable decrease of MRPL12, the 6 days treatment did 
not show such a profound change. This could be due to the level of mtRF1 that 
was still present in the organelles after treatment and decay rate, as the level is 
clearly higher than seen after 3 days of depletion. This may directly reflect the 
relation between levels of mtRF1 and MRPL12 in cells, which needs to be 
investigated in more depth. One should note here, that since the western blots 
are only semi-quantitative, the signals were measured and histogram plotted 
only in order to confirm the visual inspection that indicated no significant 
differences between signals. 
 
3.5.  Effect of mtRF1 depletion on mitoribosomes 
In light of the observation that depletion of mtRF1 may cause a direct down 
regulation of one of mitoribosomal proteins, MRPL12, as seen in the previous 
section the hypothesis that mtRF1 can really interact with monosomes to rescue 
aberrant translation became stronger. This would predict that loss of mtRF1 
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Figure 3. 5. Depletion of mtRF1 does not affect mitoribosome composition.   
(A) HEK293T cells were treated with mtRF1 (siRF1) or non-targeted (NT) siRNA for 6 days and lysates 
(700μg) separated on 10-30% isokinetic sucrose gradient followed by fraction analysis by western 
blots using antibodies against the small (DAP3) and large mitochondrial subunits (MRPL3, MRPL12). 
(B) In order to confirm mtRF1 depletion in this experiment 50μg of cell lysates (prior to sucrose 
gradient centrifugation) were collected and analyzed separately by Western blot using antibodies 
against endogenous mtRF1 and SDH as loading control. (C) Western blot signals from (A) were 
quantified via ImageQuant software and presented in graphs showing the mean with standard 
deviation for each of 3 mitoribosomal proteins, from 3 independent experiments.  
A B 
C 
would result in accumulation of stalled mitoribosomes, which could be detected 
by western blotting of sucrose gradients as an increased signal corresponding 
to the monosome fraction. Such an arrest may have been sufficient to cause the 
growth defect. To assess whether this was indeed the case, HEK293T cells 
treated with mtRF1 or NT siRNA for 6 days were lysed and separated on 10-
30% isokinetic sucrose density gradient. Separated proteins of interest were 
visualised by western blot with antibodies against polypeptides in the small 
(DAP3) and large (MRPL3 and MRPL12) mitochondrial ribosomal subunits. The 
same whole cell lysate preparation that was used for the gradient analysis was 
also separated independently on SDS-PAGE and analysed using anti-mtRF1 
antibodies, with anti-SDH antibodies as a loading control. As seen in Figure 3.5 
B the depletion was effective as the mtRF1 signal cannot be detected compared 
to siRNA-NT control. The result (Figure 3.5 A) clearly shows a similar pattern of 
distribution of MRPL3 and DAP3 in both experimental (Figure 3.5 A, bottom 
panel) and control gradients (upper panel), after 6 days of knockdown (Figure 
3.5 C) In both cases the SSU, detected by anti-DAP3, migrated to and 
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accumulated mostly in fractions 4 and 5, while a member of LSU, MRPL3, 
migrated to fractions 7, but mostly accumulated in fraction 6. Therefore, based 
on this data mtRF1 depletion did not contribute to detectable accumulation of 
monosomes. Interestingly, the decreased levels of MRPL12 did not affect the 
composition of monosome as visualised by the sucrose gradient, where there is 
still a signal detected in fraction 7 (Figure 3.5 A) in both samples siRF1 and NT 
treated. The free form of MRPL12, however, as seen in fractions 1 and 2 in the 
siRNA-NT (Figure 3.5 A, top panel) is present at a very low level after 6 days of 
mtRF1 depletion.         
 
3.6.  Investigating the steady state levels of mitochondrial mRNA 
The existence of a pool of non-ribosome associated MRPL12 has been shown 
previously (Surovtseva et al., 2011). Its function, however outside ribosomes is 
not yet known but it has been shown to directly interact with POLRMT and 
believed to contribute to activation or increase of transcription (Surovtseva et 
al., 2011). Therefore, due to the decrease of ribosome free MRPL12 upon 6 
days of mtRF1 depletion and in the further search for the cause of growth defect 
seen earlier (section 3.2) steady state levels of mitochondrial mRNAs were 
analysed by Northern blot after 4 and 6 days mtRF1 depletion in HEK293T 
cells, as well as 4 and 7 days mtRF1 depletion in HeLa cells. Overall the 4 days 
depletion of mtRF1 in both cell lines resulted in no loss of stability of all tested 
transcripts. With the exceptions of bicistronic RNA14 (MT-ATP6 in Figure 3.6) 
that is not significantly lower in HeLa cells after 4 days depletion. The rest of the 
steady state transcript levels oscillate around the control levels of mRNAs seen 
in ‘healthy’ mitochondria, which are within experimental error. After 6 day of 
mtRF1 depletion HEK293 cells do not show any significant loss of mRNA 
stability, in fact they show a slight increase of two transcripts (RNA14 and MT-
ND1) and ribosomal RNA (MT-RNR1 and MT-RNR2) with MT-COX1 remaining 
unaffected (Figure 3.6 B). HeLa cells, in contrast, as seen on the histogram 
(Figure 3.6 B, left panel) show a significant loss of stability of MT-COX1, mt-
rRNAs (MT-RNR1 and MT-RNR2) and an increase of MT-ND1 with MT-RNA14.  
However, the signals were measured by Image-Quant software, then calculated 
relative to the controls and resultant histograms are not fully quantitative. These 
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Figure 3. 6. Steady state levels of mitochondrial RNA after mtRF1 depletion.  
(A) Northern blots of total RNA extracted from HeLa cells (3 μg RNA) and HEK293T (4 days -1μg RNA, 6 
days- 6 μg RNA) treated with non-targeting (NT) or targeting endogenous mtRF1 (siRF1) siRNA. The 
blots were hybridised with probes to mitochondrial mRNAs (RNA14, MTCO1 and MTND1), mt-rRNAs 
16S (MT-RNR2) and 12S (MT-RNR1) as well as human 18S rRNA for quality and loading control. (B) The 
signals were quantified and the graph presents mean and standard deviation of three independent 
experiment repeats, which are relative to the mean of non-targeting control, a dotted line (*p <0.05, 
**p<0.01,***p<0.001).    
B 
A 
are included to indicate any subtle changes that might exhibit a trend. 
Moreover, it is clear that the northern blot does not reflect such dramatic 
changes in mRNAs levels. Therefore, apart from the subtle increase of several 
RNAs, there was no obvious pattern that could be detected between the 
different transcripts or treatments.  
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3.7.  Investigating the mitochondrial mRNA distribution on 
isokinetic sucrose gradients at steady state. 
A further aim was to test whether mtRF1 knock-down would facilitate an 
accumulation of the increased mRNA species (seen in previous section) on 
ribosomal subunits or the fully assembled monosome. I aimed to detect this by 
analysing sucrose gradients that would allow RNA distribution, which, if affected 
could reflect the stalled mitoribosome status. This was analysed by preparing a 
lysate from HEK293T cells that had been subjected to siRNA treatment for 6 
days. The lysate was separated though an isokinetic sucrose density gradient 
followed by a western and northern blot analyses of the protein and RNA 
fractions respectively. In order to detect the migration of the mtSSU, mtLSU and 
monosome two probes specific to each rRNA were used (MT-RNR1 and MT-
RNR2) in the northern blot. The signal for mtSSU first appears in fraction 4 and 
distributes evenly down to the bottom of the gradient, where fraction 11 
represents the gradient pellet (Figure 3.7 A). The 16S rRNA partitions to fraction 
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Fiure 3. 7. Northern blot analysis of mitochondrial RNA distribution on gradient after mtRF1 
depletion.  
(A) HEK293T cells were treated with mtRF1 (siRF1) or non-targeted (NT) siRNA for 6 days and lysates 
(700μg) separated on 10-30% isokinetic sucrose gradient. RNA was extracted from each fraction (1-11 
and 1/10 of an input) and analysed on a northern blot using probes to mitochondrial mRNAs (RNA14, 
MTCO1 and MTND1) and 16S (MT-RNR2) with 12S (MT-RNR1), mt-rRNAs. (B) The signals were 
quantified and presented as the graph of mean and standard deviation from three independent 
experiment repeats (*p <0.05, **p<0.01, ***p<0.001).    
 
5, then distributes to the bottom of the gradient. The signals in earlier fractions 
(4-6) represent the free uncomplexed state of each individual subunit, whereas 
signals in fractions from 8 represent the presence of monosomes. This pattern 
of monosome is also seen by the distributions of mRNA, signals of which 
become more intense again, where trapped by the monosome (fractions 8). The 
histogram plotted based on detected signal on northern blot clearly reflects this 
even distribution of both rRNA and mRNA tested between the sample (si-RF1) 
and control (NT in Figure 3.7). Therefore, based on this piece of data 6 days of 
mtRF1 depletion does not appear to affect the migration of the mitoribosomes. 
This recapitulates protein distributions seen in section 3.5. In neither case was 
there strong evidence that mitochondrial transcripts accumulate on monosomes 
following mtRF1 depletion with these conditions.  
 
3.8.  Discussion 
In this chapter that aimed to determine the function of mtRF1, siRNA were used 
to deplete this target protein from human cell lines. As part of this initial 
characterisation, which resulted in a decrease in growth rate after only 3 days 
and was even more dramatic after 6 days, both the cell morphology and 
mitochondrial network were also changed. The approaches undertaken in this 
chapter could not uncover the molecular mechanism responsible for such 
dramatic effects.  
It is commonly known that significant mitochondrial morphological changes can 
be induced by various stress conditions. Moreover, because mitochondrial 
dynamics regulates many specific cell functions, the changes in their 
morphology, such as fragmentation, can play an important role in a variety of 
processes including apoptosis (Youle and Karbowski, 2005), Calcium transfer 
(Park et al., 2001), mitochondrial quality control (Ashrafi and Schwarz, 2012) 
and cell-cycle regulation (Mitra et al., 2009). In addition, mitochondria have 
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been shown to be much less likely to fuse in a depolarized state and could 
undergo autophagy (Twig et al., 2008).  
Mitochondrial quality control and autophagy/mitophagy machinery is a broad 
subject and out of the scope to this thesis. However, it has been shown that as 
a response to the depolarisation of electrochemical potential across the IMM 
(achieved experimentally by addition of the commonly used mitochondrial 
uncoupler CCCP), a complete recruitment of Parkin to the fragmented and 
uncoupled mitochondria occurs, which together with PINK1 eventually leads to 
autophagy (Narendra et al., 2008; Park et al., 2006). Parkin is an ubiquitin E3 
ligase, the activity of which increases when accumulated in mitochondria and 
mediates the formation of 2 polyubiquitin chains. One (K48) is associated with 
proteosomal degradation of a substrate and the second (K63) is associated with 
autophagic degradation (Chan et al., 2011). Parkin is not the only E3 ligase that 
has been linked to mitochondrial dynamics. There is also MULAN, a RING 
finger protein and the small ubiguitin-like modifier (SUMO) E3 ligase (MAPL), 
both of which have been shown to be translocated to mitochondria and 
influence mitochondrial fragmentation (Li, et al., 2008; Braschi et al., 2009), 
however their detailed role is not clear.           
There is growing evidence that the cytosolic ubiquitin/proteasome system (UPS) 
is also a part of mitochondrial surveillance pathways. Accumulation of elevated 
levels of mitochondrial ubiquitinated proteins have been observed when 
proteosome activity was inhibited and many proteins have been identified as 
UPS substrates, such as mitofusin 1 and 2, Mcl1, but also VDAC1, Tom20 and 
Tom70 (Livnat-Levanon et al., 2011; Margineantu et al., 2007; Tanaka et al., 
2010; Chan et al., 2011). In addition to the mitochondria’s own proteolytic 
system in the IMM that degrades unfolded proteins (AAA proteases) (Langer et 
al., 2001) and the proteosome directed degradation of proteins from different 
mitochondrial compartments, another pathway was recently reported. In this 
route mitochondrial derived vesicles transport selected mitochondrial proteins to 
the lysosome. This process does not require depolarization and complements 
mitophagy (Soubannier et al., 2012). However, there is no evidence of the fate 
of proteins that have been stalled on the ribosomes and needs to be degraded.  
In yeast, there has been a specific ribosome-associated E3 ubiquitin ligase 
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characterised that specifically marks nonstop proteins for proteosome 
degradation in the cytosol (Bengtson et al., 2010).  
Given mtRF1 structure and the prediction that it functions on the ribosome as 
part of a mechanism exerting quality control in mt-protein synthesis, it cannot be 
excluded that it may have similar function or at least be indirectly involved. Loss 
of mtRF1 by siRNA depletion would be predicted to unbalance the system. If it 
participates in mitochondrial surveillance pathway, its depletion would result in 
nascent polypeptides being stalled on ribosomes that need to be degraded and 
ribosome recycled. In the data presented in this chapter the accumulation of 
such proteins and ribosome stalling was not observed when monitoring either 
steady state levels of proteins or RNA, or on gradient fractions of proteins or 
RNAs. Also in previous preliminary experiments performed in HeLa cells prior to 
my involvement in the project only a very subtle, not significant increase was 
seen in 35S de novo mitochondrial protein synthesis (data not shown) after 3 
day of mtRF1 depletion. The unaffected steady state levels of mitochondrial 
proteins after depletion of mtRF1 could be explained by the fact that even if 
mtRF1 takes part in translation termination it is not until the stop codon/no 
codon is present in the A-site. Thus, the synthesised polypeptide chain is 
already fully elongated when RF1 may exert its action, and the level of 
synthesised proteins most probably reflects the elongation step rather than 
termination or rescue. By using only western blot analysis it is not possible to 
determine whether the proteins seen on the membranes are folded correctly, 
not truncated or whether they are fully active and able to form complexes. 
Moreover, at this stage it was not possible to assess whether the mitochondrial 
encoded proteins are being trapped in the mitoribosomes and not being 
released and able to be chaperoned properly and inserted into the inner 
mitochondrial membrane. 
Despite the lack of robust effect on the proteins analysed, the superoxide, 
peroxide and mitochondrial mass (all part of the preliminary studies in my host 
lab) were all shown to be elevated upon mtRF1 depletion. Increased ROS can 
cause oxidative damage to mitochondria (mtDNA, lipids, proteins) (Reviewed by 
Parsons and Green, 2010), which in turn can cause release cytochrome c and 
high levels of Ca2+. The changes in Ca2+ signalling can affect mitochondrial 
normal strategic positioning within the cells and result in groups of separate 
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mitochondria grouped in different regions within a cell (Park et al., 2001), which 
was seen in this chapter, i.e. fragmented mitochondria accumulated around the 
nucleus in HeLa cells (Figure 3.3). Increased ROS can also affect membrane 
potential and this can trigger recruitment of E3 ligase to mitochondria to target 
initially proteins stalled on the ribosomes to degradation.  
In order to assess whether such a scenario is plausible, the mtRF1 depleted 
cells would have to be tested for accumulation of E3 ligases, e.g. Parkin. 
Although potentially interesting, more importantly for this thesis, this would not 
shed any new light on the possible mtRF1 function.  For this it is necessary to 
produce the candidate substrate or to try and demonstrate the occurrence of 
blocked ribosomes and truncated/ stalled proteins, which is the focus of the 
following chapters.                      
It is difficult to link the mt-RF1 depletion induced mitochondria fragmentation 
with any of the processes mentioned above that would justify the substantial 
decrease in growth rate. This finding has shown that mitochondrial RF1 is 
essential for cell viability, which confirms its important role for both 
mitochondrial and cell biology. Even though there was no significant difference 
in steady state level of most mitochondrial proteins after 3 days of depletion, 
surprisingly, the mitochondrial ribosome protein MRPL12 (MRPL12) does seem 
to be down regulated at this stage and potentially the levels of mtRF1 could 
reflect or influence the levels of this ribosomal protein. 
The second function of MRPL12 outside the ribosome in mitochondrial gene 
expression and regulation of transcription is still debated. It has been shown 
that some proteins from the mtSSU, MRPLS29 and MRPS30 play a part in 
apoptosis, connecting the mitochondrial translation with cytosolic processes 
(Surovtseva et al., 2011; Koc et al., 2001; Shutt and Shadel, 2010). Based on 
this it is tempting to hypothesize that MRPL12, as suggested earlier 
(Surovtseva et al., 2011), could play similar function to that in bacteria 
(Ramagopal et al., 1976), where accumulation of non-ribosome associated L7 
and L12 can bind RNA sequences inducing ribosome biogenesis. It is possible 
that accumulation of free MRPL12 upon mtRF1 depletion could be an indication 
of similar mechanism, where in principle ribosome stalling events can shift the 
balance between ribosome associated and free pools, in turn signal, either 
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through POLRMT binding or possibly to the nucleus that ribosome biogenesis is 
required to compensate for impaired mitochondria.     
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Is human mtRF1 a ribosome dependent 
peptidyl-tRNA hydrolase? 
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4. Chapter 4: Is human mtRF1 a ribosome dependent peptidyl-tRNA 
hydrolase? 
4.1. Introduction  
Two mitochondrial proteins, mtRF1a and mtRF1 have been shown to be 
localised to mitochondria, however only mtRF1a has been experimentally 
ascribed to have the release factor function and to recognise the two 
mitochondrial termination signals UAA/UAG, which are sufficient to terminate 
translation of all human mitochondrial open reading frames (Soleimanpour-
Lichaei et al., 2007, Temperley et al. 2010). So why do mitochondria still retain 
the other release factors such as mtRF1? It is therefore hypothesised that 
mtRF1 may still function on the A-site of ribosomes but instead of recognising 
specific codons sequences it would only bind there if mRNA is missing from the 
site mediating the rescue of stalled ribosomes.  
Structural studies of bacterial RF1 (Petry et al., 2005) have demonstrated that 
the characteristic loop containing the PXT motif of bacterial RFs faces the 
second and third bases of stop codon, whereas the tip of alpha 5 helix is 
parallel to the first nucleotide of codon, forming ‘molecular tweezers’ facilitating 
codon specificity. Significantly, mtRF1a shows high levels of similarity when 
compared with bacterial counterpart sequence. In addition both of them 
possess i) the GGQ tripeptide found in all release factors that is known to 
promote peptidyl- tRNA hydrolysis (PTH) in the peptidyl-transferase centre 
(PTC) located deep in the large ribosomal subunit, ii) the tripeptide PXT motif 
and iii) share similar alpha 5 domains. By analogy, mtRF1 would use the 
different, PEVGLS hexapeptide motif together with the extended and different 
tip of alpha 5 helix that would be positioned within the decoding centre in A-site. 
This would allow for the prediction that mtRF1 may still act on the ribosomal A-
site. A fundamental aspect of my project was to identify if human mtRF1 can act 
as a peptidyl tRNA hydrolase and whether its conserved GGQ domain is 
functional and therefore required to maintain cell viability.  
The presence of the evolutionarily conserved GGQ motif is a strong theoretical 
indicator that mtRF1 should have retained PTH activity. Frolova et al. (1999) 
have shown that mutations in the highly conserved GGQ motif, present in all 
release factor family members, result in the loss of peptidyl-tRNA hydrolysis 
activity. I therefore decided to use this information to design mutants that would 
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enable me to determine whether the GGQ motif is still significant for mtRF1 
function. The following set of experiments were designed to generate stable cell 
lines that could inducibly express mtRF1-wild type GGQ, mtRF1-AGQ or 
mtRF1-GSQ as FLAG-tagged proteins in human HEK293-Flp in cell lines. The 
cells would be induced to express the relevant protein for 3 days so that a 
growth curve could be plotted to allow me to assess changes in cell metabolism 
caused by a dominant negative effect due to expression of the mutants. 
Moreover, these constructs were designed so that silent mutations would be 
incorporated in to the gene sequence to render these transcripts insensitive to 
the siRNA that is effective against endogenous mtRF1. This strategy allowed to 
me to deplete the endogenous protein and express the mutant at wild type 
levels to avoid any phenotype being only the consequence of over-expression 
of an exogenous protein. Assuming the motif preserves its function, and the 
expressed proteins are localized to mitochondria, mutations in this region would 
be predicted to have the same consequence as depletion (as reported in 
chapter 3) including reduced growth on galactose. One hypothesis was that the 
mtRF1 mutants may engage in the A-site but fail to elicit PTH activity and so 
might remain in the A-site rather than being only transiently associated. To test 
this, the expression of the mutated proteins was induced in vivo for 6 days 
followed by a sucrose gradient analysis to examine the mtRF1 mutants ability to 
associate with the monosomes.  
   
 
4.2. Generation of stable inducible cell lines expressing mtRF1-GGQ-
SM-FLAG wild type or mutant proteins. 
The aim was to determine whether the presence of a mutated GGQ motif can 
have a dominant negative when expressed in cultured cells. It was important, 
however, to make sure that any effect was due to the mutant form of mtRF1 and 
not simply due to the presence of high levels of overexpressed protein. For this 
reason it was necessary to titrate the levels of the FLAG-tagged mtRF1 proteins 
to ensure it was equivalent to the levels of the endogenous mtRF1 that is 
constitutively present in untransfected HEK293T cell lines. Initial experiments 
treated cells for 3 days simultaneously with different concentrations of siRNA-
RF1 (5-50nM), which targets both endogenous and expressed forms, and 
tetracycline to induce expression of exogenous FLAG-tagged mtRF1 proteins. 
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This was intended to deplete the endogenous protein and at the same time 
keep the exogenous protein level low. The latter could be detected by western 
using anti-FLAG antibodies to discriminate between endo/ and exogenous 
protein. Frustratingly, the range of siRNA dilutions tested did not control the 
FLAG-tagged protein to a level comparable to the endogenous amount of 
mtRF1 (Figure 4.1 A). mtRF1 decreased gradually as the concentration of 
siRNA used increased from 5nM to 15nM, however mtRF1 levels were still 
~50% higher than the control untreated HEK293T. Despite increasing the 
siRNA concentration in the range of 30 - 50nM, the level seems to become fixed 
and did not decrease further (Figure 4.1 A). It was clear from this result that a 
different approach needed to be carried out. Thus, to determine whether the 
presence of a mutated GGQ motif can have a dominant negative effect when 
expressed in cultured cells, constructs were generated that would allow 
expression not just of FLAG-tagged versions of mtRF1-GSQ and mtRF1-AGQ 
but versions that would be insensitive to the siRNA. Thus, FLAG-tagged 
versions of each mutant and of wildtype mtRF1-GGQ were generated so that 
each construct included a site directed synonymous silent mutation (SM) in the 
region covered by the siRNA. For simplicity these SM-FLAG variants of mtRF1 
will be described as WT, GSQ or AGQ hereafter unless otherwise specified. 
The endogenous gene would still be targeted but translation of the exogenous 
transcripts would still occur. Inducible HEK293T cell lines were generated for 
each construct. As described above, the expression of the FLAG-tagged 
proteins needed to be titrated to ensure that levels were equivalent to those of 
the endogenous mtRF1 normally present in untransfected HEK293T cell lines. 
To achieve this, the cells were treated as before with siRNA-RF1 (33nM). In this 
fashion the levels of FLAG-tagged mtRF1 could be now regulated by different 
tetracycline concentration added to the cells whilst depleting the endogenous 
proteins, with an overall expression level that reflects the physiological 
condition.  
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Figure 4. 1. Regulating the levels of overexpressed mtRF1. 
(A) HEK293T untransfected or transfected with mtRF1-FLAG and tetracycline induced (3 days) were treated 
with different amounts of siRNA for mtRF1 (0-50nM) for 3 days. Each cell lysate (50µg) was analysed by 
western blot. To show the level of overexpression, anti-mtRF1 antibodies were used along with anti- β-actin 
antibodies as a loading control. (B) Expression was tested in three HEK293T cell lines stably transfected with 
mtRF1 gene containing siRNA resistant mutations and mtRF1-WT (clone # 1-1), mtRF1-GSQ (clone # 3-2) and 
mtRF1-AGQ (clone #1-6). MtRF1-GSQ-FLAG lacking the silent mutation (left panel), used previously, was used 
here as an overexpression control; and porin as a loading control. (C) Different concentrations of doxycycline 
were used to titrate expression of mutant FLAG-tagged mtRF1 proteins, whilst depleting with siRNA and 
levels were analyzed by western blot (50μg of cell lysates). HEK293T untransfected wild type (lane 6 and 7 in 
upper panel; lane 5 bottom panel), mtRF1-WT (lanes 1 to 5 top panel), mtRF1-GSQ and mtRF1-AGQ (lanes 1-
4 and 6-9 respectively, bottom panel) cells were cultured for three days in glucose in the presence of both 
33nM siRNA-RF1 and different amounts of doxycycline. (D) The levels of mtRF1 proteins were measured via 
ImageQuant software. 
 
 
Hek293-FlpIn TRex cells were transfected for a stable integration of the 
A 
B C 
D 
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constructs containing the mtRF1-GSQ, mtRF1-AGQ and mtRF1 wildtype 
variants all with the silent mutation in the siRNA targeted region. Successful 
transfectants were selected over a 2 week period using HygromycinB 
(100ug/ml). Once a population of resistant cells was established a small culture 
was induced with tetracycline for 24 hours to analyse for expression. Cells were 
harvested, a cell lysate prepared and western blot analysis performed with anti-
FLAG antibodies (Figure 4.1 B). Effective expression of mtRF1-WT and both 
mutants was observed and the levels of FLAG-tagged mtRF1 variants could be 
now regulated by addition of different doxycycline concentrations (10ng/ml, 
5ng/ml, 1ng/ml, 0.1ng/ml and 0.02ng/ml) whilst depleting the endogenous 
protein. This way expression could be regulated to only that of the variant and 
only at physiological levels. In Figure 4 where the doxycycline titration 
experiment is presented (Figure 4.1 C), there is clear depletion of mtRF1 
(Figure 4.1 C, lane 6) compared with control (untransfected wild type HEK293T, 
Figure 4.1C lane 7). There is also controlled doxycycline induction of all three 
expressed proteins: using concentrations ranging from 10 to 0.02ng/ml for 
mtRF1-WT (Figure 4.1C, top panel, lanes 1-5), and <1 to 0.02ng/ml for mtRF1-
GSQ (lanes 1-3) and mtRF1-AGQ (lanes 6-8). Based on the western results 
and the quantification of the signals (Figure 4.1 D) it was decided that the 
closest resemblance to endogenous levels of mtRF1 and thus optimal for the 
purposes of this investigation was with induction using 0.1ng/ml of doxycycline 
in all three cases. 
 
4.3.     Mitochondrial import of mtRF1-GGQ-SM-FLAG mutants. 
Before testing the functionality of the conserved GGQ motif in mtRF1 using the 
newly defined induction conditions, it was necessary to determine whether the 
expressed variants were translocated to mitochondria. Cells expressing each of 
the variants were treated with 1µg/ml of tetracycline for maximum induction for 3 
days, then the organelles were isolated and following western blot analysis the 
expressed proteins could be detected via anti-FLAG antibodies. Clear 
expression (Fig. 4.2, lane 1) and efficient translocation of each of the proteins to 
a mitochondrial compartment was shown. This was demonstrated as the FLAG-
tagged proteins were protected from proteinase K treatment (1µg and 4µg; 
lanes 2 and 4 respectively in figure 4.2). However, when the organelles were 
  mtRF1-WT-SM  Y         mtRF1-GSQ-SM  Y        
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lysed with 1%Triton X-100 the proteins lacked protection and were efficiently 
digested in all cases with 4µg of proteinase K (Figure 4.2, lane 5).  
Figure 4. 2. 
Mitochondria import of 
mtRF1-GGQ-SM-FLAG 
mutants. 
 Western blot analysis was 
performed on 10μg of 
isolated mitochondria 
from HEK293T cell lines 
expressing each of the 
gene constructs. Isolated 
mitochondria were 
treated with proteinase K 
(1 or 4μg per 100μg 
mitochondria, lanes 2-5) 
and with 1% Triton X-100 
(lanes 3 and 5), to confirm PK activity or untreated control (lane 1). Anti-FLAG antibodies were used to 
confirm the presence of overexpressed protein in each sample. Porin was used as a loading control. 
 
4.4. Expression of mtRF1-WT-GGQ is required for healthy mitochondria 
and normal cell growth. 
Since the stable transfection of all 3 gene variants and their translocation to 
mitochondrial was successful, the analysis of whether the GGQ of mtRF1 was 
functional could now be performed. Therefore for the following investigation 
0.1ng/ml of doxycycline was used to induce expression of each of the mtRF1 
variants; wild type or GGQ mutants. The cells were simultaneously depleted of 
mtRF1 over 3 days then harvested, cell counts performed, followed by a 
western blot analysis of the cell lysates.  
As seen in the graph (Figure 4.3 B) the depletion of mtRF1 resulted in 
significant growth defect compared with HEK293T-mtRF1-WT treated with NT 
siRNA (Figure 4.3, for RF1-WT+NT vs RF-WT+siRF1 p=0.0059) as observed 
before in chapter 3. If doxycycline was added to bring about the simultaneous 
expression of mtRF1-WT, the cells showed a significant rescue of mtRF1 
depleted cells phenotype (RF-WT+si vs RF-WT+si+0.1 p=0.0006). The cell 
morphology also reflected the rescue. Wild type HEK293T cells (Figure 4.3 A, 
panel a) show the characteristic shape and distribution of healthy cells in 
culture, which is also seen in transfected but uninduced HEK293 treated with 
NT siRNA (A panel b). The depletion of mtRF1 resulted in changed phenotype, 
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Figure 4. 3. Expression of mtRF1-WT-SM-FLAG is required for normal cell growth. 
HEK293Tcells expressing mtRF1-WT were treated with 33nM of either NT-siRNA or siRNA-RF1 and 
induced with 0.1ng/ml of doxycycline where indicated. (A) After 3 days cells images were taken to 
show cell morphology of:- untreated and untransfected cells (a); uninduced mtRF1-WT cells treated 
with non-targeting siRNA (b); or siRNA specific to endogenous mtRF1 (c); and (d) cells depleted for 
endogenous mtRF1 simultaneously expressing mtRF1-WT. (B) To monitor the growth, the cells were 
counted and data presented as a mean ± standard deviation based on three independent experiments 
(**p<0.01, ***p<0.001). (C) Cell lysates (50µg) were analysed via western blot to compare the levels 
of mtRF1 expression in all cell lines. Porin was used as a loading control. 
 
B 
A 
C 
cells became elongated and did not grow close to each other, as seen 
previously in chapter 3 (A panel c). After inducing expression of wild type 
mtRF1 in those cells, where endogenous has been depleted, the cell shape 
more resembled healthy HEK293 cells than those after mtRF1 depletion (A 
panel d). This was also consistent with the relative steady state levels of mtRF1 
as analysed by western. The levels are comparable between endogenous 
protein (with or without NT siRNA) and expressed forms (Figure 4.3 C, lanes 3, 
4 and 1, respectively), while the signal for mtRF1 is undetectable where cells 
were treated with siRNA to mtRF1 (Figure 4.3 C, lane 2).  
The same format of experiment was performed for each of the two GGQ mutant 
versions of mtRF1 (AGQ and GSQ). This was done to confirm the specificity of 
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Figure 4. 4. Expression of mtRF1-GSQ-SM-FLAG mutant does not restore normal cell growth 
following mtRF1 depletion.   
HEK293T cells expressing mtRF1-GSQ were treated with 33nM of either NT-siRNA or siRNA-RF1 (+NT 
or +si, respectively) and induced with 0.1ng/ml of doxycyclin (+ 0.1) where indicated. (A) After 3 days 
cell images were taken to show the morphology of (a) non-targeting or (b) specific to endogenous 
mtRF1 siRNA treatment of transfected but not induced cells; or (c) cells depleted for endogenous 
mtRF1 and simultaneously expressing mtRF1-GSQ. (B) To monitor the growth, the cells were 
counted and the result presented as a mean with standard deviation based on three independent 
experiments. (C) 50µg of cell lysates were analysed via western blot to compare the levels of mtRF1 
expression in all cell lines. Porin was used as a loading control.  
 
           
A 
the rescue described above. The phenotype caused by the depletion was not 
suppressed by expression of either the mtRF1-AGQ or mtRF1-GSQ mutant. 
The HEK293T cells transfected with mtRF1-GSQ, but not induced seem to be 
firmly attached to the surface and show characteristic shape of HEK293T cells 
(Figure 4.4 A, panel a).Growth rate as determined by cell counts shows that 
uninduced HEK293T-RF1-GSQ+NT – labelled NT, had decreased growth 
(Figure 4.4 B) when compared with uninduced HEK293T-WT+NT that is 
represented by 100%. This was due to leaky expression (see discussion) of 
B C 
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A 
FLAG-tagged protein, as can be seen on western blot in lane 2 and 3 (Figure 
4.4 C), where the lower of the two mtRF1 bands corresponds to the 
endogenous form of the protein; the upper corresponds to FLAG-tagged 
mutant. The endogenous mtRF1 could be successfully depleted (Figure 4.4 C, 
lanes 1 and 2) and the levels of expressed GSQ mutant correspond to the 
levels seen in wild type HEK293T cells (Figure 4.4 C, lane 4). The leaky 
expression of the mutant GGQ motif in the NT treated control indicated a 
negative effect even without depleting the endogenous form. Upon depletion of 
mtRF1 in uninduced mRF1-GSQ cells the negative effect was more apparent 
on both the morphology and number (Figure 4.4 A, panels b and B). Further, 
upon subsequent induction of mtRF1-GSQ mutant both the phenotype or cells 
number remained lower than NT treated controls (Figure 4.4 A, panel c and B). 
Similarly, the leaky expression of FLAG mutant also occurred here prior 
induction (Figure 4.5 C, lanes 2 and 3) explaining the decreased growth of 
uninduced HEK293T-RF1-AGQ+NT (Figure 4.5 B).  
Also the expression at endogenous levels of mtRF1-AGQ mutant (Figure 4.5 C, 
lane 4 compared with lane 1) failed to restore the normal cell growth (Figure 4.5 
B) or healthy HEK293T cells phenotype (seen in figure 4.5 A, panel a) following 
the depletion of mtRF1 endogenous form. Therefore, these findings confirm the 
dominant negative effect of both mutants on cell viability and show the 
functional importance of conserved GGQ motif in mtRF1. 
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Figure 4. 5. Expression of mtRF1-AGQ-SM-FLAG mutant does not restore normal cell growth following by 
mtRF1 depletion.  
HEK293Tcells expressing mtRF1-AGQ were treated with 33nM of either NT-siRNA or siRNA-RF1 (+NT or +si, 
respectively) and induced with 0.1ng/ml of doxycycline (+ 0.1) where indicated. (A) Morphology is depicted 
after 3 days cells of (a) non-targeting or (b) specific to endogenous mtRF1 siRNA treatment of transfected, 
but not induced cells and (c) cells depleted for endogenous mtRF1 and simultaneously expressing mtRF1-
AGQ. (B) To monitor the growth, the cells were counted and result presented as a mean with standard 
deviation based on three independent experiments. (C) 50µg of cell lysates were analysed via western blot 
to assess and compare the levels of mtRF1 expression in all cell lines. Porin was used as a loading control. 
 
           
 
C B 
A 
4.5. Expression of mtRF1-GGQ mutants does not affect mitoribosomal 
profile. 
To further analyse any possible effect of the mtRF1 variants, lysates prepared 
from cells expressing each variant were subjected to isokinetic sucrose density 
gradient and the collected fractions were analysed by western blot. I was 
previously unable to detect any evidence of mitoribosome accumulation during 
earlier mtRF1 depletion. It was still possible that mtRF1 acts as a peptidyl-tRNA 
transferase, as the previous results strongly suggested that the GGQ is required 
for protein function. One possibility was that the mutated protein would still be 
able to enter A-site but that this mutation may prevent ester bond cleavage and 
so prevent the aberrant polypeptide chain exiting and blocking the ribosome 
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and its recycling, potentially with the mutated protein still in the A-site. If so this 
would allow detection of mutated mtRF1-FLAG proteins associated with the 
monosomes by western blot. Such blockage of mitoribosomes with mutants 
would be sufficient to affect the system, limit the availability of charged tRNAs 
and explain the cause of the growth defect described here from the negative 
dominant effect of expressed mutants prior to induction and as described in the 
previous chapter.  
As seen in figure 4.6 the majority of endogenous mtRF1 is localised to the top 
gradient fractions, 1-4, (Figure 4.6 A). The position of mitoribosome subunits 
were identified using MRPL3 antibodies for mtLSU and MRPS18B for the 
mtSSU.  Free mtSSU migrates mostly in fractions 8-10, while mtLSU is present 
in fractions 11-12. The majority of all 3 expressed mtRF1 proteins (detected by 
the anti-FLAG antibody) remained in the ‘free’ fractions (1 - 4, trailing to 6) and 
not in mitoribosome associated fractions 12 - 15. Both the wild type mtRF1 
(Figure 4.6 D) and mtRF1- AGQ mutant (Figure 4.6 B) are tailing up to fractions 
9, whereas mtRF1-GSQ migrates up to fraction 6 where the strongest signals 
are detected within fractions 1-4 (Figure 4.6 C). Despite the presence of the 
expressed wild type protein or mutated variants the ribosomal profile on the 
gradient was not significantly affected. In all four cases the majority of MRPS18 
can be observed in fractions 8 and 9 with the overlap of MRPL3 in fractions 10 - 
13 indicating monosome. All membranes were also incubated with antibodies 
against MRPL12 to test its distribution as a response to the mutated expressed 
proteins. The levels of non-ribosome associated MRPL12 are almost 
undetectable in each mutant, mtRF1-AGQ or mtRF1-GSQ. When the wild type 
mtRF1 is expressed the free MRPL12 can still be detected at the top of the 
gradient (fractions 1 - 3, figure 4.6 D), however the signals are decreased 
compared with the control (Figure 4.6 A). This also demonstrates that the 
expression of the mutated forms of mtRF1 negatively affects the levels of 
MRPL12 as seen upon initial depletion in previous chapter and thus confirms the 
functional importance of the conserved GGQ motif in mtRF1.   
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Figure 4. 6. Sucrose gradient analyses of the GGQ mutants. 
(A) HEK293T wild type or (B, C, D) expressing (induced with 1µg/ml tetracycline for 3 days) the mtRF1 
variants as well as the wild type protein were lysed and proteins separated by 10-30% isokinetic 
sucrose gradient. Fractions were then subjected to western blot analysis. To determine migration of 
the small, large and 55S monosomal particles, antibodies against the small (MRPS18B) and large 
(MRPL3, MRPL12) mitochondrial ribosomal polypeptides were used. Signals were visualised in 
fractions 1- 15 (collected from top to bottom). Anti-FLAG antibodies were used to detect expressed 
recombinant proteins. 
 
A 
D 
B 
C 
  
4.6. Discussion 
This project aims to investigate recognition of mRNA-free A site on the 
ribosome by mtRF1, thereby providing some insights into the still unknown 
function of mtRF1. The GGQ tripeptide that is known to promote peptidyl-tRNA 
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hydrolysis in PTC (Schmeing et al., 2005) is characteristic of all release factors 
and an indicator of ribosome dependence, as this motif requires the ribosomal 
environment for activity. It was therefore important to first establish whether this 
motif in mtRF1 was required for function, as this would also confirm the 
interaction of mtRF1 with the mt-ribosome. This chapter demonstrates that the 
GGQ motif in mtRF1 is essential for mtRF1 function. The expression of the 
proteins with mutations within this highly conserved motif failed to suppress the 
phenotype caused by the siRNA depletion of endogenous mtRF1 (Figure 4.4 
and 4.5). In contrast the expression of the wild type FLAG-tagged variant was 
able to rescue the dramatic growth defect (Figure 4.3). The expression of both 
variants, mtRF1-AGQ and mtRF1-GSQ, appeared to be ‘leaky’ in the main 
experiment of this chapter (Figure 4.4 and 4.5), but was not observed either in 
the initial examination of the expression of the mutants shortly after transfection 
or when expression was titrated with the range of doxycycline concentrations 
(Figure 4.1).  
It is often the case that cells, which have been stably transfected to inducibly 
express a gene of interest, demonstrate a basal expression or leakiness. This is 
especially true in tetracycline/doxycycline inducible expression systems (Mayer-
Ficca et al., 2004). One of the causes of the high basal expression under 
noninduced conditions can depend on the site of chromosomal integration, as 
an important factor in Tetracycline promoter regulation, as well as false or 
cryptic promoters (Garrick et al., 1998; Johansen et al., 2002). However, the 
Flp-In System used for this project allows the integration of the gene at a 
specific genomic location. The co-transfection of cells with pcDNA5/FRT/TO-
MTRF1 variant and pOG44 plasmids allows the integration of the gene in a 
specific Flp Recombination Target (FRT) site on the genome of the host cells, 
catalyzed by Flp recombinase from pOG44. The Tet- repressor protein 
expressed by the host cells binds Tet operator and represses the expression of 
the gene until the tetracycline is added to the culture medium. Thus, the mis-
integration in to the genome under controlled condition is unlikely in this case. 
The leaky expression of the 2 mtRF1 mutants however could possibly be due to 
tetracycline traces present in culture media, which cannot be ruled out since 
tetracycline is widely used in veterinarian medicine. It may also result from 
insufficient BlastocidinS treatment resulting in the loss of the Tet repressor. 
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The leaky expression of those genes however can strengthen the finding 
presented here. The presence of mtRF1-GSQ prior to induction (Figure 4.4 C, 
lane 3) has a dominant negative effect on HEK392-mtRF1-GSQ+NT cell growth 
and results in poor morphology of these control cells (Figure 4.4 A, panel a). 
The same effect can be observed in transfected but not induced HEK293-
mtRF1-AGQ+NT control, again due to the leaky expression of mtRF1-AGQ 
mutant. The growth of both cell lines is decreased down to 35-40% relative to 
untransfected HEK293T control, while the growth of HEK293T-mtRF1-GGQ+NT 
(Figure 4.2 B) shows ~71% on average. This confirms that the conserved GGQ 
motif is required for protein function, but also shows that continuous presence of 
not functional mtRF1 in mitochondria can be toxic to some extent. Even though 
the expression of mtRF1-GGQ prior to induction cannot be detected on western 
blot (Figure 4.2 C, lane 2), the growth of those cells after mtRF1 depletion 
seems increased (on average the growth of HEK293T-mtRF1-GGQ cells was 
decreased by 36%, figure 4.2 B) compared with the mtRF1 depletion in 
HEK293T-wilde type in chapter 3, where the cell growth was decreased by 51% 
after 4 days of depletion (Figure 3.1 B). Since all cell lines were cultured and 
treated in the same way, it cannot be excluded that the trace of mtRF1-GGQ 
may still be present in cells prior to induction and therefore it is possible that the 
increase was due to leaky expression of functional mtRF1-GGQ upon depletion 
of endogenous form. Moreover, the morphology of HEK293T-mtRF1-GGQ in 
culture was observed to become more affected with time until the cells were 
aggregating, could not grow in monolayer and it was not possible to distinguish 
single cells. Those cells were harvested, lysed and then tested for the leaky 
expression by western blot (data not shown). The levels of basal expression of 
all 3 variants of protein were detected and appear higher compared with the 
initial experiment presented in this chapter. This suggests that not only the 
presence of non-functional mtRF1 may be toxic, but also the presence of 
functional GGQ at constant low levels without regulating it. As a consequence 
of constant leaky expression of mtRF1-GGQ could result in such affected 
morphology of HEK293T-mtRF1-GGQ over long time. As presented in this 
chapter the basal expression of the mutants was titrated so that they were not 
that different to the levels of the endogenous mtRF1. Although not accurately 
estimated (this was not the priority for the progress of the project), the levels of 
endogenous mtRF1 seem low on western blots, as compared with other 
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proteins, investigation of which this lab is focused on and it is possible that 
these low levels are regulated by physiological conditions. The negative 
feedback mechanism that regulates its level may depend on and reflect the rate 
of formation and accumulation of stalled ribosomes. This can be connected to 
the MRPL12 function outside the ribosomes as discussed in previous section 
(3.8).  
The toxic consequence of mutant mtRF1 in cells is with agreement with some of 
my previous data. One of the aims of my Masters degree project (MRes) was 
the investigation of the other mtRF1 domains that corresponds to the tripeptide 
and -helix motif involved in codon recognition. In order to demonstrate the 
functional activity of 'molecular tweezers' in mitochondrial release factors mtRF1 
and 1a, 2 chimeric proteins were designed. The sequence of the functional 
recognition domains of mtRF1a were exchanged into the backbone of mtRF1. 
This resulted in a chimeric mtRF1 containing the tripeptide PXT (rather than 
PEVGLS) and the -helix sequence from mtRF1a (mtRF1-PKT+α). In a 
reciprocal manner the functional domains of mtRF1 were substituted into 
mtRF1a such that it now contained the hexapeptide PEVGLS of mtRF1 and its 
α5 helix (mtRF1a-PEV+α). These chimeras were designed to test whether the 
mtRF1a domains were sufficient to support RF activity when placed in a 
different backbone or whether there were other regions apart from these 
conserved motifs that were required to facilitate the codon recognition. The 
results demonstrated that not only the substitution of PEVGLS into mtRF1a 
caused the loss of UAA/UAG recognition in vitro, but also overexpression of 
both chimeric proteins resulted in a dramatic growth defect (A. Pajak MRes 
thesis) similar to that seen in both GGQ mutants presented in this chapter (NT 
samples in figures 4.4B and 4.5B). 
Interpretation of the data presented in this chapter has its limits. It was, 
however, possible to determine that similar to the wild type protein, the GGQ 
mutants were not able to bind to ribosomes more than transiently. The sucrose 
gradient experiment also confirmed the fact they were not trapped at the A-site 
of the complex, and confirmed that mitoribosomes were not 'blocked' and 
unable to be recycled. Hence stalled mitoribosomes were not the cause of 
impaired growth due to the presence either mutants or wild type FLAG tagged 
proteins. Even though none of the FLAG-tagged expressed proteins co-
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sedimented with large mitoribosomal subunits, one mutant i.e. mtRF1-AGQ and 
wild type mtRF1-GGQ form a type of tail up to fraction 9, where it overlaps with 
signal for mtSSU (Figure 4.6 B and D). If mtRF1 associates with the ribosome 
transiently and only 'samples' the A site for possible recognition of stalled 
ribosome it is likely that the situation observed in Figure 4.6 represents the state 
after the A-site has been sampled by expressed proteins whilst the majority of 
mtRF1 proteins end up at the top of the gradient as they are dissociated from 
the monosome as the whole complex migrates down the gradient. It is unlikely 
that figure 4.6 represents the actual state and that mtRF1-GGQ and mtRF1-
AGQ mutant bind the free mtSSU, because the majority of the A-site pocket is 
formed by the mtLSU. Moreover, there is no structural and functional rationale 
for release factor to bind mtSSU, which in fact would have initiation factors 
associated (mtIF3 posterior to active 55S disassociation or mtIF2 or both prior 
translation initiation). It could be that those FLAG-tagged proteins (detected in 
fractions 8 and 9 in both figures 4.6 B and D) bound a proportion of the 
monosome population, i.e. those with empty A-sites. This could be explained by 
the mutation in the GGQ motif obliterating the catalytic function (signal in 
fraction 9 of mtRF1-AGQ suggests more mtRF1 at this position compared with 
mtRF1-GGQ in D) and in the absence of the peptide being released, mtRF1 is 
not recognized by factors that would remove it from the ribosome. The 
overlapping signals of mtRF1-GGQ or mtRF1-AGQ in the fractions reflecting 
mtSSU, may suggest some sort of rather not physiological interaction. As 
mtRF1-AGQ is not able to exert its function and due to the extended region 
corresponding to the 'codon recognition', it could have been 'locked' into the 
decoding center of mtSSU (see section 5.1). Then as a result of monosome 
disassociation (with the mutant still bound), the mtRF1-AGQ signal is detected 
in fraction 9 together with mtSSU. The disassociation of the subunits can be 
forced during sucrose gradient centrifugation or by buffers components and 
very often the balance between monosome and free subunits is shifted towards 
the free subunits. This is an unlikely explanation in this case as experiments in 
my host lab have shown that immunoprecipitated 55S do not separate if 
subsequently processed on the same format of isokinetic sucrose gradient. It is 
however a phenomenon that is observed on most of our experiments performed 
from whole cell lysates, and by comparison with published literature suggests 
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that there is a difference between tissues and cells in culture in the proportion of 
free subunits to monosome.  
The above indication of mtRF1 interaction with monosome can be supported by 
the fact that the 'tail' of expressed proteins discussed above is absent in mtRF1-
GSQ mutant (Figure 4.6 B) which reassembles more the migration pattern of 
the endogenous mtRF1 (Figure 4.6 A), levels of which are much lower than 
expressed protein. This difference indicated that the association of mtRF1-AGQ 
and mtRF1-GGQ or their 'tails' were not simply due to an increased amount of 
the protein present in mitochondria at that time. Importantly, it has been shown 
that the mutation of second glycine in the GGQ motif of bacterial RF1 resulted 
in a 3300 fold decrease in catalyzed peptide release rate, but only 800 fold 
decrease was observed when the first glycine was replaced (Shaw and Green, 
2007). Second, within the same study it was demonstrated that mutation of the 
universally conserved nucleotide (G2553) of 23S bacterial rRNA, which directly 
interacts with CCA-end of the incoming aminoacyl-tRNA to promote the 
conformational changes in, and the activation of, the large subunit catalytic 
centre, mediated the 33-fold defect in the peptide release rates (Shaw and 
Green, 2007). It was thus suggested that the productive reorganization of PTC 
can be connected to properties of the GGQ motif in release factors, but the 
existence of other points in RFs to manage the activation of the PTC was also 
possible. The mutagenesis studies of ICT1 (Richter et al., 2010) were also in 
agreement with speculations here, and also with results on bacterial GGQ 
mutagenesis. The protein harboring GSQ mutation (ICT1-GSQ) failed to rescue 
the phenotype caused by the depletion of ICT1 endogenous protein, and ICT1-
AGQ showed a similar level of rescue compared to the wild type ICT1. 
Consequently, if a conformational rearrangement in the active site of 
mitoribosomes is required for high rate hydrolysis and the second glycine 
facilitates this process, it could be that mtRF1-GSQ mutation inhibited the 
promotion of conformation change at this site completely and even the transient 
interaction was not possible, which, resulted in the shorter 'tail' seen in Figure 
4.6. Accordingly, mtRF1-AGQ mutation could hydrolyse at a lower rate and the 
transient interaction with PTC occurs, resulting in a changed conformation 
therefore longer occupation of the mutant protein in the site is possible. The 
longer 'tail' seen in the sucrose gradient analysis may thus be due to this protein 
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coming off ribosomes as they progressed during centrifugation. However, this 
remains a hypothesis and the ability of mtRF1 to bind an empty A-site needs to 
be further investigated, which is the focus of the next chapter.    
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Chapter 5 
 
Does mtRF1 associate with the A-site of 
mitoribosomes, which is vacant due to 
loss of mRNA? 
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Figure 5. 1. A fragment of human mtRF1a and mtRF1 sequence alignment. 
Two motifs α-5 in green and PXT in red interact to form codon recognition in the 
secondary structure of the protein. The crucial differences described in text are in bold.    
Chapter 5:  Does mtRF1 associate with the A-site of mitoribosomes, 
which is vacant due to loss of mRNA? 
5.1. Introduction  
The last chapter showed that mutations in the conserved GGQ motif cause a 
decreased growth rate leading to cell death. Hence, the data thus far clearly 
shows that mtRF1 is essential to maintain healthy cells and its GGQ motif is 
required for protein function. Therefore, it is reasonable to assume mtRF1 
would be able to catalyse nascent polypeptide chain release. Based on the 
proposition that the expanded codon recognition domains of mtRF1 would 
enable it to recognize and bind an empty A-site of mitoribosomes my working 
hypothesis was that mtRF1 may play a role in rescue of aberrant transcripts or 
stalled ribosomes.   
This hypothesis is supported by recent studies (Huynen et al., 2012) using a 
combination of bioinformatics and modelling. The authors used a bioinformatics 
systematic strategy, where a possible differentiation of function in mtRF1 has 
taken place after mtrf1a gene has been duplicated in the course of evolution. 
Most of the identified differences between mtRF1 and mtRF1a were localised to 
the domain 2, which clusters around the codon recognition region. This region 
brings together in space 2 features (PXT tripeptide motif and the -5 helix) that 
are separated by over 60 amino acids in the linear molecule (Figure 5.1) but act 
in concert to discern A-site mRNA sequences. Hence these 2 regions 
harbouring the most critical differences have been selected to create three-
dimensional models of each of those two proteins bound to the A-site of a 
bacterial ribosome.  
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There are amino acids insertions in mtRF1 at each of these two sites that alter 
the conformation of the codon recognition loop significantly. First of all, the -5 
helix is extended by the addition of 'RT'. This threonine points inwards into the 
mRNA binding pocket and in combination with compensatory changes in mtRF1 
causes a complete blockage of the A-site preventing any mRNA binding 
Moreover, the 'RT' insertion has taken place in mtRF1 exactly between two 
residues that in RF1 and mtRF1a interact with stop codons and decoding centre 
of the ribosome. As a consequence, this ‘RT’ insertion provides the key 
stabilization of the catalytic conformation of RF1 upon correct stop codon 
recognition (Huynen et al., 2012). The second addition is in the tripeptide motif 
that is altered to PEVGLS. The consequence is that the threonine side chain of 
PXT motif is replaced with valine in mtRF1, which is not able to make any 
hydrogen bonding with stop codon. The 'GLS' insertion extends the recognition 
loop towards the rRNA to possibly provide stronger stabilization with 
mitoribosome (Huynen et al., 2012).                
According to this model mtRF1 is able to bind at decoding centre of a stalled 
ribosome that lacks A-site mRNA. In this no-mRNA state mtRF1 then stabilises 
itself via interactions caused by the 'RT' insertion to mediate the active open 
conformation of mtRF1, which extends to the PTC and catalyses hydrolysis of a 
‘stalled’ polypeptide chain. This phenomenon, however, could not be shown in 
my previous chapters either by accumulation of stalled product and monosomes 
upon mtRF1 depletion nor did overexpressing wild type form or mtRF1-GGQ 
mutants produce clear results. Therefore it is important to ask how common 
ribosome stalling and subsequent rescue can be in mitochondria?  
As a result of defective or prematurely truncated messenger RNAs, either 
elongation or normal termination is prevented usually due to absence of 
complete codon in the A-site of the ribosome. In bacteria this is rescued by 
tmRNA, ArfA or YaeJ. It has been estimated that during normal exponential 
growth of E. coli ~0.4% of all protein synthesis terminates with ribosome rescue 
by tmRNA and the capacity of that system seems to be 3 or 4-fold greater than 
required for normal ribosome rescue demands (Moore and Sauer, 2005). Thus, 
at the frequency of 1 in every 250 translation reactions resulting in trans-
translation during normal bacterial culture growth, every ribosome in the cell 
translates tmRNA once per cell cycle. Therefore, if there were no way of 
rescuing translational stalls, the blocked ribosomes would be excluded from 
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active pool and eventually all would be queued and trapped on each defective 
mRNA. The half life of paused ribosomes in vivo has been estimated for T1/2 = 
22sec. ± 2.2sec. based on ribosome recycling and peptidyl-tRNA turn over in 
the presence of tmRNA (Brian and Hayes, 2009).  
It is possible that in mitochondria the ribosome stalling and ribosome rescue/ 
recycling are at similar rates, but the 3 or 6 day mtRF1 depletion was not long 
enough to produce detectable results, as shown in earlier chapters. Therefore, 
in order to test the hypothesis that mtRF1 is a candidate to play a role in rescue 
of stalled ribosomes with empty A-sites, this chapter aims to generate a 
substrate for mtRF1 i.e. a vacant A-site on mitochondrial ribosomes in vitro to 
investigate direct interaction with mtRF1.  
  
5.2.  Immunoprecipitation of mtRF1-WT-SM-FLAG to test for interaction 
with mitoribosomes 
It has been demonstrated that mtRF1 was not present in ribosomes 
immunoprecipitated (IP) by either mtRRF-FLAG (Rorbach et al., 2008) or ICT1-
FLAG (Richter et al., 2010). In the first case the A-site is occupied by mtRRF, 
presumably preventing entry of mtRF1. In the second case, ICT1 was 
suggested to be integrated at the surface cavity on the mt-LSU near the exit 
tunnel, which was described as polypeptide-acessible site (PAS), leaving its A-
site accessible. It could therefore potentially act as a tool of testing mtRF1 
binding to isolated mitoribosomes. However, it was first necessary to test 
whether mtRF1 could be seen to interact with ribosomal subunits by IP using 
FLAG-tagged mtRF1 as data suggested in section 4.5 and as predicted by 
Huynen et al., (2012).  
For this expression of mtRF1-FLAG (not containing silent mutations across 
siRNA targetting region) was induced in HEK293T cells for 3 days, then the 
cells were used for immunoprecipitation via the FLAG tag. In order to control for 
any unspecific binding, mitochondrial targetted luciferase-FLAG was used as a 
control under the same conditions. The IP eluate of mtRF1-FLAG (Figure 5.2, 
lane 4) clearly shows that after removing all material that did not bind FLAG-
tagged protein (SNs in Figure 5.2, lanes 3 and 6) mtRF1-FLAG was succesfully 
immunoprecipitated (Figure 5.2, lane 4, indicated by an asterisk) from 
mitochondrial 'input' (Figure 5.2, lane 1). The other bands that can be detected 
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Figure 5. 2. Immunoprecipitation of mtRF1 to detect whether there is a tight association 
with other mitochondrial components. 
HEK293T cells expressing either wildtype mtRF1-FLAG (lanes 1-4) or control mtLuc-FLAG (lanes 5-8) 
were induced with 1μg/ml tetracycline. After 3 days cells were harvested and mitochondrial lysates 
(2mg) were used for immunoprecipitations via the FLAG-tag. 5μg proteins of mitochondrial lysates 
(Mitos), 5% of beads after elution (BAE), 10% of supernatant that did not bind to beads (SN) and 10% 
elution fraction (E) of each sample were separated on 12% SDS-PAGE and visualized by silver stain. 
MtRF1-FLAG and mtLuc-FLAG are indicated by *.     
 
 
by silver staining in the mtRF1-FLAG eluate are also present in eluted fraction 
of mtLuc-FLAG, where luciferase is indicated with asterisk. Taken together this 
indicates only unspecific interactions since no other proteins could be detected 
with mtRF1-FLAG IP. This suggests as do data presented in earlier chapters, 
that mtRF1 does not interact with mitoribosome more than transiently.      
 
5.3.    Analysis of RNA content of ICT1-FLAG immunoprecipitation. 
It has been demonstrated that overexpressed and immunoprecipitated (IP) 
ICT1-FLAG can pull down the mitoribosomes (Richter et al. 2010), therefore it is 
used here as a tool for isolating mitoribosomes and generating a substrate 
mtRF1 could recognize and interact with. In the ICT1 pull-down, however, 
mtRRF was detected at low levels suggesting that some of those 
immunoprecipitated ribosomes could still have mRNA attached. In order to 
increase the degradation of mRNA in those mitoribosomes to facilitate formation 
of an empty A-site, the incubation step of mitochondrial lysates with anti-FLAG 
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beads was extended to 3h. During the procedure the mitochondrial content is 
diluted by the lysis buffer, and so are all the components required for subunit 
disassociation, or association inhibitors such as mtIF3 or mtEFG2. In addition to 
mRNA degradation this extended IP incubation step (3h), was predicted to allow 
free subunits to reform into monosomes, which have no mRNA associated and 
mRNA-free A-sites. In order to test this possibility, ICT1 IP was performed (as 
described in methods section 2.6.10) and prior to 3h incubation divided into 3 
equal samples, which were eluted after 1h, 2h or 3h of incubation with anti-
FLAG-beads. The protein and RNA content of elution fractions (10% and 80% 
respectively) as well as input and supernatant were assessed by western and 
northern blot. The 3 h incubation elution was also assessed to monitor 
monosome reformation on density sucrose gradient. 
 The result as shown by western blot (Figure 5.3 B) was that the majority of both 
mtSSU and mtLSU, marked by DAP3 / MRPS18B and MRPL3 / MRPL12, 
respectively, did not immunoprecipitate after 1h and were washed off and 
discarded in supernatant (Figure 5.3 B, lane 2). However, what was present in 
the 1h IP elution, showed that the proportion of both subunits is clearly shifted 
towards mtLSU compared to the mitochondrial lysate, where proportions are 
fairly equal (Figure 5.3 B, lane 3 and 1, respectively). The MRPS18B signal 
indicating the presence of mtSSU in this elution is barely detectable, suggesting 
that 1h IP was not enough to form monosomes and mostly free mtLSU was 
isolated in this case. After 2h of incubation, the elution contained greater 
amounts of mtSSU (Figure 5.3 B, lane 5), since the IP was via a large subunit 
protein this result indicated increased monosome reformation. There are also 
less free subunits excluded from binding, as seen in the 2h supernatant fraction 
(Figure 5.3 B, lane 4). Finally, after 3h incubation the monosome formation did 
not seem to increase significantly over 2h, however judging from the weaker 
MRPL12 signal in 3h SN (lane 6) compared with 2h SN, there was less free 
mtLSU. Next, northern analysis of RNA content of the same fractions in figure 
5.3 A shows that the 3 mRNAs tested (RNA14, MTCOI and MTNDI) are already 
severely degraded after 2h of IP elution (Figure 5.2A, lane 3), although feint 
bands can still be noticed for all 3 transcripts. Although the levels of rRNA (MT-
RNR1 and MT-RNR2) seem to decrease after 3h incubation (Figure 5.3 A, lane 
5), its quality is comparable with that one from input fraction (lane 1 of the same 
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Figure 5. 3. Analysis of RNA/protein content and migration of ICT1-FLAG 
immunoprecipitated material by isokinetic sucrose gradient. 
HEK293T cells capable of expressing ICT1-FLAG were induced with 1μg/ml tetracycline for 3 days. The 
cells were harvested, mitochondria isolated and lysed (mitochondrial lysate [ML] panel A lane 1; 
panel B lane 1) 2.75mg of which was used for immunoprecipitation via the FLAG tag. The final elution 
fractions were collected after 1, 2 or 3h of incubation. (A) mitochondrial lysate (~800ug, lane 1) prior 
to IP, together with ’flowthrough’ (lanes 2 and 4) and 80% of each elution (lanes 3 and 5) were 
subjected to RNA extraction prior to analysis by northern blot. Probes to mitochondrial mRNAs 
(RNA14, MTCO1 and MTND1); and to mt-rRNAs 16S (MT-RNR2) and 12S (MT-RNR1) indicate the RNA 
content before (lane 1) and after IP (lanes 2-5). (B) 10% of each elution fraction was analysed by 
western blot, where antibodies against MRPL3, MRPL12 and MRPS18B determined the level of co-
immunoprecipitated 39S LSU and 28S SSU respectively. (C) HEK293T total cell lysate (700µg) (Top 
panel) and 80% of the final elution fraction after 3h of incubation (bottom panel) were separated by 
isokinetic sucrose gradient. The fractions (1-10) were analysed by western blot, where antibodies 
against MRPL3 and MRPS18B determined the level of co-immunoprecipitated 55S monosome (F 7 
and 8). 
 
 
 
figure) and more importantly the signals corresponding to transcripts are not 
detectable after 3h in elution fraction (Figure 5.3 A, lane 5).    
This together shows that during the IP procedure, especially with the 3h 
incubation time, mt-mRNA is degraded promoting the reformation of now mt-
mRNA-free monosomes. These were analysed by sucrose density gradient and 
were seen to migrate and accumulate in fractions 7 and 8 (Figure 5.3 C, lowest 
panel) and providing the putative substrate that may be recognisable by purified 
mtRF1.  
 
 
A B 
C 
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5.4.   In vitro binding of mtRF1 to mitoribosomes 
The mitoribosomes prepared in this way could now be used as a substrate for 
mtRF1 binding. For this Δ49mtRF1-GST fusion protein was succesfully 
overexpressed in Rosetta cells as seen in SN fraction in figure 5.3A, lane 1 
indicated by an asterisks at size  ~73 kDa. Binding of the GST-protein to the 
beads (beads before elution [BBE], lane 3) resulted in decreased levels of it in 
the flowthrough (FT) fraction in lane 2, shown in the same figure. After 
enzymatic cleavage of the GST, Δ49mtRF1 was released (Figure 5.4 A, lane 5) 
with a proportion of it still bound to the beads (BAE, beads after elution, lane 4). 
Once pure Δ49mtRF1 was eluted, 70pmol of it was then incubated for 40 
minutes with mitoribosomes bound to FLAG-beads, then washed 3 times before 
the final elution of the immunoprecipitated mitoribosomes from the beads. It was 
shown that even though a proportion of purified Δ49mtRF1 (Figure 5.4 B, lane 
5) was observed in the supernatant fraction that contained proteins that did not 
bind monosome/beads (figure 5.4 B, lane 2) together with low levels of both 
ribosomal subunits, mtRF1 was also present in eluate. The latter corresponded 
to the IP immobilised mitoribosomes (Figure. 5.4 B, lane 1) that were confirmed 
by western analysis signals for MRPS18B representing mtSSU, and MRPL3 
and ICT1-FLAG representing mtLSU. This suggests the Δ49mtRF1 can bind 
mitoribosomes under those conditions. 
The same elution fraction was separated by sucrose density gradient where 
Δ49mtRF1 appeared both as a free form on the top of the gradient and in 
fractions 6 and 7 (Figure 5.4 C, top panel), being colocalised with proteins of 
large 39S and small 29S mitoribosomal subunits (MRPL3 and MRPS18B, 
respectively, lower panel), where monosome can be only observed in fraction 7. 
In order to estimate the actual amount of immunoprecipitated Δ49mtRF1 and 
identify specificity of molecules bound per ribosome, a serial dilution of 2-250ng 
of purified Δ49mtRF1 was used as a calibration standard and compared with 
amounts of Δ49mtRF1 and MRPL3 present in the elution fraction of the 
immunoprecipitated mitoribosome. Based on the amount of mtRF1 detected by 
western in both mito lysate and IP elution (Figure 5.4 D, lower panel) in 
comparison with the serial dilution of Δ49mtRF1, it can be estimated that there 
is approximately 2ng of mtRF1 per 10µg of ML, which represents 0.2% of all 
mitochondrial proteins. Unfortunately, without purified MRPL3 or any other 
A 
C 
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Figure 5. 4. Assay to determine if Δ49 mtRF1 can bind to ICT1-FLAG immunoprecipitated 
mitoribosomes lacking mt-mRNA.  
(A) GST-purification of Δ49mtRF1. Transfected Rosetta cells were grown to OD600 0.4-0.6 and induced 
to overexpress mtRF1-GST (~73 kDa) by 1 mM IPTG over-night at 16°C. Cells were harvested, sonicated 
and the soluble fraction was subjected to glutathione Sepharose beads (SN = post-centrifugation input 
to the column). After binding, the flow through (FT) was discarded and the beads (BBE; beads before 
elution) washed with PBS. By the addition of PreScission protease the GST-tag was cleaved off and 
mtRF1 protein could be eluted (E), whilst the GST-tag (~ 26 kDa) remained on the beads (BAE; beads 
after elution). (B) HEK293T ICT1-FLAG cell line was induced for 3 days with 1μg/ml tetracycline. After 
standard IP (where ~2.5mg of mitochondria lysate (ML) was incubated for 3h with the beads) 70pmol 
purified recombinant Δ49RF1 was added to ICT1-FLAG 55S particles still immobilised on the beads. 
This incubation proceeded for 40 min, before elution with 3xFLAG peptide (E = elution fraction). 
Supernatant was also collected (SN = all that did not bind ribosomes). Beads after elution (BAE) were 
included in the western blot analysis. (C) 80% of eluted fraction was subjected to 10%-30% isokinetic 
sucrose gradient, fractions 1 to 10 of which were analysed by western blot. Each blot was probed with 
antibodies against mitochondrial ribosomal proteins (MRPL3, as a mt-LSU marker; MRPS18B, as mt-
SSU marker), FLAG and mtRF1. (D) To estimate actual amounts of protein, 5% of eluted mitoribosomes 
with Δ49RF1 bound, 5μg of starting mitochondrial lysate (ML) along with BSA (2 to 250ng) were 
separated on SDS-PAGE and silver stained. A parallel Western blot with the same samples was probed 
with anti-FLAG, anti-MRPL3 and anti-mtRF1 antibodies.    
 
ribosomal protein, which were not avalible at that time in our lab, the precise 
ratio of mtRF1 to ribosomes could not be estimated. However, the signal for 
both mtRF1 and MRPL3 in the mitoribosome (ICT1 IP) aliquot appears similar 
on western (Figure 5.4 D), so if one assumes that the affinitiy of those two 
antibodies used are the same, it could be roughly estimated that the ratio of 
mtRF1 to monosomes in the IP eluate is not more than 1:1. Based on this 
D 
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western there is approximately 2-4ng mtRF1 in the aliquot of ICT1 IP (Figure 
5.4 D, far right lane 2ng lane of mtRF1) this amount could not be detected on 
silver stained gel (the signal for 10ng of Δ49mtRF1 is very weak on Figure 5.4 
D, top panel). The fact that ICT1-FLAG, in this fraction being a part of either free 
mtLSU or monosome, is about 20ng also suggests that the ratio cannot be 
more than 1:1 in the total population of immunoprecipitated proteins. However, 
at this stage it was impossible to determine whether the binding was specific 
and whether some monosomes bound one, four or no mtRF1 in these 
conditions. Therefore further investigations followed.           
 
5.5.  In vitro binding of mtRF1a to mitoribosomes 
Based on the fact that mtRF1a is the real realease factor and recognises 
mitochondrial stop codons in order to bind in the A-site, it can be predicted that 
if mtRF1a was purified in the same way as Δ49mtRF1 and incubated with 
similarly immunoprecipitated mt-mRNA free mitoribosomes, it should not 
interact. Purification of Δ32mtRF1a was therefore carried out using the same 
conditions as previously, where Δ32mtRF1a-GST was overexpressed in 
Rosetta cells (Figure 5.5 A, lane 1) as 75kDa fusion protein. Binding to the 
beads (BBE, lane 3) isolated it from the flowthrough (FT, lane 2), then cleavage 
of GST released ~49kDa Δ32mtRF1a (lane 5) from the column (lane 4).      
After the monosomes were incubated with 70pmol of purified Δ32mtRF1a 
(Figure 5.5 B, lane 1), trace amounts could be detected in the final elution 
together with the expected mtSSU (MRPS18B) and mtLSU (MRPL3 and ICT1) 
markers (lane 6) but this was significantly lower than Δ49mtRF1 after elution 
(lane 7). To further examine the immunoprecipitated monosome and 
Δ32mtRF1a, distribution and migration of these polypeptides from the final 
eluate was examined by 10-30% sugrose density gradient. Figure 5.5 C shows 
that even though a low level of Δ32mtRF1a was pulled down with 
mitoribosomes, it was not associated with either free large ribosomal subunits 
(fraction 6) or monosome, which is clearly present in fractions 7 and 8. 
Δ32mtRF1a was only detectable in the top 2 fractions of the sucrose gradient, 
which suggests that the majority of immunoprecipitated mitoribosomes have, in 
fact, an empty A-site and Δ32mtRF1a does not stay bound to it.  
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Figure 5. 5. Interactions of mtRF1 and mtRF1a with isolated 55S particles.  
(A) GST-tagged Δ32mtRF1a was purified from transfected Rosetta cells cultured to OD600 0.4-0.6, 
induced with 1 mM IPTG over-night at 16°C allowing overexpression of mtRF1a-GST (~75 kDa). Cells 
were harvested, sonicated and the soluble fraction exposed to glutathione Sepharose beads (SN = post-
centrifugation input to the column). After binding the flowthrough (FT) was discarded and the beads 
(BBE) washed with PBS. Δ32RF1a was eluted (E) by the addition of PreScission protease leaving GST-tag 
(~ 26 kDa) immobilised on the beads (BAE). (B) The HEK293T ICT1-FLAG cell line was induced for 3 days 
with 1μg/ml tetracycline. After standard IP (as described in methods section 2.6.10) 70pmol purified 
recombinant Δ49RF1 or 70pmol purified recombinant Δ32RF1a were added to the ICT1 immobilised 
55S/39S (beads) and incubated for 40 min. The supernatant was collected (SN = all that did not bind 
ribosomes) before elution with 3xFLAG peptide of ICT1 immobilised 55S/39S (E = elution fraction). SN 
and 10% of total elution were analysed by western blot using antibodies against MRPL3 as mt-LSU 
marker, MRPS18B for mt-SSU, FLAG, mtRF1 and mtRF1a. (C) Eluted mitoribosome IP (80%) incubated 
with Δ32RF1a was separated by sucrose density gradient (10-30-%) and obtained fractions (1-10) 
subjected to western blot analysis. 
    
5.6. Competition for binding of ribosomal A-site. 
As shown before (section 5.3) Δ49mtRF1 interacted with immunoprecipitated 
mitoribosomes in vitro, however it was observed to migrate to fractions 6 and 7 
and co-localised with signals for both, mtLSU alone and the monosome, which 
could suggest some level of unspecific binding or the binding in fraction 6 might 
represent low levels of monosome where the antibody is not strong enough to 
detect any small subunit present in that fraction. Therefore in order to exclude 
this possibility and to determine whether Δ49mtRF1 binds specifically it was 
necessary to block the A-site in the reformed monosomes to inhibit this 
interaction.  
A B 
C 
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Figure 5. 6. Blocking the A-site of the immunoprecipitated mitoribosomes.  
ICT1-FLAG was expressed in HEK293T cells for 3 days and standard IP performed. Mitochondrial lysates 
were initially incubated with anti-FLAG beads for 3h, 49mtRF1 recombinant protein was then added for 
a further 40 min (panel A shows 80% of the final elution separated by a sucrose gradient into 1-10 
fractions). (B) Mitoribosomes were preincubated with 1nmol of UAG RNA triplet for 5 minutes prior to 40 
minutes incubation with recombinant 49mtRF1 and 10% of a total elution, supernatant, BAE and mito 
lysate analysed by western. (C) 80% of total elution from B separated by a sucrose gradient (fractions 1-
10). (D) Mitoribosomes were preincubated with 100µM tetracycline for 15 minutes prior to 40 minutes 
incubation with 49mtRF1, and elution. Content of 10% of the total elution, supernatant, BAE and 
mitochondrial lysate were analysed by western blot. (E) The total elution from D was separated by a 
sucrose gradient into fractions 1-10.  
           
 
 
 
One of the methods to block the A-site under those conditions was to use 
synthetic UAG RNA triplet, which is also used for in vitro release assays to 
programme bacterial ribosomes. For this, another ICT1-FLAG 
immunoprecipitation was performed (as described earlier) with a 3h incubation 
of mitochondrial lysate with anti-FLAG beads. Bead bound mitoribosomes were 
preincubated with 1nmol of UAG triplet for 5 min prior to addition of purified 
Δ49mtRF1 for another 40 min. Figure 5.5 shows the final elution fraction 
separated by sucrose density gradient (panel C), and for comparison, an 
experiment control where no triplet was present (panel A). The majority of 
Δ49mtRF1 remains uncomplexed in fractions 1-3, but in both cases trace 
B 
A 
D 
C 
E 
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amounts co-migrate with monosome, seen in fractions 7 and 8. As described in 
the previous section the content of each fraction during the procedure was 
monitored by western blot. It shows that although mitoribosomes were 
preincubated with the RNA triplet, it did not successfully saturate all A-sites to 
block the interaction with Δ49mtRF1. In the final elution (Figure 5.6 B, lane 1) 
the signal for Δ49mtRF1 appears as do those of mitoribosomal markers 
(MRPL3, ICT1-FLAG or MRPS18B). This association is also reflected after the 
total eluate was separated by sucrose gradient (Figure 5.6 C). The Δ49mtRF1 
signal accumulates at the top of the gradient in fractions 1-3, and is again 
detectable in fraction 6 to 8, suggesting direct interaction with monosome in this 
case.  
It has been demonstrated that a broad-spectrum antibiotic, tetracycline (Tc) 
binds bacterial ribosomes. 30S ribosomal subunit-tetracycline crystal structures 
are avaliable (Brodersen et al.,2000; Pioletti et al., 2001) showing that Tc 
primarily targets bacterial ribosomes to prevent the binding of aminoacylated 
tRNA to the A-site of mRNA programmed ribosomes, thus blocking protein 
synthesis (Rasmussen et al., 1994; Aleksandrov and Simonson, 2008; and 
reviewed by Connell et al., 2003). Since the A-site and decoding centre in E. 
coli and mitochondrial ribosomes are highly conserved (Koc et al. 2010), it was 
highly likely that Tc may well bind to A-site of immunoprecipitated 
mitoribosomes thereby preventing binding of the recombinant, purified protein. 
The minimum inhibitory concentration for bacterial synthesis is 0.3-3 µM (Ross 
et al., 1998) and for crystallography studies the concentration used ranged from 
4-80 µM (Brodersen et al., 2000; Pioletti et al., 2001). Unfortunately, as seen in 
figure 5.6 D despite the FLAG-immobilised mitoribosomes being incubated for 
15min with 100µM tetracycline to saturate and block the ribosomal A-sites, this 
treatment did not affect the interaction of Δ49mtRF1 with mitoribosome (Figure 
5.6 D, lane 1 compared with lane 2) and the binding was not inhibited.   
As a consequence of Tc not being able to block the A-site of mitoribosomes a 
further strategy was devised. It was established in my host lab that mtRRF does 
not appear to be cleaved on import and that this full length protein occupies the 
A-site, and it is through this interaction that it is able to co-immunoprecipitate 
mitochondrial ribosomal proteins (Rorbach et al., 2008). Mitoribosomes were 
again immobilised via ICT1-FLAG and purified a full length mtRFF-GST fusion 
protein added and expected to inhibit the binding interactions with Δ49mtRF1. 
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First, after the full length mtRRF (FL mtRRF) was successfully purified (Figure 
5.7 A, lane 7), 70pmol of it were incubated with mitoribosomes for an additional 
40 minutes and then the elution performed. As predicted, mtRRF bound 
mitoribosomes were detected in final elution fraction together with ICT1-FLAG 
the marker of mtLSU and control for successful IP (Figure 5.7 A, lane 1). 
However, according to the prediction that mtRRF and mtRF1 aim for the same 
site, when the mitoribosomes were preincubated with Δ49mtRF1, also for 40 
minutes, prior to incubation with mtRRF, the content of the final elution 
 
 
Figure 5. 7Blocking the A-site of the immunoprecipitated mitoribosomes with mtRRF. 
(A) ICT1-FLAG was expressed in HEK293T cells for 3 days and standard IP performed. Mitochondrial 
lysates were initially incubated with anti-FLAG beads for 3h, to which either full length mtRRF or 49RF1 
recombinant was added for 40 minutes incubation. To the latter addition of full length mtRRF proceeded 
for another 40 minutes, which was followed by the final elution in both cases (lane 1 and 2, 
respectively). 10% of a total elution, supernatant, BAE and mito lysate with recombinant Δ49RF1 and FL-
mtRRF were separated by the western blot.  B, isolated mitochondria were initially divided in three 
equal volumes and two of them preincubated with full length mtRRF for 40 minutes and one with 
49RF1. These preincubated where then incubated with 49RF1 for another 40 minutes and eventually 
all three eluted.  The content of 10% of a total elution and supernatant were then analysed by western.   
 
 
A 
B 
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demonstrated that both added proteins bound simultaneously to the isolated 
mitoribosomes (Figure 5.7 A, lane 2) and mtRRF interaction was not inhibited. 
This could suggest either unspecific binding of one or another factor, lack of 
initial saturation of 55S particles with mtRF1 or it could be due to the constant 
transition state between both factors and mitoribosomes resulting in an 
equilibrium of two distinct populations of mitoribosomes, one containing mtRF1 
and the other population interacting with mtRRF. Under such conditions 
absolute inhibition is not possible. Therefore, in order to examine this, the 
experiment was performed in a reciprocal manner, where the Δ49mtRF1-
ribosome interaction was attempted to be decreased by presence of mtRRF in 
the mix (preincubated with mtRRF for 40 minutes prior to addition of Δ49mtRF1 
or Δ32mtRF1a). If the interaction of Δ32mtRF1a and mitoribosomes seen 
earlier (section 5.5) was due to a small proportion of A-sites still being occupied 
with mRNA, mtRRF could occupy those too. Thus mtRF1a was used as another 
control to test whether the minimal level of interaction of mtRF1a can be 
eliminated by preincubation of mitoribosomes with mtRRF for 40 minutes. Lane 
1 of Figure 5.7 B, however, still shows the presence of mtRF1a in the final 
eluate. Moreover, when the isolated mitoribosomes were pre-exposed to 
mtRRF (70pmol, for 40 min), then the amount of Δ49RF1 bound that could be 
detected in the eluate is comparable with the amount of Δ49mtRF1 bound 
without preincubation with mtRRF. Together this suggests that the binding of 
Δ49mtRF1 could not be inhibited by the presence of mtRRF in the sample and, 
similarly the binding of FLmtRFF to the mitoribosome could not be suppressed 
by the presence of Δ49RF1 in the samples. Therefore, the proposed hypothesis 
could not be either proved or disproved from those results and further 
investigation is required.   
 
5.7.  Discussion 
The in vitro experimentation undertaken in this chapter aimed to investigate the 
recognition, binding and specificity abilities of mtRF1 towards isolated 
mitoribosomes with empty A-sites.  
First, the data strongly suggests (Figure 5.2) that the majority of mitoribosomes 
immunoprecipitated via ICT1 have empty A-sites. This was determined by 
varying the incubation time and monitoring the mtRNA degradation over this 
A 
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period. The 3h incubation period was determined to be optimal as the rRNAs 
remained intact while the mt-mRNAs degraded during this IP procedure.  
Further, I have successfully shown that purified Δ49mtRF1 presented a level of 
interaction (Figure 5.3 B and C) with isolated mitoribosomes. It was also shown 
here that mtRF1a does not have the same affinity as mtRF1 for those isolated 
mitoribosomes, although an interaction still occurs, but it is much lower (Figure 
5.5 B). It is possible that the detected interaction represents recognition of the 
small proportion of those ribosomes that have retained mRNA in the A site. 
Since the reaction contains no other factors that this site could be occupied by, 
mtRF1a samples for activity, and is therefore found in the eluate.  
Why could this interaction not be detected in vivo with HEK293 expressed 
mtRF1 as described in previous chapter? First, the Δ49mtRF1 appears by its 
migration to be bigger than endogenous forms on westerns (Figure 5.4 B, 
compare lanes 4 and 5) and this additional length at N-terminal that 
corresponds to domain 1, exact function of which is still unknown, but it may 
'lock' the protein on the ribosome for longer than the endogenous form interacts 
in vivo. Second, if there is a factor that facilitates the mtRF1 disassociation from 
ribosomes after it serves it function, it would not be present in these in vitro 
experimental conditions, therefore the process is prolonged and associated 
protein can be visualised.  
The specificity of this ‘empty A-site’ binding could not, however, be determined 
in this experimentation. Neither of the selected potential inhibitors of mtRF1 
binding could compete out mtRF1. The UAG synthetic triplet was chosen to 
block the A-site based on the fact that its addition is able to programme the 
bacterial ribosomal A-site for in vitro release assays. Even though the decoding 
centre is highly conserved between bacterial and mitoribosomes (Koc et al., 
2010) it cannot be excluded that the triplet did not associate and with the 
available techniques this could not be controlled for. There is also another 
possibility. The mitoribosomes that were used to obtain cryo-EM structures 
were purified with tRNA bound to a P-site (Koc et al., 2003). It is possible that 
the 55S ribosome isolated via overexpression and immunoprecipitation of ICT1 
also has a tRNA still bound at the P-site. If there is no mRNA associated with 
the P-site tRNA in those ribosomes and if the UAG triplet actually bound the A-
site as predicted, there would be no physical obstacles so that the addition of 
Δ49mtRF1 could potentially push the triplet forward to the P-site. The other A-
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site blocker used was tetracycline, addition of which also did not inhibit mtRF1 
binding to the mitoribosomes. There are at least two crystal structures of Tc 
bound to the Thermus thermophilus 30S that have been determined (Brodersen 
et al., 2000; Pioletti et al., 2001). Based on these, there are six different binding 
sites on the bacterial subunit are characterised, including the one close to the A 
site that is consistent with its inhibitory role. Even though this site was then 
reported (Aleksandrov and Simonson, 2007) to be a single, predominant 
binding site for Tc that is highly occupied and much stronger at physiological 
concentrations of Tc, on bacterial ribosomes, four of the other sites are identical 
and conserved in mitoribosomes. Therefore it is not known whether the affinity 
of those conserved sites on mitoribosome is different or stronger or which of 
them Tc would select to occupy under various conditions. There is also a study 
(Zhang et al., 2006) that reported tetracycline to have inhibitory effects that 
were similar on E. coli and mitochondrial ribosomes. However, the 
concentrations reported were calculated based on in vitro translation of both 
systems. The maximum inhibitory concentration required was much higher, i.e. 
approximately 100 times more to inhibit bacterial protein synthesis compared 
with the minimum inhibitory concentration from other studies, where this effect 
was measured on cultured cells (Ross et al., 1998). Further, Zhang et al., 
(2006) reported that in order to fully inhibit mitochondrial translation 340µM 
tetracycline was required which was over 110 times more than the reported 
minimum inhibitory concentration and 3.4 times more than the concentration 
that was used in this chapter’s investigation, to block the A-site on ribosomes 
isolated via immunoprecipitation of FLAG tagged ICT1. If this is the case, then 
the approach required to be optimised and the concentration of 100µM Tc used 
in this study could simply not be sufficient to block A-site occupancy by 
incoming proteins.  
Finally, the addition of the full length mtRRF to the isolated mitoribosomes in 
this study showed interaction with the ribosomes. However, this interaction 
could not inhibit binding of Δ49mtRF1 nor could the reciprocal arrangement 
prevent mtRRF binding 55S that was prebound with mtRF1. By doing so two 
different populations of ribosomes were generated, some mitoribosomes would 
have mtRF1 bound and some others mtRRF. The ribosome could not be 
saturated with either factor probably due to the constant on and off rate of each 
of those factors. The data is also not conclusive due to the limitations of 
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Table 5. 1. Outline of the proposed set of experiments to investigate the 
competition for A-site occupancy between mitochondrial translational 
factors.  
Mitoribosomes 
+recombinant 
protein 
I II III 
Reaction 
1 
Reaction 
2 
Reaction 
1 
Reaction 
2 
Reaction 1 Reaction 2 
1st step  +mtRF1 -- +mtRRF -- +mtRRF -- 
2nd step  +mtRRF +mtRRF +mtRF1 +mtRF1    +mtRF1a +mtRF1a 
 
experimental material so that not all desired controls could be performed within 
one experiment. Each preparation yielded only enough mitochondrial lysate, 
which was incubated with the FLAG beads, to be divided into maximally three 
equal reactions, thus limiting the simultaneous controls that could be performed. 
The ideal approach would be to perform from the same mitolysate three pairs of 
reactions as presented in Table 5.1 below.  The recombinant mtRRF would be 
added in the first step for incubation to one of each of the paired reactions of 
mitoribosome samples II and III whilst recombinant mtRF1 would be added to 
the one reaction of the pair I. Then, in the second step either the recombinant 
mtRRF, mtRF1 or mtRF1a would be added. In this way, if there was any effect 
of binding caused by the addition of a factor in first step, the changes in ratios of 
the interacting proteins between two ribosomes pools could be detected and 
compared.  
Another way of answering the question of mtRF1 specificity on mitoribosomes 
and the A-site would be to use a crosslinking immunoprecipitation (CLIP) assay. 
This technique allows physiological RNA-proteins interactions to be determined. 
This is done by treating cells with UV light to facilitate in vivo crosslinking of an 
RNA species and a protein that it interacts with or is in close proximity to. The 
RNA and the protein are covalently bound to each other by UV- irradiation, and 
by using antibodies to the protein of interest the fragment of RNA that is 
protected by the protein can eventually be characterised (the procedure was 
adapted from Ule et al. [2005] and optimised in my host lab by Agata 
Rozanska). Most of the contacts between the rRNA in the ribosome A-site and 
bound tRNA are preserved (15 out of 18 contacts sites) (Koc et al., 2010), some 
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of which may be exposed as well when mtRF1 is bound and if this is the case 
and mtRF1 binds there it could be covalently bound by UV treatment to the 
fragments of rRNA. There was not enough time however, for me to explore this 
option of detecting interactions between mtRF1 and the mitoribosome. The next 
chapter instead concentrates on alternative approaches to generate potential 
substrates of mtRF1. 
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6. Chapter 6:  Further approaches to generate an experimental system 
that reconstitutes ribosomes lacking A-site mRNA sequences in order 
to test mtRF1 specificity.  
 
6.1. Introduction 
As shown previously by Soleimanpour-Lichaei et al., (2007), mtRF1 does not 
show any peptidyl tRNA hydrolase activity on bacterial ribosomes in vitro with 
UAA, AGA, AGG codons. Therefore whilst determining whether the mtRF1 
substrate proposed in this thesis’ hypothesis, and as a follow up on the previous 
chapter, it was important to perform the release assay again but without 
programming the ribosomes with any codons for the A-site. The primary aim of 
this part of the in vitro investigation in this chapter is to compare whether there 
was a difference in activity of recombinant Δ49mtRF1 proteins expressed in E. 
coli compared to those that were expressed in human HEK293 cells. The 
importance of this is that differences in activity could result from possible 
differences in folding or more likely from differences in modifications.  
However, in order to test whether mtRF1 could recognise and bind an A-site 
lacking mRNA thereby rescuing stalled mitoribosomes, both in vivo and in vitro 
approaches are required. Consequently, if the hypothesis is that mtRF1 acts as 
a rescue factor that prevents accumulation of mitoribosomes that have stalled at 
an empty A-site, then it is important to consider how often this event might 
occur under physiological conditions. My result so far suggest that this is either 
very rare or is relieved very quickly and so it has not been possible to capture 
mtRF1 ‘in flagrante’. If mtRF1 can recognise empty A-sites to potentially trigger 
release or recycling then generating an excess of this substrate in vivo may 
allow an otherwise rare event to be trapped, visualised and measured. In 
addition to the in vitro approach described in the previous chapter I aimed to 
test this hypothesis by increasing levels of potential substrate recognisable by 
mtRF1 in vivo. Two possible approaches were considered. The first would use a 
cell line generated in my host lab that expresses a mitochondrially targeted 
version of a cytosolic poly(A) specific 3’ exoribonuclease (PARN) (Wydro et al., 
2010). When full length PARN is targeted to mitochondria its activity is not 
restricted to only poly(A), but continues degradation into ORFs of most 
mitochondrial transcripts as shown in Wydro et al., (2010). It has been also 
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demonstrated that a C-terminal truncated version of PARN (mtPARN-N) 
reduces its processivity leaving most of the mt-transcripts stable but without 
termination codons. Therefore, this study will take advantage of this activity that 
should increase the level of transcripts that are predicted to migrate through the 
mitoribosome until the truncated 3’ terminus leaves an empty or partially empty 
A-site, generating a potential substrate for mtRF1.  
In mitochondria the physiological occurrence of an empty A-site may be low, 
moreover if there is more than one rescue system for different substrates as it is 
in prokaryotes, which could be the case with the three candidates for such a 
process (C12orf65, ICT1 and mtRF1), where the capacity for rescue of stalled 
ribosomes is greater than the demand (Moore and Sauer, 2005). Therefore, 
another, second approach was used in order to increase the demand and fulfil 
the capacity of potential rescue mechanisms in mitochondria. For this part of 
investigation, a bacterial endonuclease, RelE, was targeted to mitochondria 
(Temperley et al., 2010). In E. coli, RelE associates with the ribosomes and is 
part of toxin-antitoxin regulatory complex that specifically cleaves at the 3' end 
of mRNA in the A-site and targets all three bacterial stop codons, with the 
highest preference for UAG, but also shows some level of effectiveness on 
sense codons, such as CAG and UCG (Pedersen et al., 2003). Additionally, the 
cleavage occur either between 1 and 2 or 2 and 3 nucleotide of the codon 
(Hurley et al., 2010) and been shown specifically by Temperley et al., (2010) 
that in mammalian mitochondria all of the cleavage sites are between 
nucleotides 2 and 3 leaving 2 nt and only partially empty A-sites thereby 
providing a different substrate for mtRF1 than would be created by mtPARN-N. 
The stalled ribosomes generated by overexpressing in mitochondria each of 
those enzymes were challenged further by depletion of mtRF1, which would 
potentially, according to the hypothesis, minimise the rescue capacity of such 
treated cells allowing detection of the effect.       
Finally this chapter investigated the potential involvement of mtRF1 in 
mitochondrial mRNA decay using patient's fibroblasts with a characterised 
pathogenic mtDNA microdeletion that results in removal of the stop codon from 
MT-RNA14. It was shown that an mRNA surveillance pathway requires 
translating mitoribosomes to recognize the target i.e. the transcript lacking the 
stop codon was rapidly degraded unless translation was inhibited (Temperley et 
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al., 2003). There is evidence in other translation systems that provide a clear 
link between mRNA surveillance pathways with ribosomes and show that 
proteins with similarities to release factors have a role in mRNA decay. It has 
been shown that stalling of yeast ribosomes during translation elongation is 
recognized by a pair of proteins Dom34 and Hbs1p that are evolutionarily 
conserved and related to the eukaryotic translation release factors eRF1 and 
eRF3 (Clement and Lykke-Andersen, 2006). Mammalian Pelota with Hbs1 (like 
their yeast counterparts Dom34 and Hbs1p) promote release of peptidyl-tRNA 
from stalled elongation complexes (Pisareva et al., 2011). Therefore, there is a 
potential that mtRF1 is involved in degradation of the transcript in microdeletion 
patient fibroblasts and its depletion would 'protect', at least some of it.      
The approach undertaken to characterise mtRF1 substrate and its binding site 
on the ribosome described in previous chapters was not conclusive and there 
was further need to design a different approach to identify the hypothesised 
function of this protein, which this chapter is going to be focused on. Also, due 
to the difficulties narrowing down mtRF1 function in mitochondria, this chapter 
describes testing for an alternative function of the protein.  
 
6.1. In vitro Release assay with recombinant proteins 
To this end I needed to generate constructs in vectors suitable for either i) 
overexpression in bacteria of GST tagged mtRF1 and then to purify it, ii) 
constructs that would direct stable and specific integration allowing inducible 
expression of FLAG tagged mtRF1 protein in HEK293 cells. Beads conjugated 
to anti-FLAG antibody then facilitated purification. Bacterially or human cell 
expressed mtRF1 could then be tested in an in vitro Release Assay. The assay 
simulates protein synthesis termination conditions, where bacterial ribosomes 
are pre-loaded with a synthetic AUG start codon and tritiated formylmethionine-
tRNAmet in the P-site, before the introduction of the specific termination codon in 
the A-site (or no codon added) and finally the purified protein of interest. If the 
protein exhibits a release activity by cleaving the ester bond between the 
tritiated methionine and the tRNAmet, the radioactive amino acid representing 
the polypeptide will be released into the supernatant and can be measured. 
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Figure 6. 1. mtRF1 and the in vitro Release Assay.  
(A) The data presented in the histogram is from different amounts of mtRF1 protein either HEK293 
or bacterially expressed and represents the mean of triplicate release assays. The relative release 
activity is measured in counts per minute shown on axis Y. Each assay was performed without any 
stop codon and ICT1, known to have activity under such conditions, was used as a positive control. 
(B) In order to estimate the amount of proteins, obtained from the IP described previously, to be 
used in release assay, elution fractions, BSA standard range (25, 50, 100, 250 and to 500ng, lanes 1-
5) and GST-purified protein (237ng, lane 10) were separated by SDS-PAGE and visualised with 
SimplyBlue Safe stain. Samples in lane 6 (1µl of IP mtRF1 elution) and 7 (5µl of IP mtRF1 elution) 
were eluted under native conditions by competition with 3xFLAG peptide. Lanes 8 (1µl) and 9 (5µl) 
represent samples eluted under acidic condition with 0.1M glycine (pH 3.5), which were equilibrated 
with wash buffer to help preserve the protein structure and therefore function. The protein 
concentration in the elution fraction (lane 6) was estimated to be ~60ng/µl.  
 
The aim of this investigation was to show release activity of mtRF1 in vitro 
assuming that the protein would occupy the A-site transiently and no mRNA is 
required for its function. It has been shown (chapter 5) that mtRF1 does not 
immunoprecipitate with any other proteins, therefore IP can be a good tool for 
purification of the protein, which should yield a relatively pure protein that can 
then be used for in vitro assays. The IP method uses FLAG antibodies that are 
specific to the FLAG tagged mtRF1 proteins to allow isolation of them. Such 
isolated mtRF1-FLAG proteins (Figure 6.1B, 1µl in lane 6 and 5µl in lane 7), 
believed to preserve its native folding and active size, along with mtRF1 
recombinant protein GST-purified from bacteria (lane 10) (as described in 
method section 2.6.7) were tested in release assays. As shown in figure 6.1A 
compared with ICT1 control, which has been shown by Richter et al., (2010) to 
have codon-independent translation release activity on 70S ribosomes, both 
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mtRF1-FLAG (mtRF1-IP) and recombinant Δ49mtRF1 were not able to promote 
release of fMet in in vitro conditions with the absence of stop codon. mtRF1-
FLAG was also eluted in acidic conditions and then neutralised to preserve its 
structure (mtRF1-IP low pH), however using it in the release assay did not result 
in release of fMet either. The procedure was repeated using a double amount of 
ethanol to loosen the structure of bacterial ribosomes (data not shown), 
however this did not contribute to any increase in release activity detected. This 
data shows there is no difference in two tested variants of mtRF1 and neither 
recombinant mtRF1 nor mtRF1-FLAG isolated from human cells is active on 
bacterial ribosomes with an empty A-site as a substrate.   
 
6.2. Can mtPARN-N generate the substrate for mtRF1? 
Taken that truncated poly(A)-ribonuclease (mtPARN-N) expression results in 
removal of the termination codons from most of the mt-transcripts (Wydro et al., 
2010), the exonucleolytic activity of mtPARN-N cleaves the transcripts from the 
poly(A) tail and extends into the stop codon leaving a complete open reading 
frame. As the elongation step of translation continues, migration of the ribosome 
eventually reaches the end of the transcript and leaves no codon in A-site to 
terminate. Depletion of mtRF1 in these circumstances should yield accumulated 
monosomes, assuming there is no particle that would recognise and rescue 
such complexes any more.  HEK293 PARN-N expressing cells were transfected 
with siRNA-mtRF1 and siRNA-NT for 4 days, whereas the expression of 
truncated poly(A)-ribonuclease was induced for only 2 days prior to harvesting 
cells. Then followed sucrose density gradient separation of lysate, every fraction 
of which was subjected to western blot and northern blot analysis to determine if 
there is a change in behaviour of mitochondrial ribosomal proteins. Separated 
proteins of interest were visualised by western blot with antibodies against 
polypeptides in the small (DAP3) and large (MRPL3) mitochondrial ribosomal 
subunits. The same whole cell lysate preparation that was used for the gradient 
analysis was also separated independently on SDS-PAGE and analysed using 
anti-mtRF1 antibodies, with anti-porin antibodies used as a loading control. As 
seen in figure 6.2A the depletion was effective as the mtRF1 signal cannot be 
detected compared to siRNA-NT control. Unfortunately, the sucrose gradient 
results (Figure 6.2B) show no increase in accumulated ribosomes.  
A 
D 
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Figure 6. 2. Analysis of mt-RNA and mitoribosome components following mtPARN-N expression with 
and without concomitant depletion of mtRF1. 
HEK293T mtPARN-N cells were induced with 1µg/ml tetracycline for 2 days and treated with mtRF1 
(siRF1) or non-targeted (NT) siRNA for 4 days. The lysates (700μg) of each sample were separated on 10-
30% isokinetic sucrose gradient. (A) In order to confirm mtRF1 depletion in this experiment 50μg of cell 
lysates (prior to sucrose gradient centrifugation) were collected and analyzed separately by western blot 
using antibodies against endogenous mtRF1 and Porin as loading control. (B) 10 % of each fraction were 
separated by SDS-PAGE and analysed using antibodies against the small (DAP3) and large mitochondrial 
subunits (MRPL3). (C) RNA was extracted from 80% of each fraction (1-11 and 1/10 of an input) and 
analysed on a northern blot using probes to mitochondrial mRNAs (MTATP6 only, MTCOX1 and MTND1) 
and 16S (MT-RNR2) with 12S (MT-RNR1) mt-rRNAs. (D) The signals were quantified and presented as the 
graph of mean and standard deviation from three independent experiment repeats (*p <0.05, **p<0.01, 
***p<0.001).    
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A similar pattern of distribution of mtSSU and mtLSU is the same in the 
absence of mtRF1 (4 day depletion) or presence as in the control (top panel), 
after 2 days of mtPARN-N expression. In both cases the SSU, detected by anti-
DAP3, migrated to and accumulated mostly in fractions 4 and 5, while a 
member of LSU, MRPL3, migrated to fractions 8, but mostly accumulated in 
fraction 6. In order to analyse RNA in those samples, 80% of each fraction had 
RNA extracted that was subjected to northern blot analyses. Two probes each 
specific to an rRNA were used (MT-RNR1 and MT-RNR2) to detect the 
migration of the mtSSU, mtLSU and monosome in the northern blot. The signal 
for mtSSU first appears in fraction 4 and distributes evenly down to the bottom 
of the gradient, where fraction 11 represents the gradient pellet (Figure 6.2 C). 
The 16S rRNA partitions to fraction 5-7, then distributes to the bottom of the 
gradient. The signals in earlier fractions (4-6) represent the free uncomplexed 
state of each individual subunit, whereas signal in fractions from 7-8 represent 
the presence of monosomes. This pattern of monosome is also seen by the 
distributions of mRNA where mtRF1 was depleted, signals of which become 
more intense again, where trapped by the monosome (Figure 6.2C, right panel, 
fractions 8) and distributed evenly throughout the gradient. The distribution of 
mRNAs in the cells where mtRF1 was still present (Figure 6.2C, left panel) is 
focused more towards the top of the gradient. The histogram plotted (Figure 
6.2D) based on detected signal on northern blot clearly reflects this distribution 
of both rRNA and mRNA tested between the sample (si-RF1) and control (NT). 
Even though the difference is very subtle, it seems that the mtPARN-N 
overexpression resulted in a peak of mRNA (purple line in figure 6.2D) 
concentrated to one fraction (MT-COXI to fraction 6, MT-NDI to fraction 5 and 
MT-ATP6 to fraction 4) and declines with each later fraction to the last one. 
Depletion of mtRF1 'restores' the distribution to the one of control (Figure 3.6A, 
left panel), where the signal for mRNA comes back again in fraction 8 (and two 
peaks can be detected). Therefore, based on this data the overexpression of 
Poly(A)-ribonuclease and mtRF1 depletion did not contribute to significant 
accumulation of monosomes, however discrete change distribution of mRNA 
may suggest that the lack of mtRF1 promotes its accumulation on the 
monosome.  
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6.3. Can mtRelE generate the substrate for mtRF1? 
Another way of looking at potential mtRF1 activity that would be reflected on 
distribution of mRNA and monosomes in vivo was using a mitochondrially 
targeted endoribonuclease, mtRelE that cleaves specifically between nucleotide 
positions 2 and 3 of a codon in A-site of the ribosome. It was shown that the 
expression of mtRelE in mitochondria results in cleaving more than 90% of the 
tested bicistronic RNA14 transcripts (Temperley et al., 2010). In order to test 
this as an alternative substrate for mtRF1, mtRelE was overexpressed for 3 
days, then cells were subjected to the same analysis as previously (in section 
6.2). As previously, HEK293 cells but this time expressing mtRelE, were 
transfected with siRNA-mtRF1 and siRNA-NT for 4 days, while mtRelE was 
induced for 3 days prior cell harvesting and sucrose density gradient separation 
followed by western blot and northern blot investigation. The separated proteins 
were visualised by western blot with antibodies against polypeptides in the 
small (MRPS18B) and large (MRPL3) mitochondrial ribosomal subunits. Figure 
6.3A shows the depletion was effective as the mtRF1 signal cannot be detected 
compared to siRNA-NT control, with anti-porin antibodies acting as a loading 
control. The expression of mtRelE resulted in a relatively normal pattern of 
distribution of MRPL3 and MRPS18B in both controls (Figure 6.3B, lower and 
middle panels). The mtSSU, detected by anti-MRPS18B, migrated to fraction 4 
and extends evenly to fraction 7, which marks the monosome. This marker was 
somewhat stronger in fraction 4 and 5 in +mtRelE only sample depicted here 
(Figure 6.3B, lower panel), but multiple repeats of this experiment show that this 
is not a consistent phenomenon and is within experimental error of taking 
fractions. A member of mtLSU, MRPL3, migrated to fractions 7 in all three 
cases, but this signal in control with NT mostly accumulated in fractions 5 and 6 
(middle panel of Figure 6.3B) while in the si-RNA for mtRF1 sample it was 
mostly in fraction 7 (upper panel). The pattern of both 'control' +RelE and 
‘sample’ +RelE treated with siRF1 are reasonably comparable when viewed 
over multiple repeats, and due to the fact that the changes occur inconsistently 
are categorised as experimental error and no significant change in migration of 
tested proteins could be detected. This same distribution profile of ribosomal 
proteins was also seen in controls in chapter 3, where no treatment was 
introduced to HEK293T cells (Figure 3.4A, top panel).  
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Figure 6. 3. Analysis of mt-RNA and mitoribosome components following mtRelE expression with and 
without concomitant depletion of mtRF1. 
HEK293T cells expressing mtRelE were induced with 1µg/ml tetracycline for 3 days and treated with 
mtRF1 (siRF1) or non-targeted (NT) siRNA for 4 days. The lysates (700μg) of each sample were separated 
on 10-30% isokinetic sucrose gradient. (A) In order to confirm mtRF1 depletion in this experiment 50μg 
of cell lysates (prior to sucrose gradient centrifugation) were collected and analyzed separately by 
western blot using antibodies against endogenous mtRF1 and porin as loading control. (B) 10 % of each 
fraction were separated by SDS-PAGE and analysed using antibodies against the small (MRPS18B) and 
large mitochondrial subunits (MRPL3). (C) RNA was extracted from 80 % of each fraction (1-11 and 1/10 
of input) and analysed on a northern blot using probes to mitochondrial mRNAs (ATP6 only, MTCOX1 
and MTND1) and 16S (MT-RNR2) with 12S (MT-RNR1), mt-rRNAs. (D) The signals were quantified and 
presented as the graph of mean and standard deviation from three independent experiment repeats (*p 
<0.05, **p<0.01, ***p<0.001).    
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The fractions analysed were also subjected to northern blot analysis as in the 
previous section, to test whether the distribution of RNA reflected the state of 
stalled ribosomes. First of all, in the figure 6.3C it can be noticed that the signal 
for MT-ATP6 predominantly accumulates in fraction 4 as a result of mtRelE 
cleavage of bicistronic MT-RNA14. A faint signal of the uncleaved transcript 
was also detected on the same panel, where is still associated with the 
monosome in fractions 8-11. This confirms that mtRelE was both, expressed 
successfully and it was functional. The signal for mtSSU (MT-RNR1) in 
samples, [+RelE +siNT] and [+RelE +siRF1] (left and right panel, respectively) 
first appears in fraction 4 and distributes evenly down to the bottom of the 
gradient, where fraction 11 represents the gradient pellet. The 16S rRNA 
partitions to fraction 5, then distributes to the bottom of the gradient, but is 
mostly in fractions 5-7/8. The signals in earlier fractions (5-6) represent the free 
uncomplexed state of the subunit, whereas signals in fractions from 7/8 
represent the presence of monosomes. There is no difference in distribution of 
this transcript in two presented samples in Figure 6.3C. The only difference 
between the distribution of mtSSU that can be noticed with the mtRF1 being 
depleted is the lack of rapid decline of the MT-RNR1 signal from fraction 5, 
which is seen it +RelE only sample. This rapid decline of the signal is the case 
for only mtRelE treated sample (quantified in Figure 6.3D, MT-RNR1 panel, 
blue line) and is characteristic for all transcripts in the mtRelE overexpression 
sample. Comparing it with the gradient profile of all mRNA extracted from 
untransfected HEK293T (Figure 3.7 B, black line), where the signal increases 
back from fraction 7 for each tested transcript (for comparison see appendix 1.1 
for those figures merged), which indicates the presence of the monosome, a 
trend can be noticed. This piece of data suggests that the mtRelE cleavage 
resulted in dissociation of monosomes to some extent, while the mtRF1 
depletion sample represents more flat distribution of this transcript restoring the 
second peak seen in wild type HEK293T in MT-RNR1 and MTND1 transcripts. 
The other transcripts, MT-ATP6, MT-COXI and MT-RNR2 remained the same 
with or without mtRF1 depletion. This result suggests that in spite of the minor 
differences caused by mtRF1 depletion in two tested transcripts, the overall 
trend remains unchanged, additional depletion of mtRF1 did not seem to be 
involved in generation of more blocked ribosomes resulting from mtRelE 
cleavage.  
147 
 
6.4. Is mtRF1 involved in mRNA decay pathway?  
There was a subtle increase of steady state level of several RNAs upon mtRF1 
depletion seen earlier in chapter 3 (Figure 3.5). An accumulation of transcripts 
can also be seen, when mt-protein synthesis is inhibited with thiamphenicol 
(Temperley et al., 2010). If mtRF1 is really involved in quality control of protein 
translation and its loss is able to inhibit translation, even if translation inhibition 
is only slight, this should be more pronounced and detectable in the patient-
derived fibroblasts line that lacks the termination codon for the bi-cistronic 
RNA14. This is due to the mtDNA harbouring a microdeletion at bp 9204/5 
(µΔ9205) that removes nucleotides that comprise part of the stop codon in the 
orf encoding ATPase 6. In order to investigate the potential involvement of 
mtRF1 in mitochondrial mRNA decay directly, mtRF1 was silenced with siRNA 
in those patient fibroblasts and in a non-diseased control primary fibroblast line 
(control) and after 7 days of treatment subjected for analysis. The western blot 
results shows that the protein was substantially depleted in both cell lines 
(Figure 6.4B) and, as seen before, this depletion correlated with the decreased 
levels of MRPL12 in both, µΔ and control cell lines. 
The prediction was that the mtRF1 depletion in that patient's cell lines should 
inhibit degradation of µΔRNA14, as a consequence of translational inhibition, at 
the same time restoring its levels to those seen in control as shown by 
Temperley et al., (2003). The northern blot analysis in this investigation has 
confirmed that the levels of MT-RNA14 are much lower in µΔ cell line (Figure 
4.6A, lane 2) than in the control (lane 4), reflecting the rapid translation-
dependant degradation of aberrant transcripts. The depletion of mtRF1 did not 
affect the translation process and thereby did not cause the restoration of 
steady state levels of non-stop transcript and so the µΔRNA14 still remains 
degraded (Figure 6.4A, lane 1). This suggests that mt-protein synthesis was not 
inhibited and that mtRF1 is not directly involved in liberating the nascent protein 
with polylysine extensions trapped on mitoribosomes in those cells. In order to 
be sure that depletion of a translation factor can inhibit mRNA degradation in 
this fashion, ICT1 was depleted alongside in both cell lines. The loss of ICT1 is 
known to affect ribosome assembly, therefore inhibit protein synthesis (Richter 
et al., 2010). Consistent with this, ICT1 depletion caused the stabilization of 
µΔRNA14 transcript (Figure 6.4A, lane 5), comparable with the control (lane 8) 
A B 
148 
 
                
        
Figure 6. 4. Investigation of the effect of mtRF1 depletion in a patient fibroblast cell line carrying a 
microdeletion at the very 3’ terminus of RNA14 that causes the termination codon to be lost resulting 
in non-stop decay.  
(A) The patient-derived cell line carrying an mtDNA microdeletion at the RNA14/15 processing site (µΔ, 
lanes 1, 2, 5 and 6) and non-disease control primary fibroblast line (lanes 3, 4, 7 and 8) were treated with 
siRNA against either mtRF1 (si-RF1, lane 1,3,7), ICT1 (si-ICT1, lane5) or non-targeting (NT, lane 4,8). 
Northern blot analysis reveals steady state levels of mt-mRNAs (RNA14/15, RNA14, MTCO1 and MTND1), 
rRNAs (MT-RNR2 and MT-RNR1). Cytosolic rRNA 18S was used as a loading control. (B) Total fibroblast 
lysates (50µg) from the same cell lines were separated on 12% SDS-PAGE, transferred to PVDF 
membrane and interrogated with antibodies against mtRF1, MRPL12 and B-actin (loading control).   
                 
 
 
 
 
 
A 
confirming the same effect as thiamphenicol on mRNA decay and translation 
reported by Temperley et al., (2003). The steady state level of other transcripts 
tested, especially in control cell lines (Figure 6.4A, lanes 3-4 and 7-8) shows 
rather opposite results than seen in HEK293T upon mtRF1 depletion (chapter 
3). At this stage, it cannot be justified in more detail rather than a simple 
B 
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explanation that it is due to the tissue specific cell types and it is has not 
followed up in this thesis.     
 
6.5.  Can increased expression of ICT1 rescue the phenotype caused by 
mtRF1 depletion? 
The depletion of mtRF1 in the patient-derived fibroblasts, where the stop codon 
of MT-RNA14 is lost (due to a 2 bp deletion), did not affect the translation-
dependent degradation of the faulty transcript, suggesting that mtRF1 is either 
not involved at all or that its absence has been compensated for. The depletion 
of ICT1 in the same cell lines causes the lack of fully assembled mitoribosomes, 
therefore it was not possible to determine the independent roles of those two 
factors on mitochondrial quality control. ICT1 is a very small protein and if not 
integrally associated with ribosome it is presumed that it could easily enter the 
A-site of the ribosome and reach the PTC to hydrolyze the nascent polypeptide 
chain. When ICT1-FLAG is overexpressed in HEK293T cells, apart from a 
proportion of it being incorporated in newly assembled mitoribosomes, there is 
also a substantial amount of ICT1 that is free, which has also been shown to 
marginally affect the cells’ growth (Richter et al., 2010). As shown in chapter 3 
the loss of mtRF1 causes a growth defect in HEK293 and HeLa cells, which can 
be partly caused by the limited availability of mtRF1 derived GGQ activity. If that 
is the case, this deficiency could be partially rescued by overexpression of 
ICT1, which would provide some functional codon independent hydrolysis on all 
available substrates, also those that await recognition by mtRF1 activity.  
To test this potential effect of ICT1 on mtRF1 depleted cells, three sets of 
HEK293T cells were prepared, all capable of expressing ICT1-FLAG: one set 
ICT-FLAG overexpressor only for 4 days, a second set targeted with NT siRNA 
for 4 days and a final set depleting mtRF1 for 4 days. In each of the 3 sets ICT1 
expression was either induced for the full 4 days or no tetracycline induction 
was performed. The data are presented in the figure below. As shown in lanes 1 
and 2, the overexpression of ICT1-FLAG only resulted in a minor drop in 
number of cells compared with a control, which was consistent with previous 
data. The depletion of mtRF1 on its own shows a severe defect on cell growth 
(lane 6 compared with lane 4) also seen earlier, but the simultaneous 
overexpression of ICT1-FLAG did not rescue the phenotype caused by mtRF1 
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Figure 6. 5. ICT1 overexpression fails to rescue the deleterious phenotype caused by mtRF1 
depletion as measured by cell growth.  
(A) HEK293T cells capable of expressing ICT1-FLAG were treated with either 1µg/mg tetracycline, 
siRNA against NT or mtRF1 or both tetracycline and one of the siRNA reagents. After 4 days cell counts 
were performed and data plotted based on the mean and standard deviation of three independent 
experiments. (B) After counting, cells were lysed and 50ug subjected to western analysis to confirm 
depletion (lanes 5 and 6) or overexpression (lanes 1, 3 and 5) and to compare against lane 2 (cells not 
expressing ICT1-FLAG and containing mtRF1) by interrogation with antibodies against mtRF1 and FLAG, 
respectively. The dotted line indicates the initial number of cells seeded.   
A 
depletion (compare lanes 5 and 6). This piece of data strongly implies that ICT1 
cannot compensate for the loss of mtRF1 and despite the presence of 
functional GGQ motif in both proteins, their roles may be involved in recognition 
of different substrates, which is possibly determined by the rest of mtRF1 
structure that ICT1 lacks.         
 
6.6.   Does mtRF1 act as a scaffold for ribosome assembly? 
Despite of all the efforts to confirm mtRF1 involvement in quality control of 
mitochondrial protein synthesis, the data presented so far could neither 
unequivocally confirm this fact nor exclude it. One of the alternative possibilities 
for the function of mtRF1 in mitochondria could be its involvement in 
maturation/assembly of the monosome. This hypothesis was considered since 
due to mtRF1 secondary structure being predicted to fold in a similar manner as 
B 
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mtRF1a, coupled with the nucleotide extensions within mtRF1's codon 
recognition motifs, it is predicted to fill up the space of ribosomal A-site in the 
absence of mRNA. Such empty A-sites in ribosomes may not only be a result of 
translation of faulty transcripts, they could potentially also occur during 
ribosome assembly allowing a protein to occupy this cavity acting as a scaffold 
within what will become the A-site pocket. Ribosomal LSU and SSU subunits 
are recycled after translation to be used in a subsequent round of translation. If 
the monosomes assemble from ribosomal subunits that were already used in 
previous rounds of translation, the scaffolding function of mtRF1 can be also 
extended to this phase in between translation recycling and reinitiating. mtRF1 
would bind in this case to an empty ribosome and its functional GGQ motif 
would efficiently assure that any aberrant situation where a tRNA still had a 
polypeptide chain attached, are removed and the extended codon recognition 
motif of this protein could evict any residual mRNA from the decoding centre 
allowing the 2 subunits to rejoin and form a 55S particle. 
In order to test the first hypothesis a simple experiment was performed and 
adapted from (Dennerlein et al., 2010). The point was to assess if after mtRF1 
depletion de novo formed 55S can be isolated via newly expressed FLAG 
tagged ICT1. When ICT1 is overexpressed, much of it is incorporated into de 
novo ribosomes, the rest remains free. For this experiment, mtRF1 was 
depleted with siRNA for 5 days, but after 3 days of siRNA treatment, the 
expression of ICT1-FLAG was induced for the remaining 2 days of the 
experiment. After 5 days of total treatment, cell lysates were subjected to 
sucrose gradient centrifugation, fractions of which were subjected to western 
blotting analysis. The induction and depletion were also assessed and as 
shown in Figure 6.6B both, ICT1 was successfully overexpressed in both 
samples and mtRF1 efficiently depleted in siRF1. The newly assembled 
ribosomes that were formed during the experiments were then visualised by the 
presence of ICT1-FLAG, clearly seen in fractions 7 and 8 of figure 6.6A top 
panel. This is consistent with monosome being formed from the signals of 
mtSSU protein, MRPS18B, and of mtLSU, MRPL3 observed mostly in fraction 
7. A large proportion of overexpressed ICT1-FLAG remained free, mostly in 
fraction 1 and 2 in both samples, whereas the rest migrated to fractions 6/7 in 
both NT and siRF1 treated samples, where the LSU and monosome are 
expected to migrate. The amounts of ICT1-FLAG incorporated in newly 
A 
152 
 
 
 
Figure 6. 6. Analysis of whether new mitoribosomes can be formed in the absence of mtRF1.  
(A) HEK293T ICT1-FLAG cells were treated with siRNA targeted to either mtRF1 (siRF1) or control (NT) 
for 5 days. Two days before harvesting cells were induced with 1µg/ml tetracycline. Total cell lysate 
(700µg) was separated by isokinetic gradient centrifugation, prior to fractionation and western blot 
performed to analysis the integration of newly synthesised polypeptides into 55S monosomes 
(antibodies against MRPS18B and DAP3 for 28S mt-SSU, MRPL3 and FLAG for 39S mt-LSU). (B) 
Western analysis of 50µg total cell lysate probed with antibodies against mtRF1 and FLAG to confirm 
depletion and overexpression, respectively. B-actin was used as a loading control. 
 
B A 
assembled monosomes however appears the same, despite the absence of 
mtRF1. This was, however, a preliminary attempt, but it suggests that there is 
no link between mtRF1 function and assembly of mitoribosomes, at least not 
directly.   
 
6.7.   Discussion 
Due to the fact that genetic manipulations in mammalian mitochondria are 
limited and appropriate tools are not available yet, there are no models to study 
molecular mechanisms of mitoribosome stalling. Therefore, the aim of this 
chapter was to use all available techniques to investigate the substrate that 
mtRF1 may act on in regulating quality control (QC) of human mt-protein 
synthesis.     
First, the release assay demonstrated that mtRF1 activity could not be detected 
on E. coli ribosomes that had an empty A-site. This absence of release activity 
may be due to the compulsory use of heterologous assay system (bacterial 
ribosomes and human mtRF protein), which, despite the similarities may not be 
compatible between those systems for assessing the quality control. The 
ribosomes used in the assay are not physically stalled and the absence of 
mRNA in A-site may simply not be the only feature of such bacterial ribosomes 
that would be recognized by mitochondrial factor, which would potentially 
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rescue blocked complexes. The ideal approach to overcome this problem would 
be by using mammalian mitoribosomes or as second best bacterial ribosomes 
that had been stalled beforehand in release assays, to test the QC function in 
orthologous systems or the compatibility of mitochondrial factors with bacterial 
systems. In the absence of such ribosomes for in vitro assays I tried to 
maximize the generation of stalled ribosomes in vivo by using two different 
enzymes, mtPARN-N and RelE, both of which act on mt-mRNA in different 
ways. The exonucleolytic activity of mtPARN-N cleaves outside the ribosome 
digesting into the poly(A) tail and leaves no complete codon in the A-site to 
allow termination and release when the translation of the ORF comes to an end. 
In contrast, mtRelE cleaves stop codons between nucleotide positions 2 and 3 
specifically in the A-site of ribosomes.  
The results generated by the overexpression of those two enzymes in 
mitochondria were rather complicated and it was difficult to make clear and 
unequivocal conclusions, mostly due to the lack of detecting any clear 
accumulation of blocked monosomes or accurate assessment of their presence. 
Even though there was a tendency towards accumulation of transcripts on 
ribosomes, the effect of mtRF1 depletion did not yield a dramatic effect. This 
could be due to the presence of other factors harbouring the crucial functional 
GGQ motif, which could potentially compensate for the loss mtRF1 under such 
stressful situations as truncation of the majority of mammalian mt-transcripts, 
due to either mtPARN-N or mtRelE activity. It was recently reported by Vivanco-
Dominguez et al., (2012) that bacterial release factors (RF1, RF2, RF3), and 
also RRF together with tmRNA all collaborated in vitro to reduce accumulation 
of empty A-site stalled ribosomes and they proposed 3 different pathways 
involving those factors. Two of these pathways have been well accepted before, 
one of which involves a tmRNA activity following RelE cleavage, and then 
RRF/EF-G mediated ribosome recycling. The second proposes the 'drop off' of 
peptidyl-tRNA from the ribosome by RRF, RF3 and EF-G together. Their data 
however suggests a new concept of RF1, RF2 and RF3 participating in 
disassembly of ribosomes that have stalled with empty A-sites. If this is the 
case in E. coli, it is possible that a similar phenomenon can occur in 
mitochondria. In the later part of this chapter it was demonstrated that ICT1 is 
unlikely to be one of those factors that could compensate for the loss of mtRF1. 
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However, there are still mtRF1a, mtRRF and uncharacterized C12orf65, which 
could compensate and are going to be a focus of the next chapter. Those 
factors together could collaborate to be responsible for the mild effect seen in 
PARN-N/RelE experiments. Similarly, the experiment with depleting mtRF1 in 
µΔ patient's fibroblasts could not confirm the direct involvement of this protein in 
mRNA decay process. This could be because it was not possible to deplete 
mtRF1 completely in those cells and remaining traces of the protein even after 7 
days might be sufficient to cope with the introduced ‘problem' or it is possible 
that there may be other factors involved.      
Unfortunately, without having in vitro mitochondrial translation system to 
investigate the other partners, which potentially could take part in a mechanism 
of action together with mtRF1 to rescue mitochondrial stalled ribosomes, a 
simultaneous overexpression in HEK293T of at least two factors and silencing 
the others would be required, which was out of the scope of this investigation at 
the given time. Moreover, without a mitochondrial in vitro system or other 
suitable tool to investigate the interactions between mitochondrial transcripts 
and ribosomes during ribosomal stalling events, quality control may remain the 
least studied and understood phase of mitochondrial protein synthesis. One of 
the potential approaches to overcome this problem specific to the mammalian 
mitochondrial field would be use of a powerful technique, ribosome profiling, 
which is being optimized in my host lab by Maria Wesolowska. The aim of this 
technique is to investigate the mRNA fragments that are protected by the 
ribosome during protein synthesis. The analysis of them by deep sequencing 
methods will provide profiles of ribosome position on mRNA to reflect in vivo 
translation. Using this method to study the factors involved in quality control of 
protein synthesis will not only answer the question of which proteins are 
responsible, which could not be answered within this project using currently 
available techniques, but will also shed a new light on very important process in 
mitochondrial biology.               
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7. Chapter 7: Investigation of human mitochondrial protein C12orf65 
 
7.1. Introduction  
C12orf65 is the 4th member of mitochondrial class I peptide release factor 
family, which was shown to play an important role in mitochondrial protein 
synthesis, however its exact function remains unanswered. Moreover, the gene 
that codes C12orf65 is conserved in various species (Antonicka et al., 2010). It 
was first reported as a gene with a mutation that causes a premature stop 
codon in this protein. The mutation in the gene was reflected in a molecular 
impairment of mitochondrial protein synthesis and defects in assembly of 
complexes I, IV, III and V, which in turn led to a Leigh Syndrome in two 
unrelated patients. Also recently, there was a different homozygous nonsense 
mutation identified in two related patients in Japan that could underlie 
autosomal recessive hereditary spastic paraplegias (AR-HSP) with optic 
atrophy and neuropathy. This mutation resulted in reduction of mitochondrial 
protein synthesis and defects in complexes I and IV (Shimazaki et al., 2012). 
This together proves that C12orf65, similar to other release factor family 
proteins, is an essential protein in mitochondrial biology.  
C12orf65 contains a conserved GGQ motif, characteristic for all release factor 
family proteins but it lacks domains 2 and 4, where two codon recognition 
regions would be found. This truncation, similar to ICT1, makes it a relatively 
small protein of 166aa (~18 kDa). However, recent crystallographic structure 
has revealed that the conserved GGQ motif of C12orf65 is more similar to 
domain 3 of the bacterial RF2 than to ICT1 (Figure 7.1). The structure of 
C12orf65 forms a topology of a 310-β1–β2–β3–α1 with the GGQ being localized 
in the unstructured loop between β1 and β2 and it lacks, the characteristic for 
ICT1, α helix (αi) found between β2 and β3 (Kogure et al., 2012). This difference 
together with the finding that the overexpression of ICT1 can partially rescue the 
phenotype resulting from C12orf65 mutation in patients' fibroblasts (Antonicka 
et al., 2010) may indicate that the two proteins, ICT1 and C12orf65 could have 
a similar role in maintenance of mitochondrial gene expression with partially 
overlapping functions. The study of Antonicka et al., (2010) demonstrated that 
C12orf65 is localized to mitochondria, but unlike ICT1, C12orf65 does not 
exhibit peptidyl-tRNA hydrolase activity on bacterial ribosomes tested in vitro. 
The aim of this part of my thesis, further to the crystal structure information and 
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studies on patients' fibroblasts, was to investigate the real function of C12orf65 
in mitochondrial gene expression and whether the hypothesis of it being 
involved in quality control of this process can be proven. This chapter 
particularly represents preliminary data obtained from experimentation on 
cultured human cells (HEK293T and HeLa). First, in order to detect the 
endogenous form of C12orf65 in cell lysates an antibody was required. To this 
end a recombinant protein was generated, purified and used for immunisation of 
two different rabbits. Then the specific antibodies were affinity purified from the 
final bleeds. Further investigation aimed to test the consequences of C12orf65 
depletion in cultured human cells and whether it reflects the phenotype seen in 
patients' fibroblasts caused by the mutation in this protein. Finally the 
association of C12orf65 with mitoribosomes was to be tested, followed by 
generation of stable cell lines that could inducibly express wildtype C12orf65 or 
with two different point mutations across the conserved GGQ motifs.     
 
7.2. Generation of a polyclonal antibody against C12orf65 
7.2.1. Overexpression and purification of GST-fusion protein  
Generation of C12orf65 construct and cloning it into the bacterial pGEX-6P-1 
vector was successfully performed by a student Edward Carter as his MRes 
project in my host lab prior to the start of this project. For the purpose of 
generating the recombinant antigen C12orf65-GST fusion protein was 
 
Figure 7. 1. Ribbon diagrams comparing the structures of the GGQ domain in class 1 Release 
Factor family proteins. 
The β-strands and 310 helix are coloured light green and yellow respectively in all presented 
structures. The main α helix (α1) is coloured orange in C12orf65, pink in domain 3 of RF (free RF2 
from E. coli) and dark blue in ICT1 structure.  
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Figure 7. 2. Expression and purification of recombinant C12orf65 protein. 
In order to overexpress the fusion protein C12orf65-GST (~ 41 kDa) E. coli Rosetta cells were cultured to 
OD600 0.4-0.6, induced with 1mM IPTG and incubated overnight at 16°C before harvesting and sonication. 
The soluble proteins (input, lane 1) were loaded onto glutathione Sepharose beads. After incubation the 
flowthrough (FT, lane 2) was discarded and the beads (BBE, lane 3) washed with PBS. C12orf65 (~15 kDa) 
was eluted by the addition of PreScission protease and the beads (BAE, lane 4) analysed for residual 
bound material.  The elution fraction (lane 5) was then loaded onto NHS-activated Sepharose 4 Fast Flow 
beads, to which the protein should covalently bind and the flowthrough (FT, lane 6) analysed to inspect 
efficiency of binding. Each sample was loaded on 14% gel, which was then Coomassie stained.      
 
 
 
 
 
overexpressed in Rosetta cells, which can be seen in Figure 7.2, lane 1 at 
~42kDa size marker. The GST-protein binding to the beads (BBE, lane 3) 
resulted in decreased amount of it being discarded in flowthrough (FT, lane 2 of 
the same Figure). The GST was cleaved away, releasing Δ26C12orf65 (Figure 
7.2, lane 5). There was a proportion of both the cleaved version of the GST tag 
alone and also the still fused GST-C12orf65 bound to the beads (BAE, lane 4). 
Because the elution fraction (lane 5) apart from the protein of interest, which 
migrates consistent with a molecular weight ~17kDa (but of actual size 15kDa), 
also contained other proteins, the band of interest was cut out from the gel and 
sent to Eurogentec for immunisation of two rabbits.   
  
7.2.2. Antibody testing and affinity purification  
After the final bleed from two different rabbits (#93 and #94) was received, they 
were tested on total cell lysates and mitochondrial lysates at a dilution 1:1000 
(Figure 7.3A) prior to affinity purification. Both antisera gave similar results, with 
the only clear band being at approximately the right size of ~17kDa appearing in 
total cell lysates of HEK293T overexpressing C12orf65-FLAG (lanes 1 and 6, 
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band indicated by an arrow in Figure 7.3A). There is also a weak band at the 
approximately the same size present in total cell lysate of HEK293T (lanes 3 
and 4). Due to the same intensity of the band recognized at around expected 
size, the antisera from both rabbits were used for affinity purification.  
C 
               
 
Figure 7. 3. Characterisation of rabbit anti human C12orf65 polyclonal antibodies - the initial affinity 
purifications.  
(A) Western analysis of 50µg lysate of HEK293T cells (lanes 1, 3, 4 and 6) and 10µg of isolated 
mitochondria (lanes 2 and 5) probed with non purified final bleed serum from two different rabbits 
(#93 and #94), diluted 1:1000. An arrow indicates the expected size of C12orf65. (B) Western analysis 
of the first affinity purification of both antisera (top panel #93, bottom panel #94). A serial dilution of 
C12orf65 GST-purified recombinant protein (lanes 1-4), 50µg lysate of wild type (lane 6) or C12orf65-
FLAG expressing (lane 5) HEK293T and different amounts of isolated mitochondria from HEK293T 
(lanes 7-9) were decorated with affinity purified C12orf65 antibodies from both rabbits (dilution 
1:200).* indicates expected position of signal for C12orf65. (C) Second affinity purification of 
antiserum #94, dilution 1:200, where double the volume (14 ml) of antiserum was presented to the 
NHS-activated beads.  
A B 
C 
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The antiserum of each rabbit was applied onto a previously prepared column 
with recombinant C12orf65 protein covalently bound onto NHS-activated 
Sepharose 4 Fast Flow beads. In order to analyse the efficiency of binding the 
flowthrough (Figure 7.2, FT, lane 6), after the protein was loaded onto the 
column, was separated on polyacrylamide gel and Coomassie stained. There is 
no band detected in lane 6 of Figure 7.2 indicating that all applied recombinant 
protein bound to the beads. Further antibody purification continued according to 
the common protocol used in the lab and described in section 2.6.9 of methods 
(chapter 2). The resulting affinity purified antibodies from both rabbits were 
tested (Figure 7.3B) at a dilution of 1:200 on serial dilution of 10-100ng of 
recombinant C12orf65 (lanes 1-4), total cell lysates with (lane 5) or without 
overexpression of C12orf65-FLAG tagged protein (lane 6) and different 
amounts of mitochondrial lysates (50, 40 and 30µg, lanes 7- 9 of Figure 7.3B). 
The first purification of antibodies from both antisera showed a proportion of 
unspecific bands of all sizes in total cell lysates and in mitochondrial lysates. 
Amongst the unspecific signals there was a distinctive band detected in all 
samples that was level with the size of recombinant C12orf65, especially the 
signal picked up in 50µg of mitochondrial lysate (Figure 7.3B, lane 7), which 
could potentially indicate the specific signal of C12orf65. However, this could 
not be conclusive at this stage because the band of the correct size did not 
seem to get any stronger where C12orf65 was overexpressed (Figure 7.3B, 
lane 5) compared with the signal of the same size in the total cell lysate from 
HEK239Tcells (Figure 7.3B, lane 6). Therefore, in order to make sure the 
amount of the purified antibodies was not limiting a second attempt was 
undertaken. As seen in Figure 7.3B lower panel, antibodies from rabbit #94 
showed stronger affinity towards the recombinant protein and recognized 10ng 
of this protein (lane 1), therefore this antiserum was used for purification, but the 
volume of antisera initially added to the NHS-activated beads was doubled. 
Obtained antibodies were again tested on serial dilution of recombinant 
C12orf65 (2-100ng), HEK293T cell lysates with or without overexpression of 
C12orf65-FLAG tagged protein and on mitochondrial lysates (50 and 20µg). 
The lowest amount of recombinant protein detected this time was ~20ng and 
the band corresponding with the correct size appear stronger in sample where 
C12orf65 was overexpressed, but unfortunately cannot be recognized in the 
mitochondrial lysates at all. In additional to the increased amount of antisera 
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Figure 7. 4. Further characterisation of rabbit anti human C12orf65 polyclonal antibody.  
(A) Third affinity purification of antiserum # 94, dilution 1:200: before double amount (14ml) of serum 
was added, NHS-activated beads with covalently bound C12orf65 were treated with 8M urea for 3h, 
then washed with PBS. (B) Western blot of isolated mitochondria from HEK293T cells either expressing 
ICT1-FLAG tagged proteins (lanes, 1-3) or depleted of C12orf65 for 3 days (lanes 4-7) and cell lysates of 
HEK293T either expressing C12orf65-FLAG tagged protein (lane 8 ) or depleted of endogenous 
C12orf65 protein for 3 days (lane 9). 
A B 
added to the beads, the recombinant C12orf65 covalently bound with the beads 
was denatured to ensure that the epitope was exposed to antibodies on the 
column during the purification procedure. The resultant affinity purified 
antibodies (Figure 7.4A) recognized 20ng of recombinant C12orf65 (lane 1), 
potential endogenous form of the expected size in HEK293T cell lysates, where 
the signal is enriched indicating overexpression (lane 4) and most importantly 
the band of an expected size can be detected in 10µg of mitochondrial lysate 
(lane 9), which all together made it a promising result that the purified 
antibodies were specific. Therefore further analysis involved depleting the 
endogenous form of C12orf65 with siRNA, to test whether this loss of protein 
was reflected on the western blot using antibodies purified in this way.  Tested 
on a similar set of samples, which include 5-15µg of mitochondrial lysates after 
3 days of siRNA treatment, Figure 7.4B shows a clear band of the expected 
size in all samples, including 10ng of mitochondrial lysate (lane 3) and total cell 
lysates from HEK293T (lane 8). The siRNA treatment did not result in absolute 
disappearance of the candidate signal and the signal could still be detected in 
total cell lysate of HEK293T cells (lane 9). The sets of samples of mitochondrial 
lysates in the same panel shows similar results, where the siRNA treatment 
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resulted in decreased signal of interest between lysates without and with 
depletion (compare lane 3 and lane 6 of Figure 7.4B). Unfortunately, this 
promising result could not be repeated and the affinity purified antibodies seem 
to be very unstable after any time of storage in either -20°C or 4°C (data not 
shown). At this stage it is difficult to conclude whether the antibodies purified in 
for this investigation recognize a specific antigen. The mitochondrial lysates 
come from two different preparations and samples in lanes 1-3 have ICT1 
overexpressed, which potentially could have an effect on levels of C12orf65. 
Thus, the fact that the result could not be repeated and that I would have liked 
to include more extensive controls on the western blot (Figure 7.4B) and also 
due to the time constraints, the use of these antibodies was not possible in this 
project and requires further optimisation.   
 
7.3.   Consequences of the depletion of C12orf65 in human cells 
As a first part of investigation into C12orf65 function in mitochondrial gene 
expression it was necessary to answer whether C12orf65 is essential in 
cultured cells, such as HEK293T and HeLa. In order to do so, transient gene 
silencing by siRNA was performed using 3 different synthesised siRNA 
duplexes of which (# 2) was chosen for further studies. This selection was 
based on initial experiments by Dr Paul Smith, where siRNA # 2 had the most 
profound effect on mitochondrial protein synthesis at a concentration of 0.33µM.  
A known number of HEK293T cells and HeLa cells were treated with siRNA 
against C12orf65 (si-C12) then, in order to force respiration, grown in the 
presence of galactose, rather than glucose. Cells were maintained in this 
medium and examined after 3 days. The levels of protein depletion could not be 
analysed at this stage, due to the difficulties with the antibodies described 
above but transcript levels could be tested. This was done by semi-quantitative 
PCR amplification of reverse transcribed RNA isolated from cells after 3 and 6 
days of siRNA treatment and reflected the levels of mRNA of interest present in 
tested cells. As seen in Figure 7.5B, the level of C12orf65 transcripts clearly 
decreased after 3 days and this effect was even more pronounced after 6 days 
of treatment compared to NT (not targeted) samples; 18S was used as an 
endogenous control. The number of the cells decreased dramatically as a 
consequence of C12orf65 depletion. After 3 days of treating HeLa cells, there 
A B C 
E 
F 
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Figure 7. 5. Phenotypic characterisation of C12orf65 depletion in HEK293T and HeLa cells.  
(A) Growth of HEK293T cells and HeLa cells, in galactose media in the presence of siRNA against either 
C12orf65 (lanes siC12) or a non-targetting control (NT), was monitored over 3 days. Cell number 
seeded at day 0 is indicated by the dotted line. Cells were counted and presented as a mean with 
standard deviation representing three independent experiments (HeLa p=0.0327*; HEK293T 
p=0.0125*)(top panel). Lower panels show morphology changes of cells after 3 days of depletion, 
HEK293T right and HeLa left panel compared to controls (si-NT).  (B) At the time no antibody was 
available so the effect of C12orf65-targetted siRNA in HEK293T cells was monitored by PCR. Total RNA 
was extracted from cells treated with either non-targeting siRNA (NT) or targeted at endogenous 
C12orf65 and 1µg used in RT-PCR reaction as a template (random hexamers were used), then second 
step standard PCR amplified the c12orf65 gene (product of ~250 bp). Products were separated on 2% 
agarose gel and stained with ethidium bromide. Nuclear encoded 18S-rRNA was used as endogenous 
control. 
 
  
    
                                       
were twice as many control si-NT cells as si-C12 cells (Figure 7.5, left panels) 
indicating reduced growth rate.  
A similar, but less profound effect was observed. in the experiment with 
HEK293T cells, where the number of cells also decreased significantly 
compared with control after 3 days right panels). Even though the effect of 
C12orf65 depletion on cell growth of HEK293T cells is not as striking as on 
HeLa cells, the treatment has equally dramatic effect on cell morphology and 
phenotype in both cases. The C12orf65 depleted HeLa cells (Figure 7.5A, left 
B A 
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lower panel) are shrunken, they have lost their characteristic 'star' long shape 
and do not make clear contact with other growing cells, as contrasted by cells 
treated with not targeting siRNA (NT)(left upper panel). Similar effect can be 
seen after 3 days of HEK293T treatment with the same siRNA. Those cells 
show even more rounded shape Figure 7.5 A right lower panel), which makes it 
difficult to recognize the type of cells. The cells seem to be very weakly 
attached to the surface of a culture flask.  These data together suggest that 
C12orf65 is crucial and an essential protein for viability of cultured cells, which 
corresponds with the earlier report (Antonicka et al., 2010).     
 
7.4.    Effect C12orf65 depletion on cell growth and morphology  
In order to assess any changes that might occur in mitochondrial organisation 
following C12orf65 depletion after either 3 or 6 days siRNA treatment of 
HEK293 and HeLa cells, two different fluorescent dyes were used. TMRM, 
which will enter mitochondria in a membrane potential dependent manner and 
Pico Green, which will fluoresce upon binding to dsDNA. Combined staining 
allows visualization of the mitochondrial network as well as the nucleus and mt-
nucleoids. 
Following the profound decrease in cell growth rate and the overall change in 
phenotype upon C12orf65 depletion seen in previous section, mitochondrial 
network morphology also changed. After 3 and 6 days C12orf65 siRNA 
treatment (Figure 7.6 B and C) HEK293T cell mitochondria appear more 
compact, almost enlarged granules being placed on top of each other more in 
the centre of the cells surrounding nucleus compared with mitochondria of 
HEK293T transfected with NT siRNA (Figure 7.6 A), where the network seems 
to be more spread through the cell body. This difference can be noticed even 
though HEK293T cells tend to be more loosely attached to the flask surface 
when in culture and their shape is more round making it generally more difficult 
to focus on one plane. HeLa cells are generally more flat in culture and easier to 
discern morphological changes. Mitochondria of HeLa cells treated with NT 
siRNA represent a characteristic reticular mitochondrial network evenly 
distributed within normal healthy cells (Figure 7.6 D). This network becomes 
clumped together into one large patch seen after 3 days of C12orf65 depletion. 
After 6 days, these patches of mitochondria seem to be more spread but also 
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Figure 7. 6. Changes to mitochondrial morphology upon depletion of C12orf65 
Representative fluorescent images of HEK293T (A to C) and HeLa cells (D to F) after 3 and 6 days of 
C12orf65 depletion with siRNA. Mitochondria were loaded with TMRM (red) and mitochondrial DNA 
was visualised with PicoGreen, which stains both mitochondrial nucleoids and nuclear DNA green. 
siRNA targeted to mtRF1 led to visible deformation in mitochondrial network morphology in both cell 
lines after 3 and 6 days based on TMRM.     
 
more punctuate, however due to the shrunken morphology of treated cells it 
was difficult to clearly describe resulting changes.   
The experiment was performed in non quench mode, where lower dye 
concentrations were used in order to avoid dye aggregation or quenching in 
166 
 
mitochondria. The prediction would be that the lower fluorescence reflects 
depolarized mitochondria, which seem to be the case with C12orf65 depletion in 
HeLa cells after 6 days of treatment. However, the directional changes in 
mitochondrial fluorescence seen here can be only provisionally interpreted as 
no agent that would affect the membrane potential and confirm dye behaviour 
was used. Thus this data can only be used as an estimate of changes 
confirming what has been presented in chapter above.  
 
7.5.  Effect of C12orf65 depletion on steady state levels of 
mitochondrial proteins 
To further investigate the consequences of C12orf65 depletion on human 
cultured cells, its effect on steady state levels of protein was tested. For this 
HEK293T cells were treated with either siRNA- C12orf65 or siRNA-NT for 3 and 
6 days and 50µg of total cell lysates were separated by SDS-PAGE, followed by 
transfer and immunodetection of the proteins of interest. As presented by Figure 
7.7 A there were not any significant changes. The histograms, panel B, were 
generated from the densitometric measurements of the westerns in panel A and 
confirm the visual inspection. They indicate no significant difference in nuclear 
encoded, important mitochondrial proteins including the RNA polymerase 
(POLRMT) and a member of complex I (NDUFB8) after either 3 or 6 days of 
treatment. In the absence of antibodies to all the mt-encoded proteins, NDUFB8 
is used as a highly sensitive marker of complex I assembly that is generally 
absent in the absence of mt-encoded ND polypeptides. This is in contradiction 
with the data presented by Antonicka et al., (2010), where ND polypeptides 
levels were affected and so was the assembly of complex I in the patients' 
fibroblasts. The stable level of NDUFB8 shown here could simply imply that the 
6 day depletion was not enough to affect the assembly of stable respiratory 
complexes, and it cannot be excluded that a difference would be detected upon 
longer depletion. There was also no defect in mitochondrial encoded protein 
(COX II) in comparison with the control and, similarly to the earlier findings the 
components of the mitoribosome such as MRPL3, DAP3, MRPS18B and 
MRPL12 remain stable (lower band from the doublet), confirming that the 
growth rate defect in HEK293T is not due to the depletion of mitoribosomal 
proteins.    
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Figure 7. 7. Steady state levels of mitochondrial proteins after C12orf65 depletion. 
Western blot analysis of HEK293T (A) and HeLa (D) cell lysates (50μg) after 3 and 6 days of treatment 
of siRNA against C12orf65 or non-targeting (si or NT, respectively). Levels of proteins sensitive to 
inhibition of mitochondrial translation (complex I subunit NDUFB8 and COX II), mitochondrial 
ribosome proteins (DAP3, MRPS18B, MRPL3 and MRPL12) and POLRMT were analysed. Nuclear-
encoded β-actin was used as a loading control. Signals were quantified with ImageQuant software and 
the graphs represent three repeat experiments of HEK293T (B) and HeLa cells (C). None of the changes 
observed were statistically significant.   
 
 
 
 
C D 
A B 
Since the number of cells after 3 days of HeLa treatment with C12orf65 siRNA 
was more dramatically decreased one would predict this defect could be 
significantly more detectable than in HEK293T cells. Therefore, again after 6 
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days of siRNA treatment of HeLa cells, whole cell lysates were separated by 
SDS-PAGE. However, similarly to HEK293T cells, the levels of mitochondrial 
encoded COX II seem unchanged, with mitoribosomal proteins also being 
stable (MRPL3, MRPS18B and DAP3). Since western blots are only semi-
quantitative, the signal densities were measured and histograms plotted only in 
order to confirm the visual inspection that indicated no significant differences 
between signals. 
 
7.6. Depletion of C12orf65 up-regulates mt-mRNA levels. 
With the assumption that C12orf65 plays a part in mRNA decay or rescuing 
stalled ribosomes a further search for the evidence involved investigation of the 
steady state levels of mitochondrial transcripts. The steady state levels of 
mitochondrial RNAs were analysed by Northern blot after 3 and 6 days 
C12orf65 depletion in both HEK293T cells and HeLa cells. In general, the 3 
days depletion of C12orf65 in both cell lines resulted in an increase of most of 
the tested transcripts in both tested cell lines. With the exception of rRNA, which 
appears more stable, in HeLa cells 6 day C12orf65 depletion resulted in a 
significant increase of MT-RNA14 (probed with a fragment to ATP6), MTND1, 
MTCOI, MT-RNA15 (Figure 7.8 A, top left panel).  
The signals were measured with ImageQuant software, then calculated relative 
to the controls and resultant histograms although not fully quantitative, clearly 
reflect the tendency to increased transcript levels after C12orf65 depletion 
(Figure 7.8 B, left panel). After 6 days of depletion in HEK293T cells the effect is 
even more evident. The level of all mRNA and rRNA tested are significantly 
elevated (Figure 7.8 A and B, right panels). This data strongly implies that the 
accumulation of the transcripts relates to decreased C12orf65 and may 
contribute to the defective growth rate observed in previous section.      
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Figure 7. 8. Steady state levels of mitochondrial RNA after depletion of C12orf65.  
(A) Northern blot of total RNA extracted from HEK293T (4μg, right panel) and HeLa cells (1μg left 
panel) treated with non-targeting (NT) or targeting endogenous C12orf65 (si) siRNA. The blots were 
hybridised with probes to mitochondrial mRNAs (RNA14, MTCO1 and MTND1), mt-rRNAs 16S (MT-
RNR2) and 12S (MT-RNR1) in addition to human 18S rRNA for quality and loading control. (B) The 
signals were quantified and the graph presents mean and standard deviation of three independent 
experiment repeats in HEK293T (right) and HeLa cells (left), which are relative to the mean of non-
targeting control , NT (*p <0.05, **p<0.01,***p<0.001).    
 
 
B 
A 
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7.7.  Where do the increased transcripts accumulate?  
C12orf65, as a candidate protein for the quality control factor in mt-protein 
synthesis that may free stalled ribosomes on truncated mRNA in mitochondria, 
is essential to maintain healthy cells. The first characterised mutation in its gene 
causes Leigh syndrome, optic atrophy, and ophthalmoplegia (Antonicka et al., 
2010). As demonstrated in the previous section, its depletion in cultured human 
cells results in a distinct increase of all tested mitochondrial transcripts. Thus, a 
further aim was to test whether C12orf65 knock-down causes an accumulation 
of the increased mRNA on individual ribosomal subunits or the fully assembled 
monosomes, and also whether the increased rRNA assembles into monosomes 
or remains free. Sucrose gradient analysis allows investigation of the RNA 
distribution, which, if affected, could reflect the stalled mitoribosome status and 
identify the distribution of mRNA. This was analysed by preparing a lysate from 
HEK293T cells that had been subjected to siRNA treatment for 6 days. The 
lysate was separated though an isokinetic sucrose density gradient followed by 
a northern blot analyses. In order to detect the migration of the mtSSU, mtLSU 
and monosome two probes were used in the northern blot, each specific to an 
rRNA (MT-RNR1 and MT-RNR2). As seen on the gradient from HEK293T cells 
treated with non targeting siRNA (NT), the signal for mtSSU first appears in 
fraction 4 and distributes evenly down to the bottom of the gradient, where 
fraction 11 represents the gradient pellet (Figure 7.9 A, left panel). The 16S 
rRNA (MT-RNR2) partitions to fraction 5, then distributes to the bottom of the 
gradient. The signals in earlier fractions (4-6) represent the free uncomplexed 
state of each individual subunit, whereas signals in fractions from 8 onwards 
represent the presence of monosomes. This pattern of monosome is also seen 
by the distribution of mRNA, signals of which become more intense again, 
where trapped by the monosome (fractions 8). The histogram plotted based on 
detected NT control signal on northern blot reflects this distribution of both rRNA 
and mRNA across many fractions (NT in Figure 7.9A, left panel and black line in 
histograms). In contrast to the control, the 6 days C12orf65 depletion resulted in 
all mRNA tested being shifted towards the top of the gradient and accumulated 
mostly in fraction 5. The exception was MT-RNR1, distribution of which 
resembled that of the control, being localised mostly to fraction 5 and tailing 
down to the bottom of the gradient. This similarity is reflected in the histogram 
plotted from the detected signals (Figure 7.9 B pink squares). The increased 
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Figure 7. 9. Northern blot analysis of mitochondrial RNA on sucrose gradient after depletion of 
C12orf65.  
(A) HEK293T cells were treated with C12orf65 (si-c12) or non-targeted (NT) siRNA for 6 days and 
lysates (700μg) separated on 10-30% isokinetic sucrose gradient. RNA was extracted from each 
fraction (1-11 and 1/10 of input) and analysed on a northern blot using probes to mitochondrial 
mRNAs (ATP6 and ATP8 , COX 1 and ND 1) and 16S (MT-RNR2), 12S (MT-RNR1) mt-rRNAs. (B) The 
signals were quantified and presented as the graph of mean and standard deviation from three 
independent experiment repeats (*p <0.05, **p<0.01, ***p<0.001).    
 
 
A 
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MT-RNR2 accumulate mostly in fractions 5 and 6 and the tail toward the bottom 
of the gradient is much weaker compared with the control, which is also 
reflected on the histogram (Figure 7.9 A right panel, and B). Therefore, based 
 on this piece of data 6 days of C12orf65 depletion does not appear to cause 
the accumulation of the increased transcripts on monosomes. In fact these data 
suggest that the composition of the monosomes is also affected, since there is 
hardly any strong signal in fraction 7-8 where the monosome is expected as 
seen in control. In neither case was there strong evidence that mitochondrial 
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Figure 7. 10. Depletion of C12orf65 does not appear to affect mitoribosome composition.   
(A) HEK293T cells were treated with C12orf65 (si-C12) or non-targeted (NT) siRNA for 6 days and 
lysates (700μg) separated on 10-30% isokinetic sucrose gradient followed by analysis of fractions by 
western blots using antibodies against MRPS18B, MRPL3 and MRPL12. (B) Western blot signals 
presented in panel B were quantified via ImageQuant software and presented in graphs below 
showing mean with standard deviation from three independent experiment repeats of gradients after 
depleting C12orf65.  
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transcripts accumulate on monosomes following C12orf65 depletion with these 
conditions, it rather suggests it associated with either free ribosomal subunit or 
with other, large complexes or an equal density.   
 
 
7.8.   Is the composition of 55S affected by the C12orf65 knock-
down? 
In light of the observation that depletion of C12orf65 causes striking increase of 
mt-mRNAs and a change in position on gradients, now mostly co-localised with 
free ribosomal subunits, it seems possible that the MRPs may have all clustered 
at the top of the gradient as well. 
To assess whether this was indeed the case, HEK293T cells treated with 
C12orf65 or NT siRNA for 6 days were lysed and separated on 10-30% 
isokinetic sucrose density gradient. Separated proteins of interest were 
visualised by western blot with antibodies against polypeptides in the small 
(MRPS18B) and large (MRPL3 and MRPL12) mitochondrial ribosomal subunits. 
As seen in Figure 7.10 A the depletion resulted in a similar pattern of 
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distribution of MRPL3 and MRPS18B in both experimental (Figure 7.10 A, si-
c12 bottom panel) and control gradients (NT, upper panel), after 6 days of 
siRNA treatment. In both cases the SSU, detected by anti-MRPS18B, migrated 
to and accumulated mostly in fractions 4 and 5, while a member of LSU, 
MRPL3, migrated from fraction 5 to F8/9, where signal indicates monosome. 
Although similar the distribution is slightly different for these 2 polypeptides as 
with C12orf65 depletion neither protein appeared to migrate significantly beyond 
F9. Therefore, based on this data C12orf65 depletion did not contribute to 
detectable accumulation of free ribosomal subunits at the top of the gradient as 
seen in mRNA profiles in the previous section. Interestingly, the distribution of 
MRPL12 changed. This was the same MRP that was sensitive to levels of 
mtRF1, such that depletion of mtRF1 was accompanied by a decrease in 
MRPL12. This was seen in fibroblasts, HEK293 and HeLa cells. The free form 
of MRPL12 as seen in fractions 1 and 2 in the siRNA-NT (Figure 7.10 A, top 
panel) is still present but at lower level after 6 days of C12orf65 depletion (lower 
panel). The form that is associated with the mitoribosome, however, migrates in 
fractions 6-8 in the NT control, whilst in the treated sample the level of this form 
is almost undetectable. This shows that the overall distribution of mtSSU and 
mtLSU is not affected by the C12orf65 depletion and that the general MRP 
distribution does not reflect that of the mt-RNAs after C12-siRNA treatment. 
However, even though the steady state level of MRPL12 appears stable (Figure 
7.7), when tested in section 7.5, the depletion of C12orf65 caused the levels of 
MRPL12-ribosome associated form to decrease (Figure 7.10, lowest panel), 
suggesting it affected the correct assembly of MRPL12 into the LSU and 
probably monosomes. 
 
7.9. Can C12orf65-GGQ-SM-FLAG associate with mitoribosomes? 
It has been demonstrated in previous sections that C12orf65 depletion causes 
increased accumulation of mRNA on ribosomal subunits but a decrease of 
ribosome associated MRPL12. As a putative member of the mitochondrial 
release factor family C12orf65 remains a protein of unknown function, and so it 
was necessary to determine whether C12orf65 directly interacts with the 
ribosome.     
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Figure 7. 11. Analysis of interactions between C12orf65 and other components of mitochondria.  
(A) Co-immunoprecipitation of C12orf65-FLAG. HEK293T cells were induced with 1μg/ml tetracycline to 
express C12orf65-FLAG. Cells were harvested after 3 days and mitochondrial lysates (2mg) were used in 
anti-FLAG immunoprecipitations. Components of the IP (10% of elution fraction, E) and 5% of beads 
after elution (BAE) and examined by silver stain following separation on 14% SDS-PAGE. C12orf65-FLAG 
is indicated (*) and molecular weight marker sizes designated. (B) Western blot analysis was performed 
on the elution fraction following its separation by 10%-30% isokinetic sucrose gradient. Gradient 
fractions 1-10 were interrogated with antibodies to polypeptides of the 28S mt-SSU (MRPS18B) and the 
39S mt-LSU (MRPL3). C12orf65-FLAG was detected with antibodies against the FLAG epitope. (C) In 
order to analyse the effect of C12orf65 overexpression on ribosome composition HEK293T cells were 
induced for 3 days with 1μg/ml tetracycline express C12orf65-FLAG. To determine if overexpression 
caused a change in MRP distribution lysates (700µg) were loaded on 10-30% isokinetic sucrose gradient 
and fractions analysed by western blot. Antibodies against the small (MRPS18B) with large 
mitochondrial subunits (MRPL3) were used in addition to anti-FLAG that revealed distribution and 
association of the over-expressed protein    
 
B A 
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To test this inducibly expressing C12orf65-FLAG HEK293T cells were used. 
The expression was induced for 3 days, then the cells were used for 
immunoprecipitation with the FLAG tag according to the protocol described in 
methods section (2.6.10) As can be clearly seen on Figure 7.11 A in the IP 
eluate (E) C12orf65-FLAG was succesfully immunoprecipitated and it is 
indicated by a white asterisk. The other bands that can be detected by silver 
staining in the same fraction of C12orf65 eluate (E) indicate that there are 
partners that C12orf65 interacts with. The controls for FLAG IPs have been 
done many times in the host lab with mitochondrially targeted luciferase and 
other proteins to show that neither the FLAG moiety nor high expression of 
proteins gives significant binding to anti-FLAG beads. Further, in order to 
identify C12orf65 binding partners, the content of the IP elution was loaded onto 
10-30% density sucrose gradient and following the centrifugation, collected 
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fractions were subjected to western blot analysis. The resulting western blot 
was probed with FLAG antibodies to detect the position of C12orf65. As shown 
in Figure 7.11 B, its signal mostly locates to the top of the gradient (fractions 1-
3). The same result was obtained from the sucrose gradient analysis of the total 
HEK293T cell lysate with the FLAG tagged version of protein overexpressed 
(Figure 7.11 C). These together imply if there is an interaction with 
mitoribosomes C12orf65 rather weakly associates with these binding partners. 
Blotting the western with antibodies against mitoribosomal subunits proteins, 
MRPL3 (mtLSU) and MRPS18B (mtSSU) gave only weak indication that 
C12orf65 may potentially interact with mtLSU or some of its component 
proteins. To further characterise all partners that interact with C12orf65 with the 
whole IP elution fraction was separated by SDS-PAGE, stained with 
SimplyBlueTM SafeStain (Invitrogen) and the gel lane was cut out. Together 
with a negative control, elution samples (IP of mtLuciferase-FLAG) were sent 
for LC MS/MS (Liquid chromatography - tandem mass spectrometry) analysis. 
In order to avoid unspecific binding and cytosolic contamination, mitochondria 
were rigorously purified prior to lysis and IP procedure. The results were 
compared with those of mtLUC negative control and any possible contaminants 
excluded. Amongst all the protein obtained of LC MS/MS there were 14 of 39S 
LSU proteins and 3 of 28S SSU protein detected (see Appendix 1.2). However 
emPAI value for all these detected proteins was very low. The earlier 
immunoprecipitation studies from other group members did not identify 
C12orf65 as being part of or intimately associated with the mitoribosome, 
suggesting C12orf65 to be a soluble matrix protein. The LC-MSMS data 
presented here confirms this, but may suggest that it has a transient association 
with some mitoribosomal proteins.      
 
7.10. Can overexpression of ICT1-FLAG as a member of the 
mitochondrial RF family rescue the growth phenotype observed on 
C12orf65 depletion? 
Thus far the loss of C12orf65 has been shown to cause a growth defect in both 
of the tested cell lines, increased levels of mt-mRNA and incomplete 
monosomes that potentially lack a full complement of MRPL12. It has been 
demonstrated that C12orf65 can pull down several ribosomal proteins 
confirming involvement in a protein synthesis mechanism. If C12orf65 really 
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Figure 7. 12. Effect of ICT1 overexpression on cell growth upon C12orf65 depletion.  
HEK293T cells were either treated with 1µg/mg tetracycline, siRNA (NT or against C12orf65) or 
both. After 4 days treatment cells were counted and data plotted based on the mean and standard 
deviation of three independent experiments. A dotted line indicates the initial number of cells 
seeded.   
 
functions on mitoribosomes during translation what is its exact mechanism of 
action?   
There are some structural similarities between ICT1 and C12orf65, such as 
conserved GGQ motif, lack of codon recognition domains and their small size. 
ICT1 as a small protein when not associated with ribosome can easily enter the 
A-site of the ribosome and reach the PTC to hydrolyze any incomplete 
elongating polypeptide chain. This was shown in the in vitro RF assays and 
interestingly, it was shown that when ICT1-FLAG tagged is overexpressed in 
HEK293T cells, apart from a proportion of it being incorporated in newly 
assembled mitoribosomes, there is also a fair amount of ICT1 that is free, which 
also marginally affects the cells growth (Richter et al., 2010). However, if the 
function of C12orf65 depends on the functional GGQ motif, the free portion of 
ICT1 generated during overexpression may compensate for its loss.    
To test the effect of ICT1 on C12orf65 depleted cells, three sets of HEK293T 
cells were prepared: a set overexpressing ICT-FLAG for 4 days, a set depleting 
C12orf65 for 4 days and a set overexpressing ICT1 and depleting C12orf65 at 
the same time for 4 days. As shown in Figure 7.12, the overexpression of ICT1-
FLAG only resulted in a minor drop in number of cells compared with a control 
(Figure 7.12, Tet + and - ; NT+ and NT-), which was consistent with previous 
data.  
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The depletion of C12orf65 did not show any growth defect relative to the 
uninduced ICT1 cell line (Tet -). The simultaneous overexpression of ICT1-
FLAG in C12orf65 depleted cells also results in normal cell growth compared 
with uninduced control (Tet -). The apparently ‘normal’ growth of cells which 
were C12orf65 depleted but not induced, could be explained by, as seen before 
(chapter 6, Figure 6.5), leaky expression of ICT1. Thus, these data taken 
together may suggest that GGQ of C12orf65 may be required for its function as 
ICT1 could rescue the C12orf65 depletion caused grow defect.   
     
7.11. Generation of stable inducible cell lines expressing versions of 
C12orf65 with wild type or mutated variants of the GGQ motif and 
silent mutations to render them immune to the siRNA targeting 
endogenous C12orf65 transcripts. 
As a follow up from the experiment in the previous section in order to be 
unequivocally sure that the C12orf65's GGQ motif is fully functional and 
required for the function of the protein, it was necessary to generate cell lines 
that would inducibly overexpress C12orf65 with mutated versions of GGQ motif. 
Further aim would be to determine whether the presence of a mutated GGQ 
can have a dominant negative when expressed in cultured cells. It was also 
important to make sure that any effect was due to the mutant form of C12orf65 
and not simply due to the presence of high levels of overexpressed protein, like 
seen in previous sections.  
The presence of the evolutionarily conserved GGQ motif is a strong theoretical 
indicator that C12orf65 should have retained ribosome dependent PTH activity 
and mutations in the highly conserved GGQ motif, when present in release 
factor family members, result in the loss of peptidyl-tRNA hydrolysis activity 
(Frolova et al., 1999). For this two mutations across this motif were designed, 
namely C12orf65-AGQ and C12orf65-GSQ and three stable cell lines (including 
the wild type variant, i.e C12orf65-GGQ) were generated. Moreover, these 
constructs were designed so that silent mutations (SM) would be incorporated 
in to the gene sequence to render these transcripts insensitive to the siRNA that 
is effective against endogenous C12orf65, which would allow depletion of the 
endogenous protein and expression of the mutants to the wild type levels. All 
the constructs have also a FLAG sequence attached to the C-terminus to allow 
detection on western blots.   
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Figure 7. 13. Stable transfection of HEK293T cells with C12orf65-GGQ-SM-FLAG variants. 
Clones (#) of HEK293T cells transfected with FLAG tagged variants of C12orf65 were tested, using 
anti-FLAG antibody, for levels of expression after 24h induction with 1μg/ml tetracycline. Wildtype 
GGQ (lanes 7-8), GSQ (lanes 1-2) and AGQ (lanes 3-6) variants were generated that carried FLAG tags 
and silent mutations (SM) across the siRNA target rendering them immune to depletion. Porin was 
used as a loading control.  
 
After the Hek293-FlpIn TRex cells were transfected for a stable integration of 
the constructs, successful transfectants were selected over a 2 week period 
using HygromycinB (100ug/ml). Once a population of resistant cells was 
established a small culture was induced with tetracycline for 24 hours to 
analyse for expression. Cells were harvested, a cell lysate prepared and 
western blot analysis performed with anti-FLAG antibodies (Figure 7.13). 
Effective expression of C12orf65-WT-SM and both mutants was observed, the 
FLAG signal could be detected in only induced samples (Figure 7.13, lanes 2, 
4, 6 and 8) and was not recognized in samples, which were not induced (lanes 
1, 3, 5 and 7).   
 
7.12.  Import of C12orf65-GGQ-SM-FLAG mutants into mitochondria 
Before the functional complementation in human cells could be carry out, it was 
necessary to assess whether the overexpressed FLAG tagged protein localised 
to the mitochondrion. Cells expressing each of the variants were treated with 
1µg/ml of tetracycline for maximum induction for 3 days, then the organelles 
were isolated and following western blot analysis the expressed proteins could 
be detected via anti-FLAG antibodies. Clear expression and efficient 
translocation of each of the proteins to a mitochondrial compartment was shown 
(Figure 7.14). This was demonstrated as the FLAG-tagged proteins were 
protected from proteinase K treatment (1µg and 4µg; lanes 2 and 4 respectively 
in Figure 7.14). However, when the organelles were lysed with 1% Triton X-100 
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Figure 7. 14. All C12orf65-GGQ-SM-FLAG variants are successfully imported into mitochondria.  
Western Blot analysis was performed on 10μg of isolated mitochondria from HEK293T cell lines 
expressing each of the three GGQ variants, C12orf65-wildtype-SM-FLAG, C12orf65-GSQ-SM-FLAG and 
C12orf65-AGQ-SM-FLAG. Isolated untreated control mitochondria are in lane 1. Similar aliquots were 
treated with proteinase K (1 or 4μg per 100μg mitochondria, lines 2-5) or with addition of 1% Triton X-
100 (lanes 3 and 5) Anti-FLAG antibodies were used to confirm the presence of overexpressed protein 
in each sample. Β-actin was used as a loading control.   
the proteins lacked protection and were efficiently digested in all cases with 4µg 
of proteinase K (Figure 7.14, lane 5).  
 
7.13.  Discussion 
This chapter describes the preliminary data obtained during the search for the 
specific function of C12orf65 and due to the time constraints, this project was 
taken over to be continued by another PhD student in my host lab, Maria 
Wesolowska. Based on the published data, C12orf65 a member of class I 
Release Factor family was shown to play an important role in mitochondrial 
protein synthesis. Previous analyses have shown that the lack of C12orf65 in 
HeLa cells causes ROS production, decreased membrane potential, 
mitochondrial mass and cytochrome c oxidase activity, all of which inhibits cell 
proliferation and leads to apoptotic cell death (Kogure et al., 2012). These 
findings were in agreement with protein synthesis inhibition leading to decrease 
of OXPHOS complexes in fibroblasts from patients (Antonicka et al., 2010). This 
together with the solution structure of the GGQ- containing domain is not 
enough however to answer the questions about the exact function of C12orf65. 
Additionally, in this chapter it was confirmed that the depletion of C12orf65 in 
Gradient fractions Gradient fractions 
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both, HEK293T and HeLa cells resulted in significant growth defect with a 
drastic change in phenotype of cells and morphology of mitochondrial network, 
which is consistent with previous findings. Further, due to the lack of antibodies 
against ND polypeptides to test directly their steady state levels upon depletion, 
a nuclear encoded complex I protein, NDUFB8, an indicator for correct 
assembly and stability of the complex was employed. Its levels were not 
affected after 6 days of C12orf65 depletion, which was in contrast to what 
Antonicka et al., (2010), has shown. This could be due to the tissue specificity 
differences or to the fact that 6 day depletion was not long enough to cause 
such dramatic decreases as seen in patient's fibroblast where the mutation of 
C12orf65 was permanent. To confirm this however it would be ideal to analyze 
the cultured cell lines by BN-PAGE.              
Functional and structural studies lead to a suggestion that like ICT1, C12orf65 
may play a role in rescuing stalled ribosome, which may arise due to limiting 
amounts of charged tRNAs, stable secondary structures, premature stop 
codons, or truncated/degraded transcripts. Consequent analysis in this project 
revealed that upon C12orf65 depletion mitochondrial transcripts increase 
significantly, not being able to proceed for translation and accumulated, which 
was consisted with the hypothesis of C12orf65 may be participating in freeing 
the transcripts from blocked ribosomes. Surprisingly, the accumulation of those 
transcripts occurred not in the monosomes as predicted, but presumably at the 
mtSSU at the initiation phase. It would be interesting to pursue this investigation 
further by repeating the experiment from section 7.7 and after sucrose gradient 
centrifugation and fraction collection perform immunoprecipitation from fraction 
5 where the transcripts accumulate. If accumulated transcripts associate with 
mtSSU, immunoprecipitating the SSU from the fraction would deplete the 
associated transcripts as well. If that is the case, it would confirm that those 
mRNAs accumulate on mtSSU, but what would be a rationale behind it?  
C12orf65 being a matrix soluble protein has been suggested to play a role in 
processing peptidyl-tRNAs that have been prematurely released during 
elongation phase (Antonicka et al., 2010). The accumulation of such peptidyl-
tRNAs would result in depletion of aminoacylated tRNAs blocking 
mitoribosomes, which in turn would result in protein synthesis inhibition, 
C12orf65 has no structural similarities with peptidyl-tRNA hydrolases (Pth) that 
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are responsible for such function in bacteria (Das et al., 2006). Pth is an 
esterase that cleaves the ester bond between the C-terminal end of the 
polypeptide and the tRNA, whereas C12orf65 contains a GGQ motif, which is 
known to promote peptidyl-tRNA hydrolysis (PTH) in the peptidyl-transferase 
centre located in the mtLSU. Moreover, the partial rescue of the phenotype in 
patients' fibroblasts (Antonicka et al., 2010), which was also confirmed in this 
investigation, supports the prediction that C12or65 would rather have a 
ribosomal dependent PTH activity. C12orf65's association with ribosomes as 
well as the functionality of its GGQ motif need to be confirmed.  
Another possibility is that, due to the structural similarities, C12orf65 and ICT1 
can perform the same function but on different substrates, or have overlapping 
functions in different species. C12orf65 may be responsible for releasing 
peptidyl-tRNA from mtLSU after it has been disassociated. It could be that such 
complex, mtLSU and tRNA in a P-site with long polypeptide chain firmly 
engaged in the exit tunnel so that it is not able to drop off spontaneously, has a 
changed conformation and ICT1 on the mtLSU is not able to reach the PTC to 
solve the problem. In the situation when C12orf65 is not functional those 
complexes accumulate depleting the pool of free mtLSU to initiate in the next 
rounds of translation. This in turn could result in accumulation of mtSSU with 
mRNA attached to it that is ready to initiate. This is consistent with observations 
of gradients presented here. Moreover, such a state of abnormal mtLSU may 
reflect a change in the ratio between free and ribosome associated MRPL12. As 
discussed earlier (in chapter 3), such a change of ratio towards the free form of 
MRPL12 may signal to the outside of the organelle the requirement of 
mitoribosome biogenesis to compensate for the impairment, similarly to the 
mechanism in bacteria (Ramagopal et al., 1976), where accumulation of non-
ribosome associated L7 and L12 controls binding of RNA sequences inducing 
ribosome biogenesis. Such speculations need to be further investigated, and 
should take under consideration all the proteins of release factor family as they 
may all play in concert to rescue ribosome stalling and investigating one at a 
time in vivo may not shed much light on this process.   
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              A                              B                               C           
         
Figure 8. 1. The proposed function of mtRF1.  
(A) Truncated mRNA may result in an incomplete ORF, peptidyl-tRNA in P-site and aberrant translation. 
Such a complex could not be recycled and used for further translation. (B) However, it was hypothesised 
that this could be recognise by mtRF1, which would bind to empty A-site promoting release of nascent 
peptide chain and allowing the translation termination to continue as in (C).   
8. Chapter 8. Final Conclusions  
This work was focused on characterisation of two mitochondrial proteins, 
mitochondrial Release Factor 1 (mtRF1) and a factor without ascribed named 
called C12orf65. Both of those proteins were shown to be localised to the 
organelles (Antonicka et al., 2010, Soleimanpour-Lichaei et al., 2007) and 
suggested to participate in a quality control of mitochondrial protein synthesis 
(Huynen et al., 2012, Kogure et al., 2012). The concluding remarks will be made 
below regarding the progress presented by this project and its contribution to 
the published data together with the outline of potential future approaches for 
both investigated proteins.  
The main part of this PhD thesis represents the investigation on mtRF1 in 
respect of its proposed function as a release factor that binds to stalled 
ribosomes, which lack a codon in A-site and which may be analogous to the 
other mRNA surveillance pathways, e.g. tmRNA in bacteria. The work 
presented in this project shows that mtRF1 is 
 an essential protein that is required for maintaining viable cells and fully 
functional mitochondria with its loss resulting in an increased levels of 
free MRPL12 
 a release factor family member protein, whose GGQ motif is essential for 
its function 
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 able to present a level of interaction with mitoribosomes in vivo, similar to 
that represented by mtRRF under the same conditions 
 a protein that possibly functions in concert with other factors, which may 
have overlapping functions as mtRF1 substrate could not be 
characterised by different approaches. 
Despite the extensive investigation presented here the function of mtRF1 is still 
not clear. However, none of the approaches undertaken could exclude the given 
hypothesis, thus further experiments are required in order to prove or disprove 
it. The further experimentation in this case is highly limited by the available 
techniques; mainly the lack of in vitro mitochondrial translation system prevents 
to test the direct mtRF1 function. If CLIP or any other experiments involving 
cross link agents could not show potential interaction with rRNA, the questions 
about mtRF1 functionality and specificity cannot be answered without suitable 
tools that would be able to investigate the direct interactions between 
mitoribosomes, mt-mRNAs and involved factors. Such a tool could be the 
ribosome profiling techniques. When optimized it would be an ideal strategy to 
monitor in vivo mitochondrial translation providing not only insights into the 
exact positions of mitoribosomes on mt-transcripts probably revealing naturally 
occurring stalling events, but also it can provide a great model to monitor 
mitoribosomal rescue strategies. Meanwhile without having access to such 
technique, and in order to test the hypothesis that mitochondrial release factor 
family members function in the rescue of aberrant transcripts or stalled 
mitoribosomes analogous to factors involved in ribosome rescue in bacteria 
candidates, another approach would have to be undertaken. The design of the 
experiments would be to test for complementation by expression of 
mitochondrial release factor family proteins in E. coli cells lacking both arfA and 
ssrA and looking for the suppression of the bacterial phenotype. In addition to 
this in vivo experimentation, an in vitro approach could be also used to test 
mitochondrial release factors on bacterial stalled ribosomes with the expectation 
that this would elucidate their functions in both systems. Those possibilities 
would definitely open a new chapter of our understanding about two highly 
understudied aspects of mitochondrial biology, the mechanisms regulating 
mitochondrial protein synthesis and the gene expression quality control.  
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The second part of this project focused on C12orf65, a mitochondrial protein 
that have been included into release factor family members based on the 
sequence similarities with other members. It has been shown to be essential 
protein for mitochondrial biology as mutations in its gene resulted in 
mitochondrial diseases (Antonicka et al., 2010; Shimazaki et al., 2012). This 
work presents a preliminary data in a search for the function of C12orf65 in 
mitochondrial protein synthesis quality control.  
It was demonstrated here that C12orf65 is:  
 important for a healthy cell growth  
 found to transiently associate with some mitoribosomal proteins 
 responsible for correct activities occurring on mt-mRNA, probably due to 
a positive effect on mitoribosome composition. 
These conclusions however are only the first step in further investigations to 
characterise the real function of C12orf65 and needs to be expanded on. First, 
the functional characterisation of the GGQ motif in essential for the continuation 
of this project. Then, establishing whether the accumulation of the transcripts or 
failure in mitoribosomal maturation/fully assembly was a direct effect of the loss 
of this protein. Moreover, as suggested in section 7.13 looking for the complex 
on which the increased mt-mRNA accumulates would be informative and 
potentially could take the project forward. The ribosome profiling also has a 
great potential in this further work on this project and together with assigning 
mtPARN-N and mtRelE enzymes into the experimentations (similarly as 
described in sections 6.2-6.4). 
Concluding, it is clear that mitochondria play a key role in maintaining a 
functionally healthy cell and in order to ensure that all mitochondrially encoded 
proteins are properly expressed and assembled into the individual respiratory 
chain complexes, the quality control mechanisms are crucial. It has been shown 
that truncated mRNA may occur in mitochondria as a result of incorrect 
transcription, misprocessing of polycistronic RNA precursors or/and due to 
exonucleases cleavage (Borowski et al. 2010). If the mt-mRNA transcript is 
truncated the subsequent addition of poly(A) tail fails to generate a termination 
signal at the true end of the open reading frame. Eventually this results in 
truncated ORF, stalled ribosome with a peptidyl-tRNA in the P-site and an 
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empty A-site. Therefore an obvious question arises: how can mitochondria cope 
with such a problem? Until recently the regulation of this coordinated biogenesis 
and the steps of translation, especially the process of termination has been 
neglected. Recent reports on functional and structural aspects of mitochondrial 
release family members together with the data presented here, as a potential 
for future full characterisation of their roles in mitochondrial gene expression, 
contribute to a better understanding of fundamental mitochondrial biology, 
which in turn impacts on the understanding of many mitochondrial dysfunctions 
that lead to, currently untreatable, mitochondrial diseases.     
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Appendix 1.1. 
 
  
 
Figure S 1. The signals presented in chapter 3 (Figure 3.7) and chapter 6 (Figures 6.2 and 6.3) were 
quantified and presented as the graph of mean from three independent experiment repeats 
(merged version). For description of experiments see chapters 3 (section 3.7) and 6 (section 6.2 
and 6.2).   
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Appendix 1.2.  LC MS/MS analysis of C12orf65-FLAG IP 
 
The LC MS/MS was performed and analysed by H. Wessels (UNMC, Nijmegen). All 
identified proteins are listed in the table below. Contaminants such as keratin, and 
cytosolic ribosomal proteins were excluded. Mitoribosomal protein are highlighted in 
yellow.    
 
Protein ID Protein Name       EMPAI  Values 
    C12orf65 Control  
NP_619520.1 putative ATP-dependent RNA helicase DHX30 isoform 1 0.188502227 0 
NP_001164015.1 
serine/threonine-protein phosphatase PGAM5, 
mitochondrial isoform 2 0.668100537 0 
NP_001129125.1 polyadenylate-binding protein 4 isoform 1 0.285555732 0 
NP_002559.2 polyadenylate-binding protein 1 0.274274986 0 
NP_057134.1 39S ribosomal protein L11, mitochondrial isoform a 1.053525026 0 
NP_004514.2 kinesin-like protein KIF11 0.111402987 0 
NP_005372.2 nucleolin 0.324192792 0 
NP_001034708.1 protein arginine N-methyltransferase 5 isoform b 0.206792641 0 
NP_000916.2 
pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial isoform 1 precursor 0.232846739 0 
NP_009204.1 prohibitin-2 isoform 2 0.232846739 0 
NP_075066.1 39S ribosomal protein L44, mitochondrial precursor 0.279802214 0 
NP_001922.2 
dihydrolipoyllysine-residue acetyltransferase component 
of pyruvate dehydrogenase complex, mitochondrial 
precursor 0.139209961 0 
NP_112570.2 28S ribosomal protein S15, mitochondrial precursor 0.36887451 0 
NP_057575.2 39S ribosomal protein L37, mitochondrial precursor 0.165914401 0 
NP_001924.2 
dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial 0.249609141 0 
NP_065142.2 39S ribosomal protein L47, mitochondrial isoform a 0.318256739 0 
NP_003290.1 endoplasmin precursor 0.102182525 0 
NP_056255.2 
monofunctional C1-tetrahydrofolate synthase, 
mitochondrial precursor 0.060025849 0 
NP_115867.2 39S ribosomal protein L38, mitochondrial precursor 0.154781985 0 
NP_054894.1 39S ribosomal protein L15, mitochondrial precursor 0.172102298 0 
NP_055578.2 39S ribosomal protein L19, mitochondrial precursor 0.154781985 0 
NP_387506.1 28S ribosomal protein S29, mitochondrial isoform 1 0.115883993 0 
NP_000265.1 
ornithine aminotransferase, mitochondrial isoform 1 
precursor 0.140624924 0 
NP_036216.2 glutamate dehydrogenase 2, mitochondrial precursor 0.089022962 0 
NP_064576.1 28S ribosomal protein S22, mitochondrial 0.128837892 0 
NP_004918.1 39S ribosomal protein L49, mitochondrial 0.258925412 0 
NP_054880.2 39S ribosomal protein L18, mitochondrial precursor 0.359356391 0 
NP_115866.1 39S ribosomal protein L41, mitochondrial 0.519911083 0 
NP_002071.2 aspartate aminotransferase, mitochondrial precursor 0.113042193 0 
NP_054899.2 39S ribosomal protein L22, mitochondrial isoform a 0.258925412 0 
NP_054737.1 28S ribosomal protein S28, mitochondrial 0.291549665 0 
NP_060441.2 39S ribosomal protein L20, mitochondrial precursor 0.359356391 0 
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NP_066270.1 creatine kinase U-type, mitochondrial precursor 0.149756995 0 
NP_001035971.1 polyadenylate-binding protein 1-like 2 0.258925412 0 
NP_009139.1 39S ribosomal protein L3, mitochondrial 0.178768635 0 
NP_001159831.1 
serine hydroxymethyltransferase, mitochondrial isoform 
3 0.100694171 0 
NP_066957.3 39S ribosomal protein L23, mitochondrial 0.42510267 0 
NP_859047.1 peroxiredoxin-1 0.245197085 0 
NP_002148.1 10 kDa heat shock protein, mitochondrial 0.519911083 0 
NP_005338.1 78 kDa glucose-regulated protein precursor 0.084145869 0 
NP_005909.2 malate dehydrogenase, mitochondrial precursor 0.136463666 0 
NP_689482.1 
probable peptide chain release factor C12orf65, 
mitochondrial 0.389495494 0 
NP_976317.1 ribonuclease inhibitor 0.102943312 0 
NP_036205.1 T-complex protein 1 subunit epsilon 0.090776692 0 
 
 
